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The saliva of hematophagous arthropods is a powerful cocktail of substances meant 
to facilitate bloodfeding, by counteracting the host’s healing processes. Insect saliva 
can also stimulate significant immune responses, but while most research has 
focused on the proteins it contains, the glycans (sugars) that modify them remain 
overlooked. As glycans can determine a protein’s biological role, they can be 
responsible for the saliva’s effects on pathogens and their transmission. Therefore, 
in this work I set out to characterize the salivary glycans of ticks (Amblyomma 
cajennense), mosquitoes (Anopheles gambiae, Aedes aegypti), tsetse flies (Glossina 
morsitans), sandflies (Lutzomyia longipalpis) and triatomines (Rhodnius prolixus). To 
do this, I dissected and harvested saliva from each of these arthropods and 
characterized the sugar structures using a glycomics approaches. This included 
enzymatic treatment with specific glycosidases, followed by high-performance liquid 
chromatography analyses in combination with highly sensitive mass spectrometry. It 
was found that the salivary glycoproteins of these vectors are mostly composed of 
N-linked mannose-type sugars, with a predominant proportion of paucimannose 
(short) glycans; the comparison between species shows variations mainly in the 
abundance of these structures. Interestingly, there were hybrid sugars specific to 
each organism, with mosquitoes and tick glycoproteins displaying the most striking 
and potentially immunogenic structures. In particular, I show structural evidence 
that some of the salivary glycans from A. cajenensis contain terminal a-galactose 
residues, which may be responsible for the high levels of IgE anti-Gal in patients 





human mannose receptor or DC-SIGN, on either denatured or native samples, 
showed that these receptors specifically recognized N-glycans on salivary 
glycoproteins from all insect species investigated in this thesis, hinting at possible in 
vivo interactions with macrophages and dendritic cells. It is suggested that the 
endocytic activity by these cells could have a role in the host clearance (half-life) of 
the salivary glycoproteins themselves and that these interactions may be responsible 
for the specific immune responses that modulate transmission of vector-borne 
pathogens. Finally, the similarities of the glycan structures found in different species 
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Chapter 1.  Introduction 
 
Vector borne-pathogens account for some of the highest morbidity and mortality 
burden among all infectious diseases, as is the case with malaria, dengue, 
leishmaniasis and sleeping sickness (to name a few). They are transmitted by 
arthropods that act as disease vectors due to their hematophagous habit, which 
makes them pathogen carriers between the vertebrate hosts they feed from. 
However, far from being "flying syringes" that simply transport these 
microorganisms, as biological vectors they also play an active role in the successful 
development of pathogens to an infectious stage. The co-evolution of pathogens 
and vectors has resulted in parasites, bacteria and viruses well adapted to take 
advantage of their invertebrate hosts; this can range from dependency on the 
endosymbionts in midgut, to the saliva they secrete to bloodfeed. And it is their 
saliva in particular that has been of increasing interest to researchers due to the role 
it plays during disease transmission; it provides a potential target for the control of 
pathogens as soon as they enter the vertebrate host, as well as a tool to monitor of 
disease transmission.   
 
This introduction aims to provide an overview of the different vectors studied in this 
thesis, general aspects of glycosylation, and the relevance of glycosylation in the 







Figure 1.1 Taxonomical classification of the bloodfeeding arthropods studied in this thesis. 
 
1.1  The saliva of haematophagous arthropods 
 
1.1.1.  Evolution of hematophagy  
Arthropods are invertebrate animals with a segmented body covered by an 
exosqueleton, and jointed appendages that are jointed to allow movement. Their 
adaptability to different environments has made it an incredibly rich taxon, 
estimated to contain at least 80% of all living species1. Within this diversity, several 
arthropods independently evolved to be hematophagous, ingesting blood for their 





bloodfeeding nature and frequent association with vertebrates is what makes them 
efficient vectors of many pathogens.  
 
Haematophagy is a behaviour that requires many biological adaptations. 
Bloodfeeders have to track and approach a suitable host and land on its skin without 
being detected. They explore the skin surface looking for the best access to a 
bloodmeal, usually where the density of capillaries is the highest2. Two types of 
feeding can occur: telmophagy and solenophagy. In telmophagy, also known as 
“pool-feeding”, the skin tissues are lacerated and the arthropod feeds from the 
blood that wells up on the surface; this category includes tsetse flies and sandflies. In 
solenophagy, the mouthparts penetrate the skin and are specialized in locating and 
entering a capillary or blood vessel, like mosquitoes, triatomines and ticks3. 
 
As the vector penetrates the skin of the host, it will trigger pain receptors, increasing 
the possibility of being detected and interrupted. In addition to this, host defences 
such as coagulation and healing will threaten the ingestion of a full bloodmeal and 
could also harm the arthropod. These problems have acted as selective pressures on 
the saliva of haematophagous species, and the fluid has evolved to prevent or delay 
host responses4.  
 
1.1.2.  Saliva 
In humans (and many vertebrates), saliva is a liquid substance secreted by the 
epithelial cells of salivary glands. It is made up of water, mucus, enzymes, 
antimicrobial agents and even painkillers5, and serves to lubricate, digest food, and 
protect against infections. The saliva of bloodfeeding arthropods, described as 
“cocktail” of pharmacologically active compounds, can be equally complex and 
purposeful, containing anticoagulants, vasodilators and inhibitors of platelet 
aggregation3. Its localized and systemic effects can, and among other things, 





also modulates the host immune system, in order to protect the insect from an 
excessive immune response during a future feeding. Collectively, all these 
components play important roles during infection by vector-borne pathogens6-11.  
 
1.1.3.  Potential of vector saliva: markers of exposure and vaccines 
The increasing body of research into saliva can be justified by its potential use in the 
control of vector-borne pathogens. Applications range from the use of salivary 
components as biomarkers of exposure (and consequently of disease risk) or as 
vaccines that could act on the pathogen the moment it is transmitted in to the skin 
of the host7,12.  
 
1.2 Vectors and vector-borne diseases 
This work focuses on six bloodfeeding arthropod species, whose characteristics are 
summarised below. 
 
1.2.1.  Sandflies 
Sandflies belong to the Family Psychodidae, subfamily Phlebotominae; although 
there are around 900 species of sandflies, only those in the Phlebotomus and 
Lutzomyia genera are known to transmit disease. They breed in soil rich in organic 
matter that the larvae feed from, pupating and emerging as adults ~1-2 months later 
depending on the species. Adults are small, under 5mm in length, with bodies 
covered in hair-like scales and wings typically forming a v-shape when resting. Sugars 
(derived from plants or aphids) are the main source of energy for males and females; 
to develop her eggs, females also ingest blood and so they are the ones that 
transmit disease. They are night-feeders and use their short mouthparts to lacerate 
the upper layers of the skin, creating a pool of blood from which they feed3. 







1.2.1.1. Vectorial importance 
Sandflies can transmit parasites, bacteria and viruses. There are no vaccines for any 
of them, and where drugs exist, toxicity to humans and resistance by pathogens are 
an increasing problem.  
 
1.2.1.1.1. Leishmaniasis 
Leishmaniasis is a disease caused by Leishmania parasites and transmitted by the 
bite of female sandflies. Leishmaniasis is endemic in nearly 100 countries around the 
world13, mainly in resource-poor populations. The clinical manifestations, which 
depend on the tropism of the infecting species, can be classified as cutaneous, 
mucocutaneous and visceral leishmaniasis. In cutaneous leishmaniasis (CL) lesions 
develop at the site of bite where parasites have been injected into the skin; even 
after healing, stigmatizing scars remain. A small percentage of CL patients develop 
mucocutaneous leishmaniasis and may suffer severe facial disfigurement. Some 
species of Leishmania migrate to organs such as the liver or spleen causing visceral 
leishmaniasis (VL), which is lethal if left untreated.  
 
 
Figure 1.2. Leishmania transmission by a female sandfly. Leishmania parasites travel to 
different parts of the sandfly midgut and then reach the stomodeal valve, where they 
remain in their infectious stage before transmission during the next bloodmeal. Source: 






When sandflies feed from an infected host, ingested amastigotes travel throughout 
the gut where they go through several stages before returning to the stomodeal 
valve where the infectious stage develops (Figure 1.2). Unlike other pathogens like 
Trypanosoma brucei or Plasmodium sp., that reach the salivary glands of their 
vectors before transmission, Leishmania never reach the sandfly’s salivary glands, 
and are regurgitated from the stomodeal valve into the site of the bite during the 
next bloodmeal. This regurgitation is promoted by a parasite-secreted gel which 
blocks the normal ingestion of blood, forcing the sandfly to probe multiple times, 
enhancing transmission15  
 
1.2.1.1.2. Bacteria and viruses 
Bartonellosis 
Caused by the bacterium Bartonella bacilliformis, it is also known as Carrion’s 
disease or Oroya fever, and it transmitted by sandflies in the Andean region. 
Although it is geographically restricted (due to the few vector species16 and 
reservoirs17), the disease can be quite severe. Infection starts with an acute phase 
characterized by anaemia and fever that can lead to paralysis, coma and death. 
Some patients suffer a chronic phase with the development of bacteria-filled warts. 
Its mode of transmission is unclear, as bacteria have only been observed in the 
midgut18; it’s possible that they egested from this point as is the case of Leishmania.  
 
Viruses 
Sandflies are vectors for a variety of viruses. They belong mainly from the 
Phlebovirus genus (family Bunyaviridae) such as the sandfly fevers, and the 
Vesiculovirus genus (family Rhabdoviridae) like the Chandipura virus and vesicular 
stomatitis19. The clinical symptoms of these viruses range from mild fevers and 





mechanism of transmission is unknown, they are confirmed to be transmitted by 
sandfly bite19, possibly from the salivary glands as other arboviruses.  
 
1.2.2.  Tsetse flies 
There are 31 species of tsetse flies20, all belonging to the genus Glossina, with most 
species distributed in sub-Saharan Africa21. Tsetse flies are one of the few insects 
that give birth to live, fully-formed larvae. These pupate soon after and emerge ~4 
weeks later; the dark-coloured adults measure between 6-14mm, are characterized 
by a rigid forwards-facing proboscis and a hatched-shaped cell on their wing vein 
pattern20. Both males and females are haematophagous, usually feeding from 
vertebrate hosts every 2-3 days, and both are able to transmit disease.  
 
1.2.2.1. Vectorial importance 
1.2.2.1.1. African Sleeping sickness 
Tsetse flies transmit African trypanosomiasis, a disease caused by the protozoan 
Trypanosoma brucei. It is further classified intro three subspecies: T. b. brucei causes 
animal trypanosomiasis (Nagana), affecting animals like cattle and horses; humans 
are affected by the other two subspecies, T. b. gambiense (chronic infection, 
responsible for ~97% of cases) and T. b. rhodensiense (acute infection, around ~3% 
of cases). In the first stage of human trypanosomiasis, the parasites multiply in blood 
and tissues, causing fever, headaches and pain. The second stage is more severe, as 
parasites cross the blood-brain barrier and infect the central nervous system, leading 
to disturbances in behaviour, coordination, and sleep-wake cycles, and can result in 







Figure 1.3 Trypanosoma brucei life cycle in the tsetse fly and human host (Source: Dr. Aitor 
Casas-Sánchez). Tsetse flies are infected with T. brucei during a bloodmeal from an infected 
host. The parasites transform throughout various fly tissues until they reach the salivary 
glands, where they remain as infectious forms until the next bloodmeal. 
 
Tsetse flies ingest the ‘stumpy’ blood-circulating parasites forms from an infected 
host. Inside the vector, the parasites suffer various transformations as they travel 
through the tsetse gut and make their way up to the salivary glands, where they 
remain until next bloodmeal, when metacyclic promastigotes and saliva will be 
injected into a new host (Figure 1.3). 
 
T. brucei affects several aspects in the tsetse fly, including the saliva production. The 
trypanosome infection induces a transcriptional down-regulation of most genes 
encoding for salivary proteins, resulting in a significantly reduction in the expression 





which explain the feeding phenotype observed in trypanosome-infected flies23, are 
suspected to allow the successful survival in the tsetse and their transmission onto 
the next host. Besides inducing a downregulation of some secreted salivary proteins, 
few of the major salivary gland changes include upregulation of genes involved in 
cell adhesion (e.g. serpins) cell death and immune responses22.  
 
 
1.2.3.  Mosquitoes 
Mosquitoes fall within the family Culicidae, which contains well over 3500 species in 
43 genera25. They have a wide global distribution, being absent from very few places 
around the world. Like all dipterans, they have one pair of functional wings, a long 
forwards-facing proboscis, scales covering the whole body25. While both sexes feed 
of sugar as adults, and only females need to ingest blood for the development of 
their eggs. Mosquitoes undergo complete metamorphosis, and a few days after the 
bloodmeal the female will lay her eggs on or next to water.  
 
There are multiple mosquito genera and species. Of these, Anopheles and Aedes 
contain some of the most important disease vectors.  
 
1.2.3.1.  Anopheles   
Anophelines are mosquitos comprising many species that are widely transmitted 
around the world. While msoquitoes are better known for being the vectors of 
Plasmodium, the causative agent of malaria, they can also transmit other pathogens 
like Wuchereria and Brugia (which cause filariasis)26 or alphaviruses (like the 







Figure 1.4. Plasmodium life cycle in the vertebrate host and the mosquito. In malaria, the 
parasites need to reach the salivary glands, where they remain in their infectious stage until 
they are transmitted during the next bloodmeal. Taken from Ménard et al, 201328. See text 
for details. 
 
1.2.3.1.1. Vectorial importance 
Malaria 
Caused by parasites of the genus Plasmodium, malaria is endemic in 91 tropical and 
subtropical countries around the world. It is the most prevalent vector-borne 
disease, with 216 million cases reported in 2016 alone29. Of multiple species, five are 
known to affect humans: P. falciparum, P. vivax, P. malariae, P. ovale and P. 
knowlesi. The Plasmodium life cycle alternates between its vertebrate host (humans, 
primates or birds), and its definitive host (the mosquito). Once a person is infected 
by a mosquito, parasites travel to the liver and infect the hepatocytes (where a 
dormant stage may remain) before continuing to infect red blood cells. A small 
percentage of these populations differentiate into gametocytes, ready to be taken 
up by a mosquito. 
 
A female anopheline becomes infected by ingesting parasitized red blood cells, 





slender sporozoites. During her next bloodmeal, she will inject these parasites 
together with the content of her salivary glands (Figure 1.4). Most sporozoites are 
injected into the tissue while the mosquito probes in search for blood vessels, and 
some experiments have shown that ~60% remain at the site of the bite while the 
rest travel to the liver through blood and lymphatic vessels.  
 
1.2.3.2.  Aedes   
Of the three, the subfamily Culicinae contains the largest number of mosquito 
species. Within these, Aedes species are highly urbanized, laying eggs in the water 
accumulated by household containers or rubbish. Aedes aegypti has a wide global 
distribution and is known to be closely associated to human environments, and its 
locations essentially outline the risk areas for the different pathogens this species 
can transmit.    
 
Figure 1.5 Brief life cycle of dengue virus. The virus alternates between the vertebrate hosts 
(humans in this case) and the Aedes mosquito, where it infects several tissues before reaching 






1.2.3.2.1. Vectorial importance 
Aedes mosquitoes are the vectors for several arboviruses (Table 1.1). Although 
several species can vector disease, Aedes aegypti and Ae. albopictus stand out as the 
most important and prevalent ones. Most of the arboviruses they transmit have a 
worldwide distribution and are responsible for a great burden of disease; only yellow 
fever has a safe working vaccine, and treatment for all of them can only be 
symptomatic31. 
 
Transmission of these viruses occurs in a similar way for many arboviruses (e.g.  
Figure 1.5) through the bite of a female previously infected from a reservoir host 
(e.g. humans, primates, birds). Once the virus is ingested, it replicates in the body of 
the mosquito until it reaches the salivary glands and is transmitted onto the next 
host. During the bloodmeal, the pathogen is transmitted together with the 
mosquito’s saliva, which favours the successful replication of the virus and 
contributes to its pathogenicity238, 239, 240. 
 
Table 1.1. Viruses transmitted by mosquitoes of the Aedes genus32-35. 
 Virus name Family Symptoms Distribution 
Chikungunya Togaviridae 
Fever, muscle pain, fatigue, 






Fever, rash, muscle and joint pain. 
In some, severe bleeding 
(haemorrhagic fever).  
Worldwide 
Rift Valley fever Phlebovirus 
Fever, muscle and joint pain, 
headache, light sensitivity. In some 









West Nile Virus Flavivirus 
Fever, headache, rash. In some 
cases, encephalitis/meningitis, 
confusion, seizures.  
Worldwide 
Yellow Fever Flavivirus 
Fever, headache, muscle ache. In 
some, liver and kidney problems, 
jaundice, dark urine, abdominal 
pain. 
Africa and South 
America 
Zika Flavivirus 
Mild dengue-like symptoms. In 
some cases, Guillain-Barre 
syndrome occurs; during 
pregnancy, can cause severe brain 
malformations and other defects. 
Worldwide 
 
1.2.4.  Triatomines 
Triatomines, also known as kissing bugs, belong to the subfamily Triatominae, Family 
Reduviidae (Order Hemiptera). Research and control efforts have focused mostly on 
the domestic vectors of Chagas disease, namely Triatoma infestans, T. brasiliensis, T. 
dimidiata, Rhodnius prolixus and Panstrongilus megistus36. They are mostly 
distributed in the American continent, found associated to habitats like palm trees 
and rodent burrows.  
 
They undergo incomplete metamorphosis, where juvenile stages develop and 
increase in size through a series of moults, with wings appearing only in the adult 
stage (~6 months), which can measure up to 3cm in length. Males, females, and all 
juvenile stages feed on vertebrate blood, and so can be vectors of Trypanosoma 
cruzi and T. rangeli37-39. 
 
1.2.4.1. Vectorial importance 
Also known as American trypanosomiasis, Chagas disease is caused by the protozoan 
parasite T. cruzi and transmitted by triatomines. A wide variety of mammals can be 
reservoirs for the parasite, helping to maintain transmission cycles, especially in 





has one flagellum and a mitochondrion containing the kinetoplast. This parasite is 
not transmitted like other trypanosomatids diseases like leishmaniasis or sleeping 
sickness. When the triatomine feeds from an infected host, it ingests 
trypomastigotes, which will develop as epimastigotes in the midgut and then as 
metacyclic trypomastigotes. During the next bloodmeal, the triatomine’s excreted 
faeces will contain metacyclic trypomastigotes, which are infective to the vertebrate 
host. Usually by a mechanical action (e.g. scratching), they enter the host and 
become intracellular amastigotes, and then in bloodstream trypomastigotes, which 
upon successful replication burst out of the cell and are ready to be ingested by 
another triatomine36. Other ways of acquiring Chagas disease include oral ingestion 
of contaminated food40 and congenital transmission, transfusion and 
transplantation. The latter is now suspected to be responsible for the increasing 
worldwide prevalence of Chagas disease41.  
 
1.2.5.  Ticks 
Unlike the previous insect vectors, ticks are arachnids, and can be classified into 
three families: Ixodidae, Argasidae and Nuttalliellidae. They have pincer-like 
mouthparts, and range in size from 0.5 up to  20mm in engorged females3. Their life 
cycle resembles that of hemimetabolous insects, with juvenile stages closely 
resembling the adult forms. From an egg emerges a six-legged tick larva, which then 
transforms into the eight-legged nymph stage(s) before becoming a fully mature 








Figure 1.6 Image of a tick illustrating the way it feeds and transmits pathogens. As they are 
long-term pool feeders, saliva is crucial for their successful interaction with the vertebrate 
host. This means the vertebrate will be exposed for longer periods of time not only to 
salivary components, but also to pathogens and any intestinal contents the tick could 
regurgitate during this time. Source: Simo et al.8 
 
One of the reasons tick-host interaction is different from other vectors is their 
feeding behaviour, as they can remain attached to a vertebrate host for several days 
(Figure 1.6). Tick bodies are exquisitely adapted to remain effectively attached to 
their vertebrate hosts. Their chelicerae work as cutting and attachment appendages 
to better remain. Ticks also produce a type of cement through the salivary glands, 
which securely glues to them to the host to feed properly. During this time, they are 
constantly egesting both saliva and intestinal content, exposing the host to 
pathogens and a variety of immunogenic molecules.  
 
1.2.5.1. Vectorial importance 
Ticks can transmit a great diversity of infectious pathogens42 (see Table 1.2). Their 
impact extends to the strong reactions to their bite, including “tick paralysis”, a 
reversible condition that normally lasts as long as the tick is attached43,44. 
Furthermore, they can induce an allergy to red meat, caused by increased IgE levels 
against alpha-galactosyl (aGal) epitopes; the condition can sometimes lead to 
anaphylactic shock, and the allergy may last several years after exposure to ticks45. 
The nature of the putative aGal epitopes present in tick saliva is described in 






Table 1.2 Examples of tick-borne diseases1,42 



















































































The collection of sugars in an organism is termed glycome and the field of 





as glycans. The basic structural unit of glycans are monosaccharides, carbohydrates 
that cannot be hydrolysed intro a simpler form.  
 
1.3.1.  Protein glycosylation 
The co- and post-translational modification of proteins allow for the large complexity 
that can be observed in organisms independently of their numbers of genes. This is 
illustrated by the fact that organisms as different as humans and fruit flies have fairly 
similar-sized genomes. One of the most common forms of post-translational 
modification (PTM) is glycosylation (from the Greek glukus for sweet), which is the 
attachment of sugars to proteins. Many of these glycosylated proteins (or 
glycoproteins) reside on the cell membrane, and most (if not all) eukaryotic cells are 
suspected to be “coated” with sugar structures, which together with glycolipids and 
other types of surface glycoconjugates form the cellular glycocalyx. In general, 
cellular glycocalices have a role in cell-cell communication and in the interaction with 
the environment. Glycoproteins can be also released by secretory tissues were 
glycosylation plays a role in protein stability and/or protection against degradation 
by proteases46,47.  
 
Glycans are the product of complex metabolic pathways, starting with simple sugar 
structures called monosaccharides. These then enter the different glycosylation 
pathways in the endoplasmic reticulum (ER) and the Golgi apparatus, where they 
become the building blocks for the creation of sugars and eventually form part of 
the glycoproteins (and other structures like glycolipids).  
 
All monosaccharides can be described with the simple formula Cx(H2O)n, where n ≤ 
3; the nine types of monosaccharides found in vertebrate organisms are among the 
best studied structures (Figure 1.7)48. These monosaccharide units can join together, 
through glycosidic bonds, to form oligosaccharides. Unlike the linear structures 





depending on the orientation of their bonds. The linkage is the most flexible part of a 
disaccharide structure. Protein glycans have a reducing terminus (which is the part 
linked to the protein), and a terminal (non-reducing) end. They can be very diverse in 
structure, but normally the core region (reducing terminus) is conserved. There are 
different types of glycans, with two of the main ones being part of either N-linked or 
O-linked glycans in eukaryote cells.  
 
 
Figure 1.7. Monosaccharide 'building blocks' that form glycan structures in vertebrates, 
showing their names and abbreviations. Taken from Essentials of Glycobiology49.  
 
The biosynthesis of glycans occurs through enzymes called glycosyltransferases. It 
was first hypothesised back in 1957, when Luis Leloir described the process through 
which the enzyme glucosyltransferase adds glucose onto a growing polysaccharide 
to create glycogen (storage form of glucose in vertebrates). The enzyme used a 
nucleotide sugar called UDP-Glucose as a substrate, which provided the first idea of 
how glycosyl donors are involved in the construction of glycans inside the cell. 
Donors of Galactose (Gal), N-Acetylgalactosamine (GalNAc) and N-Acetylglucosamine 
(GlcNAc) can all be found in this UDP form, while Mannose (Man) and Fucose (Fuc), 
and sialic acids are present as guanosine diphosphate (GDP)-nucleosites and cytidine 
diphosphate (CMP), respectively. Each of these sugar nucleotide donors, which can 





specific substrate to its own enzyme (glycosyl-transferase), and it is the presence or 
absence of enzymes that accounts for the diversity of sugar structures in different 
organisms.   
 
The complete collection of glycans made by a cell is known as a glycome, which can 
vary according to cell type and physiological state and can provide a lot of 
information about a particular physiological condition, biological role or organism.  
 
2.2.1.1 N-linked glycosylation 
N-linked glycosylation is a modification that happens in proteins targeted to the 
endoplasmic reticulum. Its name comes from the fact that the sugar is attached to 
the nitrogen atom on the side chain of an asparagine residue, when this is part of a 
very specific sequence of amino acids within the protein. Protein modification takes 
place in two stages: first in the ER, where the addition of the sugar is used as a 
signalling molecule for the folding pathway, and then it goes on to the Golgi, where 
these sugars are trimmed or more specific modifications to the sugar structures are 
made depending on aspects like species, life stage, cell type, etc.50.  
 
 
Figure 1.8 The synthesis of N-linked glycans starts in the endoplasmic reticulum (Source: 






The biosynthesis of N-glycans involves the participation of many enzymes, most of 
them glycosyl-transferases known as ALG or "altered in glycosylation". It starts with 
dolichol (a class of lipid made up of several isoprene units), with an isoprenoid group 
at both ends, one of which has an additional alcohol group. Dolichol is found in the 
ER membrane, with a phosphate group attached to it facing the cytoplasm (Figure 
1.8). The first monosaccharide attached onto the dolichol-P is GlcNAc-P, which 
originates from UDP-GlcNAc. This process continues with the addition of a GlcNAc 
(forming Dol-PP-GlcNAc2), followed by addition of a b-mannose in linear form. Four 
a-mannose residues are then continuously added with different linkages thus 
forming the intermediate Dol-PP-GlcNAc2Man5. The appropriately named flippase 
(Rft1) then ‘flips’ this intermediate so it now faces the ER lumen and receives four 
more a-Man residues plus three a-Glc residues, resulting in the branched 
oligosaccharyl lipid (OSL) precursor, Glc3Man9GlcNAc2 that can be seen in Figure 1.9. 
The mature OSL is then transferred by the oligosaccharyl transferase complex (STT3) 
onto asparagine residues of nascent proteins that are part of a canonical consensus 
sequence, N-X-S/T, where Asn is followed by any amino acid (except proline) and 
ends with a serine or threonine. However, other non-canonical N-glycosylation sites 
have been recently identified, such as N-X-C, with cysteine as the third amino acid of 






Figure 1.9. Diagram representing the processing of protein N-glycans during the transit from 




Figure 1.10 There are three types of N-linked glycan structures: oligomannose, complex and 
hybrid. In all cases the innermost GlcNAc of the oligosaccharidic chan is attached to an 
asparagine (N) when it is followed by an amino acid (X ¹ proline), and then a serine (S) or 
threonine (T). Paucimannose glycans (not depicted) are structures containing four or less 
mannose residues. Blue square: GlcNAc; red triangle: Fuc; green circle: Man; yellow circle: 







2.2.1.2 O-linked glycosylation 
O-linked glycans are usually built upon a GalNAc that is attached to the oxygen atom 
on the side chain of a serine or threonine residue. As there is no known consensus 
sequence, it can be difficult to predict what proteins might be O-glycosylated. There 
are four major core structures, which can be extended –as in N-glycosylation– by a 
series of enzymes, to produce branched sugars. The addition of a b1-3Gal is the 
most common extension, while core 2 comes from the addition of a b1-6GlcNAc to a 
core 1 structure. Core 3 and 4 are less common, normally found only in mucins or 
glycoproteins of gastrointestinal or bronchial tissues. 
 
Syntheis of O-linked oligosaccharides begins with the incorporation of donor sugars 
into the Golgi apparatus, where O-GalNAc glycans are attached onto a protein 
through a set of glycosyltransferases (some of which can be shared with the N-
glycosylation pathway), starting in the cis- and advancing towards the trans-Golgi. 
Some enzymes from N-glycan biosynthesis are also involved in O-glycan processing 
(e.g. addition of some GlcNAc residues). The first step if the addition of the GalNAc 
to a serine or threonine by the GalNAc-transferase (GALNT). Mucin-type O-
glycosylation is highly abundant, with the first step of their biosynthesis controlled 
by the GALNTs; they are essential for many organisms, and are normally found in 
animals, but not bacteria, yeast or plants53. Mucins are an essential for many 
organisms, being particularly abundant in the function of airways and 
gastrointestinal tract, among others, not only providing a physical protection to 








1.3.2.  Glycosylation in Arthropods 
The interest of understanding arthropod glycosylation came mainly from the 
increasing use of insect cell lines are to express recombinant proteins, as they can 
produce large amounts of protein and have a eukaryotic glycosylation machinery 
(unlike E. coli, for example)55. Although a lot of the research into arthropod 
glycosylation has been carried out in the model organism Drosophila melanogaster, 
some research has looked at insect cell lines used to express recombinant proteins.  
 
1.3.2.1. N-linked glycosylation in insects 
Insects were generally expected to produce paucimannose and high-mannose type 
N-linked glycans. However, the annotation of the Drosophila genome allowed the 
discovery of the glycosyation machinery necessary to produce complex type 
structures, and eventually experimental evidence demonstrated a diversity in 
glycosylation that was comparable to that of mammals56. Analysis of the honeybee 
venom showed insects were capable of core N-glycan fucosylation with a1-3 linked 
fucose modification that is recognised by IgE antibodies in people allergic to bees57. 
Eventually, research on other organisms confirmed the wide variety in glycosylation 
capacity of insects and arthropods, revealing its importance in all physiological 







Figure 1.11 Differences between insect and mammalian protein glycosylation pathways 
(Modified from Shi and Jarvis, 200763). Insects are normally expected to produce mostly 
paucimannose and high-mannose type sugars, while mammals have the capacity to produce 
more complex and hybrid-type glycans. Many studies however have shown that some 
insects, and arthropods in general, have the capacity to make complex-type glycans as well, 
with important implications for pathogen transmission in the case of bloodfeeders.  
 
1.3.2.2. O-linked glycosylation  
In arthropods, various O-linked glycan modifications have been reported. An 
example is the core-1 O-glycan structure Galβ1-3GalNAcβ-Thr/Ser has been 
described, and where present, it could account for a large percentage of the 
glycoprotein’s mass56. Mucins found in Spodoptera frugiperda and Trichoplusia ni 
cell lines, commonly used for the production of recombinant proteins, revealed 
great variation between the two species; while S. frugiperda produced short 
oligosaccharides, T. ni they observed large, sulfated O-linked glycans64. Mucin-type 
glycosylation has been reported as an essential part of developmental processes in 
Drosophila65, and mutations of GALNTs affect the viability of the flies66. O-linked 







1.4 The human immune system: carbohydrates and their 
receptors  
The saliva of bloodfeeding arthropods is of great interest due to the multiple effects 
it has on the human immune system, both localized and systemic. Strikingly, 
research has focused on the protein components of the saliva, when the glycans that 
modify these proteins could also be playing significant roles in immune modulation. 
To put this research into a biological context, it is important to touch upon some 
aspects of the immune system, such as the main cells saliva might encounter and the 
lectin receptors that could recognise and bind salivary glycoproteins. 
 
1.4.1.  Immune cells in the skin 
The skin is the largest organ in the human body and constitutes the first line of 
defence against environmental threats as well as potential invaders. It not provides a 
physical barrier but forms an important part of the immune system, actively 
defending against and clearing foreign particles (Figure 1.12). It is also the point of 
interaction with bloodfeeding arthropods, and the site of entry for any pathogens 
they transmit.  
 
The innate immune system is the immediate defensive response, where cells such as 
neutrophils, macrophages, and dendritic cells can start and manage the immune 








Figure 1.12. Immune cells found in healthy skin. Source: Malissen, 201468. The skin 
constitutes the first barrier of defense against foreign particles and pathogens. It forms an 
active part of the immune system and is the site of interaction between vertebrate hosts 
and bloodfeeding arthropods.  
 
1.4.1.1. Neutrophils 
Neutrophils are the most abundant circulating white blood cells, and act as the first 
responders during an infection. They travel from the bone marrow to the site of 
inflammation where they ingest and kill pathogens, which are then degraded in the 
lysosome after phagocytosis. After serving their purpose, they die off in the tissues 
and are later degraded by macrophages. Neutrophils have various cell-surface sugar-
binding receptors, including selectins (mainly responsible for the neutrophil’s rolling 
movement along vessels), Toll-like receptors (that recognise various microbial 




Like neutrophils, macrophages are phagocytic white blood cells found in all tissues, 
where they clear cellular waste, foreign particles, and pathogens from the body. 





response against pathogens in the tissues. Apart from this, they function as antigen 
presenting cells (APCs); after phagocytosing an invader, they break it up and present 
parts of it to T cells. In receptor-mediated phagocytosis, the phagosome, fuses with 
the lysosome (low pH degradation through enzymes) and forms a phagolysosome 
where the pathogen is destroyed.  
 
Macrophages can stimulate both inflammatory and anti-inflammatory responses, 
through cytokines that are released depending on the tissue environment they are 
in. They can live in tissues for several years before being replaced by circulating 
monocytes. These cells express various glycan-binding receptors in their surface, 
including dectin-1, TLR2 and TLR4 (recognition of peptidoglycans and LPS), DC-SIGN 
(pathogen recognition) and MR (clearance, activation)70.  
 
1.4.1.3. Dendritic cells (DC)  
DCs live in tissues like macrophages, and as immature DCs they constantly take in 
particles and substances from their environment through various endocytic 
processes. When an ingested particle is recognised as foreign, they switch to their 
mature form, and travel outside their tissue to the lymph nodes to present this 
antigen to a T-cell. As such, they represent an important link between innate and 
adaptive immunity.  
 
1.4.2.  The role of carbohydrates and their receptors  
Both carbohydrates and their receptors play fundamental roles in the interaction 
and processes of the human immune system. It is a complex role to understand 
considering that the process of glycosylation itself is influenced by the expression of 
the metabolic enzymes and the availability of the sugar transporters, among several 






A good immune defence system depends on proteins and receptors being able to 
identify pathogen associated molecular patterns (PAMPs), which are common to 
many pathogens and absent from the host body. Very often, PAMPs are 
carbohydrate structures, which can be recognised and bound by receptors bearing 
carbohydrate-recognition domains (CRDs).  
 
 
Figure 1.13. Lectin structures, with at least one C-type lectin-like domain (CTLD). Taken from 
Brown et al, 201869. CTL can recognise a variety of glycan structures and trigger signaling 
pathways in response to different antigens.  
 
1.4.2.1. C-type lectin receptors  
C-type lectin-like receptors have carbohydrate recognition domains (CRDs) with 
conserved motifs and can be classified according to their sugar specificity (Figure 
1.13). Those having the tripeptide Gln-Pro-Asp (QPD) motifs recognize Gal/GalNAc, 
whereas the Gln-Pro-Asn (EPN) motifs bind Man, Glc, GlcNAc and L-Fuc71,69. Of all C-






1.4.2.1.1. Mannose Receptor (MR) 
Also known as cluster of differentiation 206 (CD206), the MR is an endocytic 
receptor found mainly on macrophages and dendritic cells. It has multiple roles, 
including the recognition of carbohydrate PAMPs, which could be cleared, and 
presented to T cells when they arrive to the tissues72. The MR is made up of three 
domains: the carbohydrate recognition domain (binds sulfated Gal or GlcNAc, the 
highly conserved FNII domain (binds collagen) and the CTLD (recognises 
glycoconjugates that have terminal Man, Fuc or GlcNAc) (Figure 1.14).  
 
In immature dendritic cells, the MR plays an important part in the internalization of 
antigens and facilitates their presentation and has been considered as a target to 
increase the immunogenicity of an antigen72. In macrophages, MR does not induce 
phagocytosis of glycosylated molecules exhibiting MR ligands. In general, it appears 
that the MR does not produce a specific response by itself, but instead might 
influence the signalling induced by other receptors. In addition, it appears to polarize 
the immune response towards a Th2 type, as seen during infection with Schistosoma 
cercariae73. The MR has a crucial role during infection with different parasites. In 
Leishmania for example macrophages are one of the main cell types infected, and 
high expression of the MR in these cells was correlated with a non-healing lesion 
phenotype74,75. In T. cruzi, an increase of MR recycling in the cell contributes to the 







Figure 1.14. Structural properties of the mannose receptor. Taken from Martinez-Pomares, 
201272 The mannose receptor has different carbohydrate binding domains with different 
roles in pathogen recognition. The CTLD region in particular recognises mannose, fucose and 
N-acetylglucosamine structures, which are most commonly expected in arthropods.  
 
1.4.2.1.2. Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing 
Non-integrin (DC-SIGN) 
DC-SIGN (cluster of differentiation 209 – CD209) (Figure 1.15) is a receptor highly 
expressed by dendritic cells, some T cell populations, and macrophages77. The 
specificity of this receptor is for high-mannose structures, with the highest affinity 
being for Man9, and decreasing accordingly as mannose residues decrease Man8-
Man378. Pathogens interact with DC-SIGN in various ways. In fact, this receptor was 
first discovered because HIV, which is decorated with high-mannose-type glycans, 
uses DC-SIGN to bind to dendritic cells and travel from mucosa to the lymphoid 
system where it attacks T-cells71. In fact, because Leishmania also targets DC-SIGN, 
co-infection of the two can result in increased severity of both conditions79. Another 





binding can impair the activities of dendritic cells80. Importantly, Dengue virus is 




Figure 1.15. Structure of DC-SIGN. Source: Nature reviews82. DC-SIGN is a c-type lectin that 
can bind mannosylated glycan structures, with a predilection for high-mannose type-glycans78 
 
1.4.2.2. Mannose Binding Lectin (MBL) and the lectin complement 
pathway  
Collectins are a family of proteins that have collagenous and carbohydrate 
recognition domains (among other types), and include the mannose binding lectin 
(MBL), which activates the lectin pathway of complement. Like other soluble 
proteins involved in complement, MBL is produced primarily in the liver, and travels 
through the blood and lymphatic system to the extracellular fluids, until needed. It 
can also be found intracellularly83. 
 
The structure of MBL can be seen in (Figure 1.16). Each polypeptide chain is made 
up of a cysteine-rich N-terminal region, a collagenous domain, an a-helical coiled 
domain (also known as the neck region), and the CRD at the C-terminal region83. The 
MBL molecule is normally structured as a hexamer, each containing between 15-18 
Man binding sites. It binds selectively (in a Ca2+-dependent manner) to terminal 
Man, Fuc and GlcNAc, but does not recognise galactose or sialic acid. This is due to 
the EPN amino acid motif, which helps the body’s immune system to differentiate 





complement activation (alternative, lectin and classical -activated in this order), each 
of them recognising pathogens through different ways but all having the same 
outcome of cleaving C3. After this point, they recruit inflammatory cells (including 
monocytes which then transform into macrophages at the site), opsonize antigens 
for phagocytosis, and also create protein complexes that form a hole in a pathogen’s 
membrane leading it to lysis. If after the activation of the alternative pathway there 
are still pathogens inducing an acute phase, this will lead to the production of MBL, 
which then activates the lectin pathway. All pathways eventually lead to the 
formation of the attack complex, which disrupts the pathogen cell membrane and 
lyses the cell. MBL plays important roles during infection by several vector-borne 
pathogens, including Leishmania84-86, T. brucei, T. cruzi87-90, Plasmodium 91-93, and 
Dengue virus94-96 among others. How glycans present in saliva from the respective 
vectors modulate activity of the mammalian lectin pathway during pathogen 
transmission is unknown.  
 
 
Figure 1.16. The Mannose Binding Lectin. The cartoon shows an MBL subunit with three 
terminal CRDs (a) and an example of an MBL multimer that can be found in circulation. MBL 
can bind to Man, GlcNAc, and Fuc residues, but not sialic acids (Sia) or Gal. Modified from 






1.4.2.3. Toll-like receptors (TLRs)  
These are receptors that were first discovered in the model fly Drosophila 
melanogaster, and are a family of 10 genes, each specific for different PAMPs. They 
are composed a transmembrane domain, an extracellular domain made up of 
repeating units of leucin-rich regions (whose variation allows for the recognition of 
various PAMPs), and a cytoplasmic domain that relays the signal indicating a 
pathogen has been recognized. Two of these, TLR2 and TLR4, both found on the cell 
surface, can recognise carbohydrates on extracellular pathogens.  
Among the PAMPs recognised by TLR2 and TLR4 are the LPS of gram-negative 
bacteria, peptidoglycans in gram-positive bacteria, mannan in Candida and 
Saccharomyces, GPI anchors from Trypanosoma, Plasmodium and Toxoplasma, 
Leishmania lipophosphoglycans, and N-linked glycans from Taenia97. 
 
 
1.4.3.  Immunity to vector saliva 
The saliva of hematophagous animals facilitates the free ingestion of blood, by inhib 
its inhibiting normal homeostatic responses such as coagulation, platelet 
aggregation and pain98. The effects can vary between bloodfeeders, reflecting a 
diversity of adaptations to hosts and other conditions (Figure 1.17). Several works 
have been published, some of which I will use here as examples. The saliva of 
sandflies, depending on the species, can produce a Th1 or Th2 type response, which 
can often depend on the salivary protein a host is exposed to99-101; in some cases, 
the protective response generated by certain salivary proteins can be harnessed 
towards a vaccine that combines parasite and vector antigens102-105. The saliva of 
tsetse flies can accelerate infection with T. brucei, which was associated with an anti-
inflammatory effect of the salivary proteins106. The saliva of Anopheles aquasalis can 
inhibit complement activation107, while a vaccine using a salivary protein named 





parasitemia)108. In some cases, allergic responses can be triggered, as happens with 
ticks (discussed in detail in Chapter 4) and sometimes with mosquitoes like Aedes109. 
 
 
Figure 1.17 The saliva of hematophagous arthropods is relevant not only during bloodfeeding, 




































1.5 Aims and justification of this thesis 
1.5.1.  Aims 
To determine the structure and function of salivary-glycoproteins in bloodfeeding 
arthropods of medical importance and compare the relevance of these glycoproteins 
across a different vector species where saliva plays different roles during pathogen 
transmission.  
 
1.5.2.  Objectives 
a. To determine the glycans present in the salivary glycoproteins through standard 
glycobiology methodologies like treatment with glycosidases and detection with 
lectin.  
b. To characterize the structure of the salivary N- and O-glycans of vector salivary 
proteins using a combination of liquid chromatography and mass spectrometry 
(MS) and MS/MS, and HPLC analysis before and after exoglycosidase treatments.  
c. To explore the recognition of vector salivary glycoproteins by human immune 
cell surface receptors.  
d. To verify the presence of the meat allergy-inducing a-Gal epitope in the saliva of 









Chapter 2.  Insights into the salivary N-glycome 




During Leishmania transmission, sandflies inoculate parasites into the skin of a 
vertebrate during blood feeding. These insects facilitate the blood intake with their 
saliva, whose components have anti-haemostatic and anti-inflammatory activities, 
and can modulate the host’s immune response. Sand fly salivary proteins have been 
extensively studied, but the biological roles and nature of protein-linked glycans 
remain overlooked. Here, we characterized the profile of N-glycans from salivary 
glycoproteins of Lutzomyia longipalpis, vector of visceral leishmaniasis in the 
Americas. In silico analysis suggests nearly half of Lu. longipalpis salivary proteins are 
predicted to be N-glycosylated. SDS-PAGE coupled to LC-MS analysis of sandfly 
salivary, before and after enzymatic deglycosylation, revealed several candidate 
glycoproteins. To determine the diversity of N-glycan structures, enzymatically 
released sugars from sand fly salivary glycoproteins were fluorescently tagged and 
analyzed by HPLC, combined with highly sensitive LC-MS/MS and MALDI-TOF-MS, 
and exoglycosidase treatments. We found that the N-glycan composition of Lu. 
longipalpis mostly consists of a series of oligomannose sugars, with Man5GlcNAc2 
being the most abundant, in addition to few hybrid-type species. Interestingly, some 
glycans appear modified with a group of m/z 144, whose identity has yet to be 
confirmed. In overlay assays, salivary glycans are recognized by the human mannose 
receptor, suggesting a possible recognition pathway by the immune system. The 
dominance of mannosylated N-glycans also found in Glossina morsitans (tsetse) 








2.2.1.  Sandflies: Lutzomyia longipalpis, vector of visceral leishmaniasis 
Sandflies are tiny insects with a powerful bite, capable of transmitting diseases such 
as leishmaniasis, which threatens 350 million people worldwide110. They can also be 
vectors for bacteria and viruses19. With every bite, female sandflies inject into the 
host a saliva composed of molecules meant to facilitate bloodfeeding; they can 
modulate the host immune system111 and affect pathogen transmission112,113. These 
effects have increased research interest in sandfly saliva, which has shown promise 
through the discovery of markers of biting exposure (to determine risk of disease), or 
even as components in a vaccine against leishmaniasis103.  
 
Lutzomyia longipalpis is the vector of Leishmania infantum, which causes visceral 
leishmaniasis, in the American continent. It has a wide distribution, being found from 
northern Argentina up to the south of the United States. Within this wide range, Lu. 
longipalpis has become a complex of species that has adapted well to various 
ecological landscapes. Part of this success is due to the sandfly’s promiscuous 
feeding nature, accepting to feed on a wide variety of hosts. This generalist and 
hardy survival nature also translate into the lab, making Lu. longipalpis the easiest 
and most widely colonized sandfly species in the world. It has become a model for 
experimental transmission not only of L. infantum, but of other species like L. 
mexicana, because as a permissive vector it will allow the development and 
transmission of several species.  
 
2.2.2.  Glycosylation in sandflies 
Glycans may have special relevance in the saliva of medically important arthropods, 
because of the fundamental role this biological fluid plays during of pathogen 





arboviruses and malaria are all harboured in the salivary glands of their respective 
vectors and therefore are co-transmitted with saliva through a bite. In contrast, 
Leishmania parasites are transmitted from the stomodeal valve, where infectious 
stages remain, and contact with saliva occurs at the bite site on the host114. 
However, people living in leishmaniasis-endemic regions can be constantly exposed 
to the saliva of uninfected sandflies, which can have consequences for successful 
parasite infection115. 
 
In all eukaryote cells, including those of insects, the addition of glycans to proteins is 
a highly conserved and diverse post-translational modification. Protein glycans can 
be classified into two main types: N-glycans (attached to an asparagine residue in a 
specific sequon Asn-X-Thr/Ser), and O-glycans (attached to serine or threonine 
residues). These glycoconjugates play various biological roles, including in processes 
within the human immune system as well as its interaction with pathogens116. 
However, few studies address the types and roles of glycans in insects, mostly using 
the model fruit fly Drosophila melanogaster. In Drosophila, functions have been 
attributed to the different glycan classes, such as morphology and locomotion (for 
N- glycans) or cell interaction and signalling (for O-glycans)117.  
 
Up until know, proteins have been the focus of the vast majority of works on sandfly 
saliva. A few reports have described the presence of salivary glycoproteins in this 
insect, but to our knowledge no detailed structural studies have been published to 
date. As little information exists on the sand fly glycoproteome, we set out to identify 
the salivary glycoproteins in the Lu. longipalpis sandfly and structurally characterize 











Figure 2.1. Analysis of the sandfly glycosialome. Saliva was dissected from 5-day old, sugar fed 
Lu. longipalpis females. Glycoproteins were subjected to enzymatic release by PNGase F, and 
glycans were fluorescently labelled with procainamide for analysis by LC and MS as indicated 
in the Methods section. 
 
2.3.1.  Glycosylation prediction 
The NetNGlyc server118 was used to predict potential glycosylation sites by 
examination of the consensus sequence Asn-Xaa-Ser/Thr, where x: aa¹proline.  
 
2.3.2.  Lutzomyia longipalpis salivary gland dissection and extraction of 
saliva 
Lu. longipalpis were obtained from a colony at the London School of Hygiene and 





(Sigma, St. Louis, MO) with protein inhibitor (Sigma, St. Louis, MO), pierced salivary 
glands with a needle, and centrifuged to obtain saliva. The supernatant was stored at 
-80°C.  
 
2.3.3.  SDS polyacrylamide gel electrophoresis and staining 
Proteins from sandfly saliva were fractionated on a 12.5% polyacrylamide gel before 
and after deglycosylation with Peptide-N-Glycosidase F (PNGase F) from 
Flavobacterium meningosepticum (New England Biolabs, Massachusetts, US). Bands 
were then visualized using InstantBlueTM Protein stain (Expedeon, California, US). 
 
2.3.4.  Concanavalin A (Con A) blotting 
Saliva samples, before and after treatment with PNGase F (New England Biolabs, US) 
were fractionated on a 12.5% polyacrylamide gel under standard conditions, 
transferred onto a PVDF membrane, and blocked with 1% BSA in PBS-Tween 20 
overnight at 4°C. Membrane was incubated with 1ug/ml biotinylated ConA lectin 
(Vector Labs, Peterborough, UK) for 1 hour at room temperature. After washing with 
0.5% PBS-Tween20, the membrane was incubated with 1:100,000 streptavidin-HRP 
(Vector Labs, Peterborough, UK). SuperSignal West Pico Chemiluminescent substrate 
(ThermoFisher, Massachusetts, US) was used to detect the bands. Egg albumin, a 
highly mannosylated N-linked glycoprotein119, was used as positive control.  
 
2.3.5.  Mass spectrometry analysis 
To identify the glycoproteins that were susceptible to PNGase F, bands of interest 
were sliced from the gel and sent to the Dundee University Fingerprints Proteomics 
Facility. Briefly, the excised bands were subjected to in-gel trypsination followed by 
alkylation with iodoacetamide. The resultant peptides were then analyzed by liquid 
chromatography- tandem mass spectrometry (LC-MS/MS) in a Thermo LTQ XL Linear 






2.3.6.  Proteomics identification of glycosylated salivary proteins 
Tandem MS data were searched against the Lu. longipalpis database downloaded 
from VectorBase (https://www.vectorbase.org/proteomes) using the Mascot 
(version 2.3.02, Matrix Science, Liverpool) search engine. Search parameters were a 
precursor mass tolerance of 10 ppm for the in-solution digest using the LTQ-Orbitrap 
Velos and 0.6 ppm for the lower resolution LTQ instrument. Fragment mass 
tolerance was 0.6 Da for both instruments. One missed cleavage was permitted, 
carbamidomethylation was set as a fixed modification and oxidation (M) was 
included as a variable modification. For in-solution data, the false discovery rate was 
filtered at 1%, and individual ion scores ≥30 were considered to indicate identity or 
extensive homology (p<0.05).  
 
2.3.7.  Release of O-linked glycans 
Saliva samples underwent reductive β-elimination or hydrazinolisis to release O-
glycans after PNGase F treatment. Briefly, samples were 0.05 M sodium hydroxide 
and 1.0 M sodium borohydride at a temperature of 45°C with an incubation time of 
14-16 h followed by solid-phase extraction of released O-glycan.120 O-glycans were 
analyzed using PGC-LC coupled to negative ion ESI-MS/MS alongside fetuin O-
glycans as a positive control.  
 
2.3.8.  Enzymatic release of N-linked glycans  
The N-glycans from sandfly saliva were released by in-gel deglycosylation using 
PNGase F as described in121. For deglycosylation using PNGase A, peptides were 
released from gel pieces by overnight incubation at 37°C with trypsin in 25mM 
ammonium bicarbonate. The supernatant was dried, re-suspended in water and 
heated at 100°C for 10 min to deactivate the trypsin. Samples were dried by vacuum 





100mM citrate/phosphate buffer (pH 5.0) for 16 hours at 37°C122. Samples were 
separated from protein and salts by protein-binding plate. The glycans pass straight 
through the protein binding membrane but all wells were flushed with extra water 
to ensure full recovery and then dried by vacuum centrifugation prior to fluorescent 
labelling.  
 
2.3.9.  Fluorescent labelling and purification of released N-glycans 
Released N-glycans were fluorescently labelled via reductive amination reaction with 
procainamide using a Ludger Procainamide Glycan Labelling Kit containing 2-picoline 
borane (Ludger Ltd.). The released glycans were incubated with procainamide for 1 
hour at 65°C. The procainamide labelled glycans were cleaned up using LudgerClean 
S Cartridges (Ludger Ltd) and eluted from the column with water (1mL). The samples 
were evaporated to dryness under high vacuum using centrifugal evaporation and 
re-suspended in water (100μL) for further analysis. 
 
2.3.10.  Online HILIC-SPE LC-MS analysis 
Procainamide labelled glycans were taken up in 0.1 % TFA (v/v) in 78% acetonitrile 
(v/v) and desalted on-line using hydrophilic interaction liquid chromatography solid 
phase extraction before direct elution onto the mass spectrometer. Glycans were 
injected onto a HILIC trap column (ACQUITY UPLC® BEH-Glycan 1.7 μm, 2.1 × 150 
mm) at a flow rate of 1.5 µl/min using an UltiMate 3000 LC (Thermo Scientific, 
Massachusetts, US). The trap was washed with 0.1% formic acid in 90% ACN (v/v) for 
4 min followed by elution of samples using an isocratic gradient of 0.1 % formic acid 
in 27 % ACN (v/v) for 12 min. Glycans were analysed using electrospray ionisation 
tandem mass spectrometry (ESI-MS/MS) on an amaZon speed ETD ion trap MS 






2.3.11.  ESI-LC-MS and ESI-LC-MS/MS analysis  
Procainamide labelled samples were analysed by ESI-LC-MS. 25 µL of each sample 
was injected onto an ACQUITY UPLC® BEH-Glycan 1.7 µmn, 2.1 x 150 mm column at 
40 °C on the Dionex Ultimate 3000 UHPLC attached to a Bruker Amazon Speed ETD 
(Bruker, UK). The running conditions used were: Solvent A was 50 mM ammonium 
formate pH 4.4; solvent B was acetonitrile (acetonitrile 190 far UV/gradient quality; 
Romil #H049). Gradient conditions were: 0 to 53.5 min, 24% A (0.4 mL/min); 53.5 to 
55.5 min, 24 to 49 % A (0.4 mL/min); 55.5 to 57.5min, 49 to 60% A (0.4 to 0.25 
mL/min); 57.5 to 59.5 min, 60% A (0.25 mL/min); 59.5 to 65.5 min, 60 to 24% A (0.4 
mL/min); 65.5 to 66.5 min, 24% A (0.25 to 0.4 mL/min); 66.5 to 70 min 24% A (0.4 
mL/min). The Amazon Speed settings used were: source temperature 250 °C, gas 
flow 10 L/min; Capillary voltage 4500 V; ICC target 200,000; max accu time 50.00 ms; 
rolling average 2; number of precursors ions selected 3, release after 0.2 min; 
Positive ion mode; Scan mode: enhanced resolution; mass range scanned, 200-1500 
m/z; Target mass, 900 m/z. 
 
 
2.3.12.  Matrix Assisted Laser Desorption/Ionization Time-of-Flight 
(MALDI-TOF) mass spectrometry analysis of PA-labelled glycans 
Samples were processed and labelled with PA (aminopyridin) and analysed by 
MALDI-TOF-MS, before and after treatment with exoglycosidases (Jack bean α-
mannosidase (JBAM) and α-1,3 mannosidase) and hydrofluoric acid (HF) which, 
under control conditions, releases phosphoryl and sulphate groups. Phosphodiester 
bonds were cleaved by treating the dried glycan fractions with 3μL of 40% aqueous 
hydrofluoric acid ([aq.HF] on ice in the cold room) for 36h prior torepeated 
evaporation. The digests were analyzed using MALDI-TOF MS and MS/MS. MALDI-
TOF-MS spectra were annotated in terms of monosaccharide composition (Fx Hy Nz) 
applying the Glyco-Peakfinder tool [40], followed by manual interpretation in-line 





fragmentation analysis of selected ion species, using Bruker Daltonics FlexAnalysis 




2.4.1.  Identification of Lu. longipalpis salivary glycoproteins. 
An in silico analysis of the salivary proteins reported for Lu. longipalpis111,123, which 
revealed that 48% of the proteins are predicted to have conventional N-glycosylation 
sites (Net-N-Glyc server; http://www.cbs.dtu.dk/services/NetNGlyc/) (Table S1). 
However, this list only includes those proteins available on the NCBI database, as 
studies published to date have focused on major secreted proteins, and no deep 
sequencing has been carried out for salivary glands of this sand fly species.  
 
In-gel protein staining allowed the visualization of several protein bands ranging 
from ~20kDa to ~100kDa in Lu. longipalpis saliva. To identify glycoproteins, saliva 
samples were analyzed by Coomassie blue staining SDS-PAGE, before and after 
treatment with PNGase F (Fig. 1). This enzyme acts between the asparagine and the 
innermost GlcNAc residue, cleaving most types of N-linked glycans. Treatment with 
PNGase F resulted in a reduction of the apparent molecular mass of several protein 
bands. Bands migrating with an apparent molecular mass around 65, 55, 45, 37 and 
30 kDa were susceptible to the enzyme, consisting with a widespread N-







Figure 2.2. Enzymatic cleavage of Lu. longipalpis salivary glycoproteins with PNGase F. 10 µg 
of salivary proteins were incubated overnight with (+) and without (-) PNGase F to cleave N-
glycans. Samples were resolved on a 12 % SDS-PAGE gel and (a) Coomassie-stained or (b) 
transferred onto a PVDF membrane and blotted with Con A. Egg albumin (OVA) was used as 
a positive control. MWM: molecular weight marker. *PNGase F enzyme. 
 
Protein bands visibly susceptible to the enzyme were excised and sent to the 
University of Dundee Fingerprints Proteomics Facility for LC-MS/MS identification. 
From the protein top hits, we excluded proteins those without recognizable 
glycosylation sequons (Net-n-Glyc), obtaining a list of 55 potentially glycosylated 
proteins (Table S2.1). Fourteen of these potential glycoproteins are present in the 
predicted secreted salivary proteins111,123 listed in Table S1, including LJM11, LJM111 
and LJL143, which have been researched as potential vaccine components111 against 
Leishmania infection. Protein family distributions show five of our candidates belong 
to the actin family, while others like tubulin, 5’nucleotidase/apyrase, peptidase M17 
and the major royal jelly protein (yellow protein) are represented in our list by two 
glycoproteins each. All other hits seem to indicate glycosylation is not related to 
protein family.  
After identification and annotation of the glycoprotein candidates, protein families 
were classified using Blast2GO124. The biological process classification revealed 86% 





30.23% in nucleobase-containing compound metabolic processes (GO:0006139), 
23.26% in carbohydrate derivative processes (GO:1901135), and 23.26% purine-
containing compound metabolic processes (GO:0072521). According to the 
molecular function classification, 81.25% of these proteins are involved in binding 
activities: 64.58% in ion binding (GO:0043167), 54.17% in heterocyclic (GO:1901363) 
and organic cyclic (GO:0097159) compound binding, and 45.83% in small molecule 
binding (GO:0036094). Additionally, 79.17% the glycoproteins were involved in 
catalytic activities, such as the 33.33% with hydrolase activity (GO:0016787). The 
cellular component classification shows 87.1% of the glycoproteins are intracellular 
(GO:0044424), of which 77.42% are cytoplasmic (GO:0005737) and 67.74% are 
located in intracellular organelles (GO:00043229).  
 
2.4.2.  Salivary glycoproteins from Lu. longipalpis are modified with 
mannosylated N-glycans 
To determine the N-glycome of salivary glycoproteins of Lu. longipalpis, the 
oligosaccharides were released by PNGase F followed by derivatization with 
procainamide, which allows us to determine the pattern by HILIC and increases the 
signal for MS analysis125. Furthermore, a comprehensive interrogation of N-glycomic 
profiles was conducted using diagnostic ions from MS/MS fragmentation data, in 
addition to knowledge of the N-glycosylation patterns of the tsetse fly salivary 
glycoproteins, which is mainly composed of paucimannose glycans. Overall, the 
pattern of procainamide-labelled glycans on HILIC showed that the N-glycome of Lu. 
longipalpis is mainly composed of 16 different structures (Table S2.2), elucidated 
from ten separate compositions due to the presence of isomeric glycans. Most 
oligosaccharides are of the oligomannose type, being the most abundant species the 
paucimannose Man5GlcNAc2-Proc (21.16 min; Figure 2.3). In addition, few hybrid-
type species (with a retention time of 15.12-17.24 min) were detected, containing 
potentially an a1-6 core fucose residue linked to the reducing GlcNAc or not 







Figure 2.3. HILIC-LC separation of procainamide labelled N-glycans from Lu. longipalpis (top) 
and G. morsitans (bottom). See Materials and Methods for details. 
 
All glycan structures were corroborated by positive ion MS/MS fragmentation 
spectra, including the most abundant species, Man5-GlcNAc2-Proc, of m/z [727.81]2+ 




Figure 2.4. Positive-ion mass spectra profile (m/z 540-1500) of released N-glycans from Lu. 
longipalpis (top) and G. morsitans (bottom) salivary glycoproteins. Ion signals corresponding 






The oligomannose-type structures comprised 82% of the N-glycome (Table S2.2), 
while the remaining are mainly represented by hybrid-type glycans (either a 
trimannosyl modified with a Fuc residue on the chitobiose core or paucimannose 
structures containing an unknown modification) (see below). Furthermore, 
comparing the sandfly and the tsetse fly salivary N-glycomes, both profiles are 
strikingly similar regarding the content of mannosylated species, except that in 
tsetse the highest peak (Figure 2.3, bottom panel) corresponds to the tri-antennary 
core Man3GlcNAc2-Proc structure of m/z [565.81]2+ (Figure 2.3).  
 
The spectrum obtained with PNGase A release of glycans did not offer any additional 
information (Figure 2.5), indicating the possible absence of core alpha1-3-




Figure 2.5. HILIC-LC separation of PNGase A (top) and PNGase F (bottom) released N-
glycans. Comparison after digestion with both enzymes indicates de likely absence of an 
α1,3 fucose linked to the innermost GlcNAc residue. 
 
Comparison of N-glycans between tsetse and sandfly saliva shows that both profiles  
are strikingly similar in the composition of oligomannose structures. Notable 
differences include structure abundances, Man5GlcNAc2 and Man3GlcNAc2 for 
sandfly and tsetse, respectively. There are a few differences, notably a series of 
doubly charged [M+H]2+ ions with m/z [667.30] 2+ (Hex3HexNAc3), and the m/z 





2.4). Conversely, the m/z [740.89] 2+ structure, of composition 
Hex3HexNAc4DeoxyHex1, was found in sandfly saliva but not in tsetse. Interestingly, 
the doubly charged m/z [748.89] 2+ species is present in both insect samples, but 
constitutes an isomeric difference with the two different structures having the same 




Figure 2.6. Positive-ion MS/MS fragmentation spectrum of Man5GlcNAc2-Proc structure 
 
The presence of mannosylated N-glycan structures, in insect salivary glycoproteins, 
was confirmed through a lectin blot using Con A, which binds specifically to terminal 
a-mannose residues on glycoproteins126 (Figure 2.2). Con A recognized seven bands 
of Lu. longipalpis salivary glycoproteins, which are no longer bound in PNGase F-
treated samples.  
 
2.4.3.  A series of sandfly salivary glycans with unidentified modifications  
A more detailed analysis of the saliva by MALDI-TOF revealed the existence of a 
series of glycans containing an unidentified modification of m/z 144 (Figure 2.7). This 
modification was mainly found in two isomeric structures, one with a retention time 
of 25.0 min (Figure S2.13) and the other of 26.5 min (Figure S2.14). The two isomers 
have a m/z 1292, which corresponds to a Man4GlcNAc2 glycan (Figure S2.5). This was 
confirmed by treatment with JBAM, which caused a loss of 2 and 3 hexoses for each 
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positions in the two structures and, in both structures, this modification was lost 
after treatment with aqueous hydrofluoric acid (aq.HF) (Table 2.1). 
 
 
Figure 2.7. Positive-ion MS/MS fragmentation spectrum for m/z [718.89]2+ corresponding to 
the composition Hex4HexNAc2–Proc. Asterisk indicates fragments containing the m/z 144 
modification. 
 
Susceptibility to aq.HF suggests this group may contain a phosphoryl group, but due 
to their very low abundance we were unable to determine its chemical nature. 
Interestingly, a second set of paucimannose structures appears to have another 
unidentified modification of m/z 80, located on the innermost mannose of the 
chitobiose core (Fig S8), but again due to limitation in sample these structures were 
not further characterized.  
 
Table 2.1 Summary of treatments of the isomeric structures detected by MALDI-TOF-MS, 
seen in Figures S2.13 and S2.14. 
Treatment Isomers (RT, min) 
 25.0 26.5 
No treatment m/z 1295.5 m/z 1295.5 
Jack Bean  
α-mannosidase 













2.4.4.  No O-linked glycans were found in sandfly saliva 
Moreover, saliva samples were subjected to b-elimination to release of O-glycans; 
surprisingly, no O-glycans were found in sandfly saliva Figure 2.8. 
 
 
Figure 2.8. b-elimination release of O-glycans. Released and reduced O-glycans were 
separated using a porous graphitised carbon column coupled with ESI-MS. No O-glycans 





At remarkably low protein quantities of saliva injected in a sandfly bite (nanograms 





(facilitating a bloodmeal for eggs development), to systemic (influencing the 
transmission of leishmaniasis). Lu. longipalpis is a sandfly species widely distributed 
in the American continent127, where it transmits L. infantum, the  parasite that 
causes visceral leishmaniasis and can be lethal in the absence of treatment. Lu. 
longipalpis salivary proteins and their biological roles have been well studied111,123; 
however, the sugars that modify these proteins remain mostly unexplored. They 
were first reported by Volf et al128, who used lectins to detect mannosylated N-type 
glycans. Mejia et al129 report high mannose glycans in Lu. longipalpis saliva, with 
some potential hybrid-type structures (also based on lectin specificity). Further work 
has looked at the predicted glycosylation sites for some vector species130,131. Our 
work presents the first time a mass spectrometry approach has been used to study 
the salivary N-linked glycans of Lu. longipalpis saliva. Sandfly salivary glycoproteins 
consist mainly of oligomannose glycans (ranging from the core Man3GlcNAc2 to 
Man9GlcNAc2), with some hybrid-type structures. Studies on the saliva of the tsetse 
fly G. m. morsitans (vector of sleeping sickness), revealed a similar composition of 
mainly paucimannose and high mannose glycans (this Chapter and Chapter 4). This 
suggests conserved salivary glycosylation pathways, as further described in Chapter 
5. 
 
Insect protein glycosylation studies have been carried out primarily on the 
Drosophila melanogaster fly, suggesting the presence of various carbohydrate 
structures132,133. It is generally accepted that N-linked type glycoproteins in 
arthropods are mainly of the high-mannose or paucimannose type, accounting for 
over 90% of glycan complexity in Drosophila134. Bee venom extract was the first 
indication of the capability of insects to produce complex type N-glycans. 
Vandenborre et al.135 explored glycosylation differences comparing several 
economically important insects and found them to be involved in a broad range of 







Although O-glycans have been documented in invertebrates, with a wide variety of 
O-linked glycosylation is reported for Drosophila56, with important functions such as 
normal muscle development 117,136. Furthermore, the cell lines of Drosophila56 and 
several lepidopterans (moths)137 form mucin-type O-glycans. Unexpectedly, we were 
unable to detect O-glycans from sandfly saliva neither by b-elimination nor 
hydrazinolysis, even though bioinformatics analysis predicted the presence of 
proteins with putative O-glycosylation sites (data not shown). However, it is worth 
noting there is no real consensus sequence as in N-linked glycosylation, and 
predictions can be unreliable. Interestingly, similar results have been found in 
Glossina (unpublished), suggesting that for some reason these vectors may not be 
able to O-glycosylate proteins in salivary tissues. 
 
A surprising finding in this work are the glycans possessing an unidentified group of 
m/z 144. This modification, which was found in very low abundance (<1%), isomeric 
Man4GlcNAc2 glycans, appears susceptible to aqueous HF and located on different 
mannose residues as judge by digestion with JBAM (Fig. S7 and S8). A literature 
search revealed the presence of this m/z 144 as anhydrosugars on glycans from 
other organisms, including bacteria, viruses and sea algae138,139. However, the 
identity of the structure has not been solved, and its biological role is unknown. 
 
Antigenic sandfly salivary proteins are currently being explored as biomarkers or 
potential vaccine candidates. As recombinant versions of these proteins are normally 
expressed in non-insect cells140, care should be taken to ensure the glycoprotein’s 
activity remains the same. While well-known salivary proteins from Lu. longipalpis 
such as apyrase completely lack glycosylation sequons, others such as vaccine 
candidates LJM11, LJM17 and LJL143111 could, in fact, be potentially glycosylated. 
Several salivary proteins known to have a role in Leishmania infection141-143 are in 






The biological role(s) of protein glycosylation in the saliva of sandflies (and other 
blood feeder insects) is uncertain. It is possible that glycans help to stabilize insect 
salivary proteins once they enter into the bloodstream of the vertebrate host. 
Alternatively, based on the structures herein detected, these glycans may have an 
influence over other in vivo processes. This could be the case in the interactions with 
cell surface carbohydrate recognition domains like the mannose receptor and DC-
SIGN, which are C-type lectins on macrophages and dendritic cells; they play a role in 
both innate and adaptive immune systems144 and in the recognition of pathogen 
associated molecular patterns. In this work, we show these two proteins were able 
to specifically recognize a subset of N-glycans in sandfly proteins, which suggests a 
potential recognition of the receptors in vivo. Since mannose-type ligands are not 
common on the host’s own cells, the interaction of these receptors with pathogens 
and foreign molecules is specific78. The recognition of salivary proteins by 
macrophages could be involved in their uptake and subsequent stimulation of saliva-
specific immune responses, or the clearance of salivary components from the bite 
site. It is important to highlight that these lectin receptors exhibit differential binding 
specificity. For example, DC-SIGN exhibits the highest level of binding with high-
mannose sugars like Man9GlcNAc2, and affinity decreases with less mannose 
residues78. This means only certain glycoproteins are likely to bind and stimulate a 
response, if any, from the cells carrying these receptors.  
 
This, in turn, could be of importance within the context of Leishmania infection as 
both macrophages and dendritic cells have been shown to have critical roles in the 
initial stages of infection and subsequent dissemination of the parasite inside the 
vertebrate host145. In order for Leishmania to survive and multiply inside the host, it 
must be internalized by macrophages, and the MR can play a role in this process; 
promastigotes have reportedly avoid using this receptor during invasion, as MR 





saliva of Lu. longipalpis can prevent macrophages from presenting Leishmania 
antigens to T cells146; however, the effects of saliva are species-specific, as for 
instance the saliva of Ph. papatasi inhibits the activation of these cells147. Leishmania 
also exhibits interaction with the DC-SIGN receptor (particularly amastigotes and 
metacyclic promastigotes) and varies depending on species148. It remains to be seen 
whether the mannosylated glycoproteins in saliva impair or facilitate these 
interactions and their outcomes.  
 
Finally, it is also worth considering the roles glycoproteins could play inside the 
sandflies themselves. Both male and female sandflies feed on sugar solutions 
obtained from plant sources, and in order to survive they ingest them continuously 
throughout their lives. Some sandflies even show a marked preference for certain 
plant species. Cavalcante et al. showed that Lu. longipalpis ingests saliva while sugar 
feeding149. Lectins, proteins that exhibit specificity for different sugar structures, are 
crucial in plant defences against herbivores150. Perhaps the glycoproteins in insect 
saliva have a role in binding to these lectins to avoid any damaging effects of sugar 
feeding; this could also be extrapolated to arthropods that are exclusively 
herbivorous (including common pests and vectors of plant pathogens). Moreover, 
the ingestion of saliva during the bloodmeal may also impact parasite differentiation 
in the fly’s gut. In fact, infectious forms of Leishmania reside in the stomodeal valve 
until they are transmitted to a host, and may affect L. infantum metacyclogenesis in 
the sandfly midgut151. Parasite interaction with saliva and its components could 
therefore start well before they are co-transmitted to the host. 
 
On the other hand, sandfly-borne pathogens such as bacteria and viruses reach 
infectiousness inside the salivary glands until they are transmitted. When viruses 
replicate, they use the host cell machinery, which includes the insect glycosylation 





discussed in Chapter 5, understanding the glycosylation of insect salivary glands is 
relevant not only for sandfly-borne viruses but for all virus vectors. 
  
In summary, this work describes for the first time the glycan structure of sandfly 
salivary glycoproteins. Furthermore, we discuss the implications of these findings 










Chapter 3.  Exploring the salivary 
glycoproteome of bloodfeeding arthropods: the 





African sleeping sickness is caused by the parasite Trypanosoma brucei, which is 
transmitted by the bite of an infected tsetse fly vector while feeding. During a tsetse 
infection, trypanosomes induce a severe (~70%) transcriptional down-regulation of 
tsetse genes encoding for salivary proteins, which reduces its anti-haemostatic and 
anti-clotting properties. To better understand trypanosome transmission and the 
possible role of glycans in insect hematophagy, we characterized the N-glycome of 
tsetse saliva glycoproteins. 
 
Tsetse salivary N-glycans were enzymatically released, tagged with either 2-
aminobenzamide (2-AB) or procainamide, and analyzed by HILIC-UHPLC-FLR coupled 
online with positive-ion MS and MS/MS. 2-AB and procainamide labelled glycans 
showed good comparability, although procainamide labelling displayed higher 
fluorescence and MS signal intensity. We found that the N-glycan profiles of T. 
brucei-infected and naïve tsetse salivary glycoproteins are almost identical, 
consisting mainly of highly processed Man3GlcNAc2-Proc in addition to several other 
paucimannose, high mannose, and few hybrid-type glycans. We suggest that 
although the repertoire of tsetse salivary N-glycans does not change during a 





may reduce activation of immune cell glycan receptors and therefore facilitate 
parasite transmission into the vertebrate host.  
 
3.2 Introduction 
Haematophagous insects (many of them vectors of disease) have evolved special 
adaptations to ensure a successful bloodmeal from a vertebrate host. Key among 
these is their saliva, which is essential at the time of blood feeding. In these insects, 
salivary proteins counteract the pain and itch of the bite, while fighting host healing 
responses such as vasoconstriction and haemostasis 98. At the same time, salivary 
compounds can elicit immune responses that are specific to each bloodfeeding 
species, which in turn can affect the pathogens they transmit 98. Studies have also 
shown how vector salivary proteins are useful in disease control, either as markers 
of biting exposure and risk111 or as components of vaccines17. However, to date no 
studies have focused on the glycosylation of these proteins, and the role they could 
be playing during hematophagy or in the vector-host-pathogen interactions.  
 
N-glycosylation is a highly common post- and co-translational modification where 
the carbohydrate chain is covalently attached to an asparagine residue on a protein 
containing the consensus sequon Asn-X-Thr/Ser152. A vast majority of secreted, non-
cytosolic proteins are glycosylated241. N-glycans have a wide variety of functions, 
encompassing structural and modulatory properties to the binding of other proteins 
and cell-cell interactions153. As they are secondary gene products, glycoprotein 
biochemistry varies not only between species but also cell types within the same 
organism. N-glycosylation can affect protein folding, protein stability, ligand binding, 
and protein antigenicity51,152.  
 
In the discipline of glycobiology, insects remain a neglected area of study. Most 
research has focused on Drosophila 117, with some studies looking at beetles, 





paucimannosidic N-glycans, with some hybrid and -in less abundance- complex 
structures present in some species63. In Drosophila, N-glycans are important in 
several aspects, such as cell adhesion, morphogenesis, and locomotion, to name a 
few117. Compared to Drosophila, the structure and roles of N-glycans in 
haematophagous arthropods has been poorly investigated, particularly the salivary 
glycoproteins of disease vectors. Andrews et al. (1997) revealed glycoproteins in 
Anopheles gambiae salivary glands, 14 of which were female-specific. Poehling and 
Meyer (1980) discovered four low molecular weight glycoproteins in the salivary 
glands of female An. stephensi mosquitoes and Arca et al. (2007) suggested the 
30kDa allergen of Ae. albopictus may be glycosylated. N-linked glycoproteins have 
also been detected in the salivary glands of Ph. duboscqi sandflies128, suggesting they 
may have important functions for blood feeding in this vector.  
 
Tsetse flies are medically and economically important arthropod vectors in sub-
Saharan Africa, where they transmit the African trypanosomes that cause human 
African trypanosomiasis (HAT) and animal trypanosomiasis (Nagana disease). Both 
male and female tsetse flies are blood feeders, inoculating the host with around 4 µg 
saliva23whose components alter the host responses to the bite154. When tsetse feed 
on an infected mammalian host, they obtain blood form trypanosome parasites, 
which may establish infection within the vector to be transmitted to another 
mammalian host during the next blood meal.  
 
In this work we characterize and compare the tsetse fly (Glossina spp.) salivary 
glycome from naïve and trypanosome-infected flies. Using highly sensitive liquid 
chromatography and mass spectrometry, we revealed the presence of several 
salivary glycoproteins in tsetse saliva, with oligosaccharides characterized mainly by 
pauci-mannose and high-mannose N-glycans. Our work presents for the first 
structural analysis of salivary glycans from tsetse flies, and a comparison with 







3.3.1.  Tsetse flies 
G. m. morsitans adults were obtained from the tsetse insectary at the Liverpool 
School of Tropical Medicine (LSTM), where they are maintained at 26 ˚C and 65-75% 
relative humidity and fed for 10 minutes every two days on sterile, defibrinated 
horse blood (TCS Biosciences Ltd., Buckingham, UK). Saliva was collected in sterile 
PBS and stored at -20 °C. 
 
3.3.2.  Infection of G. m. morsitans 
Teneral (unfed) male G. m. morsitans were infected with T. b. brucei by combining 
1.5 ml T. b. brucei (TSW196)-infected rat blood with fresh, sterile, defibrinated horse 
blood (using the assumption each fly will consume 20 µl blood) to give a 
concentration around 5x105 parasites /ml (parasites kindly provided by Prof. Wendy 
Gibson). Flies were maintained for 4 weeks then dissected 48 hours after their last 
blood meal. Saliva was extracted and stored.  
 
3.3.3.  Enzymatic deglycosylation 
PNGase F (New England Biolabs): Glycoproteins were deglycosylated according to 
the manufacturer’s instructions. Briefly, 1x glycoprotein denaturing buffer (5 % SDS, 
0.4 M DTT) was added to 10 µg G. m. morsitans saliva and incubated at 100 ˚C for 10 
minutes. 1x G7 reaction buffer (0.5 M sodium phosphate pH 7.5), 1 % NP40 and 1µl 
PNGase F were added and incubated at 37˚C overnight. A negative control of G. m. 
morsitans saliva was ‘mock treated’ under the same except PNGase F. Egg albumin 






3.3.4.  SDS-PAGE analysis of salivary proteins 
Salivary proteins were resolved by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). For Coomassie blue staining, InstantBlue (Expedeon, 
Cambridge-UK). For Schiff’s stain, Pierce Glycoprotein Staining kit was used 
(ThermoFisher, UK).  
 
3.3.5.  Western Blotting 
Saliva from G. m. morsitans was treated with PNGase F (New England Biolabs), 
resolved by SDS-PAGE and transferred onto a Hybond-polyvinylidene difluoride 
(PVDF) membrane (Amersham Biosciences) at 90V for 1 hour. Transfer was verified 
with Ponceau Red (Sigma-Aldrich), blocked for 1 hours (PBS-T containing 5% skim 
milk powder) and incubated in 1:10,000 dilution primary anti-G. m. morsitans saliva 
overnight at 4˚C. The primary antibody, anti-G. m. morsitans saliva antibody was 
raised in rabbits (kindly provided by Prof. Jan Van Den Abbeele, from Institute of 
Tropical Medicine Antwerp, Belgium). The membranes were washed and probed at 
room temperature for 1 hour with 1:20,000 secondary goat-anti-rabbit antibody 
(ThermoFisher, UK). The membranes were again washed in PBS-T. Super Signal West 
Dura substrate (ThermoFisher, UK) was used.  
 
3.3.6.  Concanavalin A blotting 
Saliva samples, before and after treatment with PNGase F (New England Biolabs, US) 
were run on a 12.5% polyacrylamide gel under standard conditions, transferred onto 
a PVDF membrane, and blocked with 1% BSA in PBS-Tw 20 overnight at 4°C. 
Membrane was incubated with 1ug/ml biotinylated Con A lectin (Vector Labs, 
Peterborough, UK) for 1 hour at room temperature. After washing, the membrane 
was incubated with 1:100000 streptavidin-HRP (Vector Labs, Peterborough, UK). 
SuperSignal West Pico Chemiluminescent substrate (ThermoFisher, Massachusetts, 






3.3.7.  Overlay assays with C-type lectins 
Saliva samples were treated overnight with PNGase F (New England Biolabs, US) to 
remove glycans. Samples were run on a 12.5% polyacrylamide gel, transferred onto 
a PVDF membrane, and blocked overnight with 1% BSA (Sigma). Membranes were 
incubated with CTLD4-7Fc (0.5µg/µl) or DC-SIGN (0.5µg/µl) (R&D Systems) for 1 
hour, washed, and then incubated with anti-human IgG conjugated to HRP for 1 
hour. After washing, WestDura substrate (ThermoFisher Scientific, US) was used to 
develop the membranes. 
 
3.3.8.  Stimulation of macrophages with tsetse saliva and flow cytometry 
analysis 
Promonocytic cells of the U937 and U937 + DC-SIGN lines155 were differentiated 
using 100ng/ml PMA for 48 hours, washed and followed by 48 hours of rest. Cells 
were transferred onto 96-well plates and then stimulated with different 
concentrations of tsetse saliva, lipopolysaccharide (Sigma) as positive control or left 
unstimulated for 2 hours. Golgi stop (BD sciences) was added to prevent cytokine 
secretion and left for another 2 hours. Cells were washed and then incubated with 
antibodies for 45 min at 4C in complete darkness. Antibody panel was used to 
measure: DC-SIGN, Mannose receptor, Toll 2, Toll 4, CD80, CD86, CD11b, TNFa, IL10 
and IL12. Cells where then washed and the different conditions evaluated by flow 
cytometry.  
 
3.3.9.  Mass spectrometry analysis 
To identify the glycoproteins that were susceptible to PNGase F cleavage, 10 µg 
salivary proteins were enzymatically cleaved, resolved in a 12 % precast gel (Novex) 
and Coomassie stained. Bands of interest were extracted and sent to the Dundee 





to in-gel trypsination then alkylated with iodoacetamide. The resultant peptides 
were analyzed via liquid chromatography- tandem mass spectrometry (LC-MS/MS) in 
a Thermo LTQ XL Linear Trap instrument equipped with a nano-LC. 
 
The data was supplied in MASCOT format. The gi| numbers for the top hits in each 
band were searched in NCBI Protein (http://www.ncbi.nlm.nih.gov/protein) to yield 
the FASTA format of the protein sequence. This was then queried in PROWL 
(http://prowl.rockefeller.edu/) to reveal the predicted molecular weight and also to 
predict tryptic peptides in the sequence. The FASTA protein sequence was also 
queried in the SignalP 4.0 Server software187 to predict the signal peptide location 
and NetNGlyc 1.0 (http://www.cbs.dtu.dk/services/NetNGlyc/) to reveal potential N-
glycosylation sites.  
 
3.3.10.  Release of N-linked glycans  
The N-glycans from teneral fly saliva were released by in-gel deglycosylation using 
PNGase F as described in [2]. For deglycosylation using PNGase A, peptides were 
released from gel pieces by overnight incubation at 37°C with trypsin in 
25mMammonium bicarbonate. The supernatant was dried, re-suspended in water 
and heated at 100°C for 10 min to deactivate the trypsin. Samples were dried by 
vacuum centrifugation and the tryptic peptide mixture was incubated with PNGase A 
in 100mM citrate/phosphate buffer (pH 5) for 16 hours at 37°C [3]. Samples were 
separated from protein and salts by protein-binding plate. The glycans pass straight 
through the protein binding membrane but all wells were flushed with extra water 
to ensure full recovery and then dried by vacuum centrifugation prior to fluorescent 
labelling.  
 
3.3.11.  Release of O-linked glycans 
The O-glycans were released according to Kozak et al242. Briefly, teneral fly saliva 





acid (TFA) using a centrifugal filter device (10 kDa, molecular weight cut off 
membrane) and dried down for 16 hours by vacuum centrifugation. The O-glycans 
were released by addition of hydrazine and incubated at 60°C for 6 hours. Hydrazine 
was removed by centrifugal evaporation. The samples were placed on ice for 20 min 
(0°C) and were re-N-acetylated by the addition of a 0.1 M sodium bicarbonate 
solution (200 µL) and acetic anhydride (21 µL).  Samples were mixed and incubated 
at 0°C for 10 min. A further aliquot of acetic anhydride (21 µL) was added to each 
sample followed by vortexing and incubation at room temperature for 60 min. 
Released O-glycans were cleaned up by passing them through a LudgerClean CEX 
cartridges (Ludger Ltd). The glycans were eluted off the cartridges using water and 
dried by vacuum centrifugation prior to fluorescent labelling. 
 
3.3.12.  Fluorescent labelling with 2-Aminobenzamide and purification 
Released N- and O-glycans were fluorescently labelled via reductive amination 
reaction with 2-AB using a Ludger 2-AB Glycan Labelling Kit containing 2-picoline 
borane (Ludger Ltd.). The released glycans were incubated with labelling reagents 
for 1 hour at 65°C. The 2-AB labelled glycans were cleaned up using LudgerClean T1 
Cartridges (Ludger Ltd.). 2-AB labelled glycans were eluted from the LudgerClean T1 
Cartridges (1ml) with water. The samples were evaporated to dryness under high 
vacuum using centrifugal evaporation and re-suspended in water (100 μl) for further 
analysis. 
 
3.3.13.  Fluorescent labelling with Procainamide and purification 
Released N- and O-glycans were fluorescently labelled via reductive amination 
reaction with procainamide using a Ludger Procainamide Glycan Labelling Kit 
containing 2-picoline borane (Ludger Ltd.). The released glycans were incubated with 
labelling reagents for 1 hour at 65°C. The procainamide labelled glycans were 
cleaned up using LudgerClean S Cartridges (Ludger Ltd). Procainamide labelled 





samples were evaporated to dryness under high vacuum using centrifugal 
evaporation and re-suspended in water (100 μL) for further analysis. 
 
3.3.14.  Exoglycosidase sequencing  
Exoglycosidase digestion was performed according to Royle et al. [4]. The released, 
2-AB labelled N-glycans were incubated with exoglycosidases at standard 
concentrations in a final volume 10 µL in 50 mM sodium acetate (for incubations 
with JBAM, 250 mM sodium phosphate, pH 5.0 was used) for 16 hours at 37°C. 
Glycans were incubated with different exoglycosidases in different sequences: (i) 
Streptococcus pneumonia ß-N-acetylglucosaminidase (GUH); (ii) Jack bean α-(1-
2,3,6)-Mannosidase (JBAM); (iii) Bovine kidney α-(1-2,3,4,6)-Fucosidase (bkF). After 
digestion, samples were separated from the exoglycosidases by binding onto a 
LudgerClean Post- Exoglycosidase clean-up plate (Ludger Ltd.) for 60 min followed by 
elution of the glycans from the plate with water. The samples were analyzed by 
HILIC-UPLC. 
 
3.3.15.  UHPLC analysis 
2-AB labelled samples were analyzed by HILIC-UPLC using an ACQUITY UPLC® BEH-
Glycan 1.7 µm, 2.1 x 150 mm column at 60 °C on a Dionex UltiMate 3000 UHPLC 
instrument (Thermo, UK) with a fluorescence detector (Ex = 250 nm, Em = 428 nm), 
controlled by Chromeleon data software version 6.8. Gradient conditions were: 0 to 
53.5 min, 24% A (0.4 mL/min); 53.5 to 55.5 min, 24 to 49 % A (0.4 mL/min); 55.5 to 
57.5min, 49 to 60% A (0.4 to 0.25 mL/min); 57.5 to 59.5 min, 60% A (0.25 mL/min); 
59.5 to 65.5 min, 60 to 24% A (0.4 mL/min); 65.5 to 66.5 min, 24% A (0.25 to 0.4 
mL/min); 66.5 to 70 min 24% A (0.4 mL/min). Solvent A was 50 mM ammonium 
formate; solvent B was acetonitrile (Acetonitrile 190 far UV/gradient quality; Romil 
#H049). Samples were injected in 24% aqueous/76% acetonitrile; injection volume 
25 µL. Chromeleon software retention index function with a cubic spline fit was used 





was used as a system suitability standard as well as an external calibration standard 
for GU allocation on the system. 
 
3.3.16.  Online HILIC-SPE LC-MS analysis 
Procainamide labelled glycans were taken up in 0.1 % TFA (v/v) in 78% acetonitrile 
(v/v) and desalted on-line using hydrophilic interaction liquid chromatography solid 
phase extraction before direct elution onto the mass spectrometer. Glycans were 
injected onto a HILIC trap column (ACQUITY UPLC® BEH-Glycan 1.7 μm, 2.1 × 150 
mm) at a flow rate of 1.5 µl/min using an UltiMate 3000 LC (Thermo Scientific). The 
trap was washed with 0.1% formic acid in 90% ACN (v/v) for 4 min followed by 
elution of samples using an isocratic gradient of 0.1 % formic acid in 27 % ACN (v/v) 
for 12 min. Glycans were analysed using electrospray ionisation tandem mass 
spectrometry (ESI-MS/MS) on an amaZon speed ETD ion trap MS (Bruker).  
 
3.3.17.  ESI-LC-MS and ESI-LC-MS/MS analysis 
Procainamide labelled samples were analysed by ESI-LC-MS. 25 µL of each sample 
was injected onto an ACQUITY UPLC® BEH-Glycan 1.7 µmn, 2.1 x 150 mm column at 
40 °C on the Dionex Ultimate 3000 UHPLC attached to a Bruker Amazon Speed ETD 
(Bruker, UK). The running conditions used were: Solvent A was 50 mM ammonium 
formate pH 4.4; solvent B was acetonitrile (acetonitrile 190 far UV/gradient quality; 
Romil #H049). Gradient conditions were: 0 to 53.5 min, 24% A (0.4 mL/min); 53.5 to 
55.5 min, 24 to 49 % A (0.4 mL/min); 55.5 to 57.5min, 49 to 60% A (0.4 to 0.25 
mL/min); 57.5 to 59.5 min, 60% A (0.25 mL/min); 59.5 to 65.5 min, 60 to 24% A (0.4 
mL/min); 65.5 to 66.5 min, 24% A (0.25 to 0.4 mL/min); 66.5 to 70 min 24% A (0.4 
mL/min). The Amazon Speed settings used were: source temperature 250 °C, gas 
flow 10 L/min; Capillary voltage 4500 V; ICC target 200,000; max accu time 50.00 ms; 
rolling average 2; number of precursors ions selected 3, release after 0.2 min; 
Positive ion mode; Scan mode: enhanced resolution; mass range scanned, 200-1500 








3.4.1.  Tsetse salivary glycoproteins are mainly N-glycosylated 
As a first step, we performed a bioinformatic analysis to find potential glycosylation 
sites on tsetse salivary proteins, looking at proteins having the Asn-X-Ser/Thr 
sequons. Using the NetNGlyc server118, we found that 72% of Glossina proteins have 
at least one glycosylation site (Table S3.1). However, although the consensus 
sequence is a prerequisite for the addition of glycans to the asparagine, it does not 
guarantee their glycosylation in vivo. Schiff’s stain was used to detect 
polysaccharides in glycoconjugates through an oxidation reaction that produces a 
magenta colour. After separating saliva by SDS-PAGE, Schiff’s staining indicated 
several glycoproteins at different molecular weights Figure 3.1. 
 
 
Figure 3.1 Schiff’s staining of G. m. morsitans salivary glycoproteins after enzymatic cleavage 
with PNGase F. 10 µg G. m. morsitans salivary proteins (A) and egg albumin (B) were incubated 
overnight with (+) and without (-) PNGase F to cleave N-glycans from any present 
glycoproteins. These were resolved on a 12 % SDS-PAGE gel (Novex) and stained with Colloidal 
Coomassie Blue or Schiff’s Staining. There was a notable shift in migration in 4 bands (1-4) 
following PNGase F treatment when stained with Coomassie blue, and these bands 
disappeared following Schiff’s staining, confirming these proteins are N-glycosylated. Asterisk 














To learn the types of glycosylation present in tsetse saliva, we first treated samples 
with PNGase F in similar conditions to that described in Chapter 2.  The loss of mass 
resulting from the removal of glycans can be visualized as an electrophoretic shift 
shift by SDS-PAGE. PNGase F treatment of saliva resulted in a shift in the molecular 
weight of several glycoproteins, demonstrating they are N-glycosylated. A much 
darker area was observed at the higher molecular weight proteins following 
enzymatic cleavage, indicating the presence glycoproteins that are only detected 
because of their faster migration following this loss of mass. Furthermore, after 
treatment with PNGase F we cannot detect the glycoproteins by Schiff’s stain, 
indicating they are N-linked, and that any fucose residues attached to the core 
GlcNAc are likely to be a-1,6 linked. G. morsitans salivary proteins were annotated 
using mass spectrometry Figure 3.2 and complemented using published data.  
 
 
Figure 3.2. Enzymatic cleavage of G. m. morsitans salivary glycoproteins with PNGase F. G. m. 
morsitans salivary proteins (A) and egg albumin (B) were incubated overnight with (+) and 
without (-) PNGase F (New England Biolabs) a) 10 µg PNGase F-treated G. m. morsitans salivary 
proteins (A) and egg albumin (B) were resolved via SDS-PAGE and Coomassie-stained. There 
was a notable shift in migration in 4 bands (1-4) following PNGase F treatment. These bands 
were excised from both treatments, trypsinised and analysed via MALDI-TOF MS to reveal the 
identity; 1. 5’ Nucleotidase; 2. TSGF 2/Adenosine deaminase; 3. TSGF 1; 4. Tsal 1/2. * PNGase 
F. c) 1 µg PNGase F-treated Egg albumin (A) and teneral G. m. morsitans saliva (B) were 
resolved by SDS-PAGE and transferred onto a PVDF membrane. This was blocked with CARBO-
free blocking solution (Vector Labs) and probed with 2 µg/ml biotinylated Concanavalin A 






Table 3.1 Mass spectrometry and bioinformatics data for Figure 3.2. This table details the 
molecular weight, glycosylation data and peptide coverage of each protein that is labelled in 
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P3.1 ≈57 kDa gi|289739673 TSGF12 ≈54 kDa 1 Asn339 - 59% 
P3.2 ≈55 kDa gi|289739673 TSGF12 ≈54 kDa 1 Asn339 - 59% 
P4.2 ≈42 kDa gi|8927464 Tsal14 ≈44 kDa 1 Asn346 - 80% 





3.4.2.  Characterization of G. m. morsitans salivary N-glycan structures by 
Hydrophilic Interaction Liquid Chromatography and Mass 
Spectrometry 
 
To determine the N-glycome of G. m. morsitans saliva, glycans where released by 
PNGase F, purified and tagged 2-aminobenzamide, a fluorescent label for 
chromatographic detection. HILIC analysis revealed 13 peaks that correspond to N-
glycan structures. The peak of highest intensity (abundance) corresponds to the core 
structure Man3GlcNAc2-Proc. After treatment with PNGase A, which cleaves all N-
linked glycans even when there is a fucose residue a-1,3 linked to the core GlcNAc, 
the profile of glycans did not show difference to the one obtained by PNGase F 
digestion (Figure S3). This confirms the fucose seen in peak 3 in Fig 2 is likely to be a-
1,6 linked. 
 
Figure 3.3. Teneral Fly Saliva N-glycans before and after digestion with exoglycosidases. 
Aliquots of the total PNGase F-released 2-AB-labeled N-glycan pool were incubated with a 
range of exoglycosidases, as shown in each panel. (a) before digestion, (b) GUH; Streptococcus 
pneumonia in E Coli b-N-acetylglucosaminidase, (c) JBM; Jack bean α-(1-2,3,6)-Mannosidase, 
(d) bkF; Bovine kidney α-(1-2,3,4,6)-Fucosidase. Following digestion, the products were 





percent areas and structures of the different glycans detected by this method are listed in 
Table 3. 
 
Table 3.2 Exoglycosidase digestion data for 2-AB labelled N-glycans released from Teneral Fly 
Saliva by PNGase F. c Numbers are percentage areas b Digestion product only. Undig, 
undigested whole glycan pool. Glycan symbols: GlcNAc (blue square), Man (green circle), Gal 




To further characterise the structure of these glycans, they were treated with 
exoglycosidases of different specificities: GUH, resulted in a reduction of peaks 4, 6 
Undig GUH JBM bkF + JBM
0.00
5.94 6.38 0.00 0.00









12 8.84 2.13 3.08 0.00 0.00
0.00 0.00




6 5.74 1.53 0.00 0.46
7 6.17 8.41 10.04
0.00
0.00
5 5.18 3.09 5.55 0.00 0.00
2.23 4.05 0.00
4 4.96 4.06 0.00 3.32
0.00
2 4.34 55.35 52.06 0.00 0.00
3 4.83
0.00 90.64 91.44
1 3.84 1.59 2.85 0.00
HPLCP
eak Id
GU          
(2-AB)
Enzymes used a








and 8, indicating the presence of a terminal non-reducing b-GlcNAc residues in these 
structures. On the other hand, disappearance of the peaks after treatment with 
JBAM, which hydrolyses terminal α-1-2, α-1-3 and α-1-6 linked mannose residues, 
identifies all structures (except 4, 6 and 8) as oligomannose. Peak information after 
enzymatic treatment is further detailed in table C. 
 
Salivary glycans were labelled with procainamide, a fluorescent tag that increases 
the sensitivity of detection by mass spectrometry, and then analyzed by positive ion 
mode Electrospray Ionization MS (ESI-MS). The resulting mass spectra confirms the 
findings by HPLC, showing the presence of 12 different glycan structures (Figure 3.4,  
Table S3.2). Salivary N-glycan structures are mainly oligomannose, Man3-9GlcNAc2, 
[m/z]2+ 565.74, 646.74, 727.79, 808.81, 889.84, 970.87, and 1051.90 (respectively).  
with the presence of three complex type glycans with truncated antenna: 
Man3GlcNAc2Fuc, Man3GlcNAc3, and Man4GlcNAc3. Glycan structures were further 
corroborated by positive ion MS/MS fragmentation spectra, including the most 
abundant species Man3GlcNAc2 [m/z]+ 1130.55 as well as Man3GlcNAc2Fuc [m/z]+ 
1276.57 and Man3GlcNAc3 [m/z]+ 1333.59 (Figure 3.5). Details on these structures 
can be found in Table S3.2.  
 
Figure 3.4. Summed mass spectra of Procainamide labelled N-glycans released from Teneral 







Figure 3.5 Singly charged MS2 positive-ion fragmentation spectra of procainamide labelled 
structures of teneral fly saliva corresponding to: a) m/z 1130.49, b) m/z 1276.52, c) m/z 
1333.57 ions. 
 
3.4.3.  Infection with T. b. brucei alters G. morsitans salivary protein 
concentrations, but glycosylation remains unaffected 
 
Since it has been shown that infection with T. brucei affects the production of saliva 
in the tsetse fly, we wanted to explore if it affected salivary glycosylation as well. 
Initially, we used SDS-PAGE compared the profiles of saliva from flies that were 
uninfected (controls), with those that had either a salivary gland or a midgut 
infection with T. b. brucei (Figure 3.6). As expected, there was a slight decrease in 
the intensity of the bands for flies with salivary gland infection, even though equal 
concentrations of proteins were loaded. Midgut infection also seemed to have an 
effect on the quantity of some salivary proteins. Notably, proteins around 190kDa, 










































































Figure 3.6 SDS-PAGE of Glossina morsitans salivary profiles obtained from different stages of 
infection. Saliva samples are as follows: Lane 1 = young unfed flies (Teneral); Lane 2 = 4-week 
old, bloodfed flies (Bloodfed); Lane 3 = flies with salivary gland T. brucei infection (Salivary 
inf.); Lane 4 = flies with midgut T. brucei infection (Midgut inf.) 
 
Next, we also investigated whether T. b. brucei infection alters the glycosylation 
pattern of salivary proteins, since N-glycosylation is important for protein secretion. 
As before, glycans were released using PNGase F and labelled with procainamide, 
then analyzed by HILIC and MS. Figure 3.7 shows the HILIC chromatogram, where 
both naïve and infected saliva have the same glycan profile. A comparison of the 
peaks from teneral, naïve and infected fly saliva are detailed in Table 3.3. This is 
confirmed by the MS spectra (Figure 3.8), showing that salivary glycan structures 
and abundances remain unaffected by infection with T. brucei. However, when 
comparing teneral versus naïve flies, there seems to be a variation in several peaks 
(e.g. Table 3.3, peaks 4, 9, 10 and 13), which could be an effect of blood ingestion. 
 




































Figure 3.7 Comparison of HILIC-(U)HPLC profiles of N-glycan released by PNGaseF from: a) 
Teneral Fly Saliva, b) Naïve Fly Saliva, c) Infected Fly Saliva. Structures of the N-glycans are 
listed in Table 3 with the relative abundance listed in Table 3.1 
 
Table 3.3 Comparison of relative abundance of N-glycans released by PNGase F from teneral, 
naïve and infected tsetse fly saliva 
HPLC Peak Id 
Teneral Naïve Infected 
GU  % Area GU  % Area GU  % Area 
1 3.84 1.59 3.84 0.51 3.84 0.83 
2 4.34 55.35 4.34 54.67 4.34 53.55 
3 4.83 2.23 4.83 2.78 4.83 3.80 
4 4.96 4.06 4.96 10.57 4.96 10.23 
5 5.18 3.09 5.18 1.48 5.18 1.70 
6 5.74 1.53 5.74 1.67 5.74 1.74 
7 6.17 8.41 6.17 8.17 6.17 8.86 
8 6.66 1.76 6.66 1.39 6.66 1.28 
9 7.06 5.94 7.06 3.93 7.06 3.55 
10 7.97 7.70 7.97 5.15 7.98 4.87 
11 8.71 1.37 8.72 2.27 8.72 1.97 
12 8.84 2.13 8.84 1.35 8.84 1.33 
13 9.54 4.86 9.54 6.06 9.54 6.28 
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Figure 3.8 Comparison of summed mass spectra of Procainamide labelled N-glycans released 
from: a) Naïve Fly Saliva b) Infected Fly Saliva, analysed by ESI-MS. Numbers refer to the 
structures shown in Table 1. Glycan symbols: GlcNAc (blue square), Man (green circle), Gal 
(yellow circle), Fuc (red triangle). 
 
3.4.4.  Trypanosome infection does not alter immunogenicity of tsetse 
salivary glycoproteins 
 
The effects of trypanosome infection on immunogenicity of tsetse salivary 
glycoproteins was evaluated by immunoblotting. We compared the saliva of flies 
with both midgut and salivary gland infection, before and after treatment with 
PNGase F (Figure 3.9). For probing, we used a polyclonal anti-G. m. morsitans saliva 
serum, obtained from inoculation of rabbits. Recognition of G. m. morsitans saliva 
before and after cleavage of the glycans appears to remain unaffected. However, we 
can observe something interesting during salivary gland infection. The polyclonal 
serum only detects the high molecular weight proteins (100-130kDa) after the 


















































downregulation of other salivary proteins during infection and seems to be 
concealed both in the saliva of uninfected flies and those with midgut infection.  
  
 
Figure 3.9 T. brucei infection does not alter immune recognition of tsetse salivary proteins. a) 
~2 µg PNGase F-treated G. m. morsitans saliva proteins and fractionated via SDS-PAGE and 
transferred onto a PVDF membrane. This was blocked with 5 % skimmed milk in PBS-T, probed 
with an anti-G. m. morsitans saliva antibody (1:10,000) and a goat-α-rabbit secondary 
antibody (1:20,000) conjugated with HRP; b) Nigrosine-stained membrane; c) Concanavalin A 
detection of mannosylated glycans. Experiment carried out by Chris Williams. 
Interestingly, saliva from T. b. brucei salivary gland-infected flies displayed a ~20kDa 
band that is faintly seen on the SDS-PAGE gel and is absent from uninfected saliva 
following western blotting.  
 
3.4.5.  Similar to G. morsitans, salivary glycoproteins from mosquitoes and 
triatomines seem to be mainly mannosylated 
 
Considering these results, we wondered how the saliva of tsetse flies would compare 
to that of other vector insects; we obtained saliva from Ae. aegypti, An. gambiae, 
Rhodnius prolixus and Triatoma infestans. ConA blotting of saliva from these species, 
before and after treatment with PNGase F, revealed the presence of several N-linked 
mannosylated glycoproteins (Figure 3.10). This initial approach suggests shared 
salivary glycosylation pathways, where the saliva of these vector species (and 
possibly others not analyzed yet) is mainly oligomannose. Ongoing work is looking at 
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differ between insects, and if we can find O-linked glycoproteins which have been 
absent in the tsetse fly.  
 
Figure 3.10. Detection of mannosylated salivary N-glycoproteins with Concanavalin A. Saliva 
from female Aedes aegypti (1,2), Anopheles gambiae (3,4), Rhodnius prolixus (5,6) and 
Triatoma infestans (7,8), were run on SDS-PAGE before (-) and after (+) treatment with 
PNGase F (P-f). Egg albumin (OVA) and Bovine Serum Albumin (BSA) were used as positive 
and negative controls, respectively. After transfer onto a PVDF membrane and blocking (1% 
BSA in 0.05% TPBS), membranes were incubated with 0.5 µg/ml biotinylated Concanavalin A 
(Vector Labs) for 30 min and washed with 0.05% TPBS. Following incubation with 1:100,000 
streptavidin-HRP (Vector Labs) for 30 min and washing, substrate (SuperSignal™ West Dura, 
ThermoFisher) was added. Panel A: ConA detection, Panel B: nigrosine-stained membranes 
after chemoluminescence development.  
 
3.4.6.  N-glycans from G. morsitans salivary glycoproteins are recognised 
by mannose receptors on human macrophages and dendritic cells. 
 
To further understand the potential biological role of the G. m. morsitans salivary 
glycoproteins, we explored how the abundant mannosylation was recognised by 
cells from the immune system. Endocytic C-type lectin receptors, such as 





grabbing nonintegrin (DC-SIGN), can recognize exposed mannose residues on 
glycoproteins. Using recombinant CTLD4-7-Fc and recombinant Human DC-SIGN Fc 
Chimera proteins, the carbohydrate-binding domains from these two receptors, we 
performed overlay assays using saliva before and after treatment with PNGase F 
(Figure 3.11).  
 
 
Figure 3.11. Recognition of salivary glycoproteins by C-type lectin receptors. Samples were 
untreated (-) or treated (+) with PNGase F to remove glycans. G. morsitans (Gmm) or Lu 
longipalpis (Lulo) saliva were run on SDS-PAGE and transferred onto a PVDF membrane and 
then probed with either (a) CTLD4-7Fc or (c) DC-SIGN (c) egg albumin (OVA) and BSA were 
used as positive and negative controls, respectively. After exposure to the lectins, 
membranes incubated with anti-human IgG-HRP, and developed by chemiluminescent using 
SuperSignal West Pico as substrate. (e) recognition of sandfly glycoproteins by CTLD4-7Fc 
and DC-SIGN recombinant fractions.  




















Our results show that CTLD4-7-Fc recognized 4 glycoproteins in Gmm saliva, while 
DC-SIGN recognized only two of them. Disappearance of the signal after PNGase F 
confirms specificity of binding to N-linked mannosylated glycans. We repeated the 
overlay assay using saliva of Lu. longipalpis, and observed wide recognition of several 
proteins. 
 
3.4.7.  O-linked glycoproteins were not detected in G. m. morsitans saliva 
 
In O-linked glycosylation, the sugar is transferred to a serine or threonine on the 
polypeptide243, and their release from the proteins can be performed by b-
elimination or hydrazinolysis. Analysis by ESI-MS after b-elimination did not show 
any O-glycans released from tsetse saliva. This confirms the results obtained before 
by Schiff's staining after treatment with PNGase F (Fig. S2), and together with the 
results obtained from PNGase A treatment, suggests that the faint bands observed 
after deglycosylation (+) are likely a result of incomplete enzymatic digestion. 
 
 
Figure 3.12. β-elimination of tsetse fly salivary glycoproteins. Released and reduced O-
glycans were separated using a porous graphitised carbon column coupled with ESI-MS, as 




Our work reveals for the first time, the composition and structure of the sugars that 





African trypanosomiasis. We found that the tsetse salivary profile contains several 
glycoproteins, which enzymatic analysis coupled with highly sensitive 
chromatography and mass spectrometry have revealed to be mainly oligomannose, 
with the addition of some hybrid-type glycans. They range from the core 
Man3GlcNAc2 to Man9GlcNAc2, with the former being the most abundant structure. 
Three hybrid structures have terminal GlcNAc, Man3GlcNAc (m/z 667.37), 
Man4GlcNAc3 (m/z 1495.65), and Man5GlcNAc3 (m/z 889.90). Only one glycan was 
found to be fucosylated, FucMan3GlcNAc2, suggesting that the majority of the sugars 
remain unmodified after processing. 
 
Many studies on insect glycobiology have focused on the model fly, Drosophila 
melanogaster, where they have been implicated in several biological functions, from 
embryonic development up to flight and movement117. As the field of invertebrate 
glycobiology expands, more work has been published on other insects such as bees, 
butterflies and beetles60, 135. In general, insect glycans have been described as mostly 
oligomannose, although complex glycans with terminal GlcNAc have also be found to 
be common135. Others with terminal sialic acid have rarely been found 156. Core 
fucosylation, both a1-3 and a1-6, is also quite common in insect glycans 157 and 
described as involved in allergic responses158. Tsetse salivary glycans fit with this 
pattern, exhibiting the commonly described glycans.  
  
Some studies have previously described the presence of some salivary glycoproteins 
in tsetse flies. Back in 1981, Patel et al. suggested that G. m. morsitans contained 
four salivary glycoprotein bands, while Ellis et al. (1986) reported as many as 7 in G. 
m. centralis saliva. There have been suggestions of predicted N-glycosylation sites in 







Caljon et al (2010) reported on the putative glycosylation of salivary 5’nucleotidase 
(5’Nuc) apyrase, a salivary protein that interrupts formation of the haemostatic plug 
by hydrolysing ATP and ADP161. NetNGlyc identifies four glycosylation sites in the 
peptide sequence, and Caljon et al report a 5kDa loss in mass after PNGase F 
treatment (which agrees with our results); strikingly, they also show that 5’Nuc 
transcription only occurs in salivary glands. The potent activity of a recombinant 
non-glycosylated form of 5’Nuc suggests glycosylation itself is not important for its 
activity; however, it might play a role in the recognition of this salivary protein by 
cells of the immune system and its subsequent clearance from the bloodstream. 
Interestingly, bioinformatic analysis of the 5’Nuc apyrases of Anopheles, Aedes, 
Rhodnius and Triatoma a also predicted to have 2 or more glycosylation sites (data 
not shown). Van Den Abbeele and colleagues (2010) demonstrated the reduction of 
apyrase activity following T. b. brucei infection by quantifying the release of Pi from 
ADP and ATP, and it is thought that a similar protocol could be performed on N-
glycosylated and N-deglycosylated saliva to reveal the role of glycosylation in salivary 
proteins with apyrase activities, including 5’ Nuc23.  
 
Glycoproteins have also been described in other tsetse tissues. Rose et al (2014) 
identified peritrophins and peritrophin-like glycoproteins in the peritrophic matrix 
(PM) of G. m. morsitans162. These proteins are involved in maintaining the stability of 
the PM, a structure that surrounds in the bloodmeal and protects the fly from 
harmful components present in the bloodmeal.  
 
There are few reports of salivary glycosylation in other bloodfeeding insects. One 
such example is Chrysoptin, a glycoprotein found in the saliva of haematophagous 
deerflies of the Chrysops genus, which inhibits platelet aggregation by preventing 
the binding of fibrinogen to the glycoprotein IIb/IIIa receptor163; the authors found 
that glycosylation was essential for the activity of chrysoptin. Another example are 





the saliva of Lu. longipalpis, but only through lectin recognition (this thesis, Chapter 
3). On the other hand, salivary glycoproteins related to sugar feeding have also been 
found. a-glucosidase is an enzyme that plays a role in sugar metabolism (normally in 
the midgut), supplying monosaccharides to different pathways. Suthangkornkul et al 
(2015) described the presence of this enzyme in the saliva of the mosquito Culex 
quinquefasciatus, and showed it was an N-linked glycoprotein susceptible to 
digestion with Endo H164. In other bloodfeeders, this enzyme has additional 
functions, such as heme detoxification in the midgut of the triatomine Rh. 
prolixus165.  
 
The abundance of oligomannose glycans leads us to hypothesize about possible 
ways these might interact with the host immune system. Several receptors involved 
in host responses have carbohydrate binding domains166. One example is the 
mannose receptor, or MR. The MR is an endocytic receptor expressed in certain 
populations of macrophages and dendritic cells, where it participates in the 
clearance of molecules and antigen presentation, among others72. The C-type lectin-
like domain (CTLD) of the MR can bind glycosylated molecules with terminal Man, 
Fuc or GlcNAc. Here we show that a recombinant CTLD4 can recognize several N-
glycans from tsetse saliva. Studies have suggested that macrophage activation is 
detectable soon after infection in mice167. T. brucei variant surface glycoproteins 
have a role in macrophage activation168, perhaps promoting a Th1 response. Another 
study showed that infection with T. brucei caused a reduction in several macrophage 
receptors, including the MR 169. Binding of tsetse salivary glycoproteins to the MR 
might modulate some of these processes, but it remains to be seen exactly how. 
Interestingly, in a mouse trypanosomiasis model using T. musculi, injection of 
mannose or knockdown of the MR resulted in reduced parasite loads170. Caljon et 
al106 showed that tsetse saliva accelerates the onset of infection with T. brucei 





also be involved in the clearance of salivary components from tissues or 
bloodstream.  
 
Another example of these receptors is the DC-SIGN, a dendritic cell receptor 
involved in antigen presenting and the initial recognition of pathogens. Its 
carbohydrate recognition domains bind to high-mannose oligosaccharides, which 
mediates dendritic cell recognition of pathogens like Mycobacterium tuberculosis 
and Leishmania 171,172. Here, we use a recombinant fraction of the DC-SIGN and 
show that it recognizes some salivary glycoproteins from tsetse saliva. Strikingly, the 
DC-SIGN seems to recognize less tsetse glycoproteins than the MR, possibly due to 
the specificity of the receptors78. We have carried out some preliminary experiments 
using a cell line in its native form versus one that overexpresses the DC-SIGN 
receptor; this allowed us to compare the effects of saliva stimulation between the 
two, to try and elucidate how much of the response is caused by salivary glycans 
engaging this receptor. We measured the expression of various receptors such as 
DC-SIGN and MR, as well as cytokines like TNFα and IL-10. Initial results suggest that 
the DC-SIGN receptor might be responsible for modulating the pro-inflammatory 
effects of saliva, in a dose-dependent manner. Future experiments will include 
testing different saliva concentrations from other vector species, as well as using 
glycosylated controls such as egg albumin (known to be highly glycosylated) and see 
if similar effects are achieved.  
 
A third instance in which these glycans might have a role is the activation of the 
complement system. Complement can be activated by the classical, alternative and 
lectin pathways. The latter is initiated when the mannan-binding lectin or ficolins 
recognize and bind to carbohydrates on pathogens. Mannan-binding lectin binds to 
several sugars, including mannose, GlcNAc and Fuc, through which it recognizes 
pathogens like T. cruzi, Leishmania and Plasmodium173. Ficolins on the other hand 





However, there are no reports of lectin complement pathway activation by either 
Glossina or Trypanosoma spp. 
 
Considering the known effects of T. brucei infection on tsetse saliva, we also sought 
to find any effects on glycosylation. Both composition and abundance of salivary 
glycans remained unaffected by infection with trypanosomes both at the midgut and 
the salivary gland infection stages. However, when we looked at immunogenicity 
using a polyclonal anti-G. morsitans serum, we did observe an interesting effect. 
During salivary infection, when protein content appears to be most downregulated, 
the removal of glycans appears to expose some antigenic epitopes to the polyclonal 
serum. This suggests some salivary epitopes are masked from the immune system by 
glycans and are recognised in vivo after processing by antigen presenting cells. This is 
not observed in uninfected flies, possibly hidden by the higher abundance of other 
proteins that are also recognized by the antiserum. We also observed variations in 
the relative abundance of some glycan structures in teneral versus naïve flies; this 
suggests that the bloodmeal itself could be causing changes in the salivary protein 
glycosylation profile, something that would be interesting to explore further.  
 
Surprisingly, we did not detect any O-glycans, such as mucins, by either HILIC or MS. 
Mucins are serine and threonine rich secreted proteins, heavily glycosylated175 and 
are expected to be found in saliva. Sialome work in G. morsitans morsitans describes 
the presence of nine mucin polyptides, which are members of the hemomucin 
family154. Predictions showed that these proteins had anywhere between 12 and 40 
O-linked glycosylation sites. Rose et al (2014) describe the presence of hemomucin, 
an O-linked glycoprotein in the tsetse proventriculus, but its glycosylation levels 
were not studied162.  
 
The saliva of haematophagous arthropods has evolved over millions of years to fight 





bloodmeal. As bloodfeeding evolved independently several times in insects, the 
salivary components in each group will have developed different adaptations. Some 
things, however, can remained conserved. Our results show that the saliva of other 
bloodfeeders like mosquitoes and triatomines has several N-linked glycoproteins rich 
in oligomannose structures. This seems to hint at conserved salivary glycosylation 






Chapter 4.  In pursuit of the a-gal epitope in 




Ticks differ from other bloodfeeding arthropods because they remain attached to 
their vertebrate host for several days at a time, exposing their host to salivary and 
intestinal contents. An alarming increase of red meat allergy syndrome worldwide is 
caused by elevated production of IgE antibodies against a-galactosyl epitopes, 
believed to be stimulated by the bites of different species of ticks. However, the 
origin of this antigen in the tick is not clear. In Brazil, researchers have shown that 
the exposure of a-1,3-galactosyltransferase-knockout mice to Amblyomma sculptum 
saliva induced the production of anti a-gal antibodies; this provides the first 
evidence that this species may be associated with red meat allergy, and that saliva is 
the source of this sugar. Here I characterize the salivary sugars of A. sculptum, with a 
special focus on the glycoproteins containing a-gal residues. Enzymatically released 
sugars from salivary glycoproteins were fluorescently tagged and analysed by HPLC 
before and after glycosidases, in combination with highly sensitive LC-MS/MS. The 
results showed that A. sculptum salivary glycans are composed by a mixture of 
oligomannose- and complex-type structures, with some of the latter species being 
modified with a terminal a-Gal residue. Proteomic analysis shows two proteins, 
vitellogenin and heme lipoprotein, as the possible a-gal carrying glycoproteins in A. 
cajennense saliva. This is the first study to show the presence of the a-Gal epitope in 
tick saliva; importantly, the two candidate glycoproteins can be found in several tick 
species and could be potentially responsible for causing red meat allergy in other 









Ticks are small arthropods belonging to the class Arachnida and subclass Acari. They 
are telmophagic feeders, meaning they lacerate the tissues to create a pool of blood 
from which they feed. The larvae, nymph and adult stages of ticks all require 
vertebrate blood for survival and reproduction. Almost all ticks can be classified into 
two families, Argasidae (soft ticks) and Ixodidae (hard ticks), with most species falling 
into the latter. Soft ticks can feed from a host in ~1 hour, whereas hard ticks usually 
attach themselves to a host for days at a time. This means their saliva needs to be 
more powerful to be able to continuously feed for longer periods of time. Ticks have 
a pair of acinar-type salivary glands that join into the saliarium, a tube that empties 
into the buccal cavity where the outward flow of saliva an ingestion of blood take 
place; during feeding the salivary glands of Ixodid ticks can increase up to 25 times in 
mass, and salivation can be induced by dopamine or pilocarpine176,177. 
 
The link between allergy to red meat and exposure to tick bites was first proposed in 
Australia back in 2007, when Van Nunen et al studied 25 people with a confirmed Ig-
E antibodies to red meat proteins178. Of these individuals, 23 had a history of allergic 
symptoms to red meat consumption, with some even having suffered symptoms of 
anaphylactic shock. Interestingly, 24 of the patients recalled being bitten by ticks in 
the past and developing a large localized reaction to the exposure. The year after, 
Chung et al published a study on the high prevalence of hypersensitivity to 
Cetuximab, an antibody-based drug used to treat different types of cancer179. In an 
effort to understand these reactions, they discovered these patients had high levels 
of IgE antibodies against galactose-α-1,3-galactose (absent in humans), prior to the 
administration of the drug. It turned out that the Fab portion of the cetuximab heavy 





Gal antigen is abundantly present in the glycoconjugates of different mammals, 
except in humans, apes and Old World monkeys, who lack the 
α1,3galactosyltransferase enzyme due to the inactivation of the gene in an ancestral 
species180. Therefore, humans recognise the α-Gal as foreign and produce antibodies 
against it. High levels of serum anti-Gal antibodies are characteristics in individuals 
with Chagas disease or leishmaniasis patients, although it is always of the IgG class 
181. 
 
Eventually, as more cases of meat allergy appeared, their geographical distribution in 
the US hinted at a clustering of events, and after discarding other possibilities (e.g. 
helminth coinfections), evidence pointed toward tick bites as the likely cause182. 
Previously underreported, cases of tick-induced allergy to red meat started to 
appear worldwide, linked to different species of ticks (Figure 4.1). However, the 




Figure 4.1. Cases of red meat allergy up to 2015 reported in the literature and the species of 






Few cases of meat allergy have been registered in Brazil, where it is suspected to be 
highly underreported and often misdiagnosed185. A member of the Amblyomma 
cajennense complex186, A. sculptum is one of the most abundantly distributed tick 
species in Brazil and possibly the main cause of red-meat allergy in this region. In 
2016, Araujo et al 185 studied the saliva of this tick species as the possible source of 
the α-Gal epitope. Using an α-1,3-galactosyltransferase knockout mouse model, they 
showed the mice produced anti-α-Gal antibodies when challenged by extract saliva 
or tick bite. However, no works have described the sugars present in the saliva of 
this or any other tick species; this work therefore sought to characterise the salivary 
glycans of the Brazilian tick Amblyomma sculptum, with a special emphasis in 
galactosylated structures potentially responsible for causing the α -Gal allergy. 
 
4.3 Methods 
4.3.1.  Amblyomma sculptum saliva 
Saliva samples were obtained from the colony of Amblyomma sculptum housed in 
the Instituto de Ciências Biológicas of the Universidade Federal de Minas Gerais, 
Brazil. Females were collected during the final 48 hours of feeding from mice 
(estimated by the size of the abdomen), normally 8 to 10 days after they started to 
feed. Saliva was obtained from female ticks using an injection of pilocarpine to 
induce salivation176 
 
4.3.2.  Mass spectrometry analysis 
To identify the glycoproteins that were susceptible to PNGase F, 10 µg salivary 
proteins were enzymatically cleaved, resolved in a 7% polyacrylamide gel and 
Coomassie stained. Bands of interest were extracted and sent to the Dundee 
University Fingerprints Proteomics Facility. Briefly, the excised bands were subjected 





were analyzed via liquid chromatography- tandem mass spectrometry (LC-MS/MS) in 
a Thermo LTQ XL Linear Trap instrument equipped with a nano-LC. 
 
The gi numbers for the top hits in each band were searched in NCBI Protein 
(http://www.ncbi.nlm.nih.gov/protein) to yield the FASTA format of the protein 
sequence. The FASTA protein sequence was also queried in the SignalP 4.0187. Server 
software to predict the signal peptide location and NetNGlyc 1.0118 to reveal 
potential N-glycosylation sites. 
 
4.3.3.  Fluorescent labelling with procainamide and purification 
Released N-glycans were fluorescently labelled via reductive amination reaction with 
procainamide using a Ludger Procainamide Glycan Labelling Kit containing 2-picoline 
borane (Ludger Ltd.). The released glycans were incubated with labelling reagents 
for 1 hour at 65°C. The procainamide labelled glycans were cleaned up using 
LudgerClean S Cartridges (Ludger Ltd). Procainamide labelled glycans were eluted 
from the LudgerClean S Cartridges with water (1mL). The samples were evaporated 
to dryness under high vacuum using centrifugal evaporation and re-suspended in 
water (100 μL) for further analysis. 
 
4.3.4.  Exoglycosidase sequencing  
Exoglycosidase digestion was performed according to Royle et al. [4]. The released, 
2-AB labelled N-glycans were incubated with exoglycosidases at standard 
concentrations in a final volume 10 µL in 50 mM sodium acetate (for incubations 
with Jack bean α-mannosidase, 250 mM sodium phosphate, pH 5.0 was used) for 16 
hours at 37°C. The enzymes used were: (i) Jack bean α-(1-2,3,6)-Mannosidase (JBM), 
(ii) coffee bean a-glactosidase (CBAG). After digestion, samples were separated from 
the exoglycosidases by binding onto a LudgerClean Post-Exoglycosidase clean-up 
plate (Ludger Ltd.) for 60 min followed by elution of the glycans from the plate with 






4.3.5.  SDS polyacrylamide gel electrophoresis and staining 
Samples were analysed by SDS-PAGE before and after treatment with the 
endoglycosidase PNGase F (New England Biolabs, Massachusetts, US). Gel was 
stained using InstantBlueTM Protein stain (Expedeon, California, US). 
 
4.3.6.  Lectin blot 
Tick saliva samples, before and after treatment with PNGase F (New England Biolabs, 
US) were run on a 7% polyacrylamide gel under standard conditions, transferred 
onto a PVDF membrane, and blocked with 1% BSA in PBS-Tw 20 overnight at 4°C. 
Membrane was incubated with 1µg/ml biotinylated Concanavalin A (ConA) lectin or 
2 µg/ml Aleura aurantia lectin (AAL) (Vector Labs, Peterborough, UK) for 1 hour at 
room temperature. After washing, the membrane was incubated with 1:100000 
streptavidin-HRP (Vector Labs, Peterborough, UK). SuperSignal West Pico 
Chemiluminescent substrate was used. 
 
4.3.7.  IB4 lectin blot  
Tick saliva samples, before and after treatment with PNGase F (New England Biolabs, 
US) were fractionated on a 7% polyacrylamide gel under standard conditions, 
transferred onto a PVDF membrane, and blocked with 1% BSA in PBS-Tw 20 
overnight at 4°C. Membrane was incubated with 0.3 µg/ml of biotin-conjugatedIB4 
lectin diluted in blocking buffer (1% BSA + PBS-Tween20) for 3 hours. After washing, 
the membrane was incubated with 1:100000 streptavidin-HRP (Vector Labs, 






4.3.8.  Recognition of salivary glycoproteins by C-type lectin receptors on 
host immune cells 
Saliva samples were treated overnight with PNGase F (New England Biolabs, US) to 
remove glycans. Samples were run on a 12.5% polyacrylamide gel, transferred onto 
a PVDF membrane, and blocked overnight with 1% BSA (Sigma). Membranes were 
incubated with CTLD4-7Fc (0.5µg/µl) [generously provided by Dr. Martinez-Pomares, 
University of Nottingham) for 1 hour, washed, and then incubated with anti-human 
IgG conjugated to HRP for 1 hour. After washing, WestDura substrate (ThermoFisher 
Scientific, US) was used to develop the membranes. 
 
4.4 Results 
4.4.1.  Analysis of A. sculptum salivary proteins 
Tick salivary proteins were visualised through silver staining, showing several minor 
proteins and a major salivary band at ~100kDa (Figure 4.2). To identify any 
galactosylated glycoproteins, saliva was purified using a column with Marasmius 
oreades agglutinin (MOA) lectin, which is Galα1,3Gal/GalNAc-specific; this resulted in 
the purification of the ~100kDa salivary protein. Further treatment with PNGase F 







Figure 4.2. Identification of a-galactosylated proteins from A. sculptum. (A) Silver staining of 
A. sculptum saliva (S), and saliva purified using a MOA lectin column (M). (B) Coomassie gel 
showing major protein bands in tick saliva, before (-) and after (+) treatment with PNGase F. 
(C) IB4 lectin blotting, indicating recognition of major salivary protein, which is blocked after 
PNGase F treatment.  
 
The two visible bands ~100kDa observed by Coomassie staining were excised (before 
and after treatment with PNGase F) and sent for proteomic analysis, together with a 
sample of the protein isolated by the MOA lectin column. Results were then blasted 
against all known protein sequences of A. sculptum on the NCBI database. Once 
protein hits were obtained, we searched the NetNGlyc online server to see which 
proteins contained the canonical N-XS/T sequon, indicative of a potential 
glycosylation site; only those hits common to identifications before and after 
treatment with PNGase F are included on this list (Table 4.1). The top hit shown for 
band 1 is putative vitellogenin-2 from A. sculptum (NCBI accession 604804137), and 
for band 2 it has the same name, but different accession number (NCBI accession 
604800820); the second hit is a partial sequence of the first one. Both of these 
sequences are part of the top hits for the MOA-purified protein. Other top hits for 
include putative vitellogenin for other Amblyomma species, such as A. parvum and 






Table 4.1 Top hits for the major bands in A. cajennense saliva susceptible to PNGase F. Acc: 
Accession number; UP: Unique Peptides; MW: Molecular Weight (kDa);  








604804137 putative vitellogenin-2 
[Amblyomma cajennense] 
8102.18 51.42 1 33 76 384 1546 177.1 
604804135 putative vitellogenin-2, 
partial [Amblyomma 
cajennense] 
6038.87 50.42 1 51 70 248 1543 177.1 
604808137 putative vitellogenin-2 
[Amblyomma parvum] 
2608.38 20.45 1 6 33 131 1545 177.4 
604800820 putative vitellogenin-2 
[Amblyomma cajennense] 
2258.37 54.73 1 5 32 104 698 79.2 
604825322 putative vitellogenin-2, 
partial [Amblyomma triste] 
1831.10 15.90 1 3 22 101 1239 141.9 
604809419 putative vitellogenin-2 
[Amblyomma parvum] 




1330.71 31.92 1 32 32 51 1557 169.7 
604794253 hypothetical protein 
[Amblyomma cajennense] 
1027.90 24.92 1 26 26 47 1324 151.0 
604808135 hypothetical protein 
[Amblyomma parvum] 
564.70 19.97 1 10 19 30 1497 166.1 
604799854 hypothetical protein, partial 
[Amblyomma cajennense] 
538.12 35.79 1 8 17 24 760 82.8 
604819057 putative ca2+-binding actin-
bundling protein 
[Amblyomma triste] 
392.22 16.39 1 12 12 13 891 103.1 
604800828 putative heat shock protein 
90 [Amblyomma 
cajennense] 
216.02 11.57 1 7 7 7 795 90.9 
604796863 putative serine proteinase 
inhibitor, partial 
[Amblyomma cajennense] 
214.57 34.09 1 7 7 10 220 24.7 
604799908 putative elongation factor 
2-like isoform 1 
[Amblyomma cajennense] 
205.24 13.63 2 8 8 9 844 94.5 
604825176 putative vitellogenin-3, 
partial [Amblyomma triste] 
139.53 3.61 1 2 2 3 830 92.9 
604793620 putative animal heme 
peroxidase [Amblyomma 
cajennense] 
124.54 5.73 1 3 3 3 593 68.4 
604798634 putative actin [Amblyomma 
cajennense] 
124.54 11.17 2 4 4 5 376 41.8 
604799986 putative actin-binding 
cytoskeleton protein 
filamin, partial [Amblyomma 
cajennense] 

















604800196 putative tick serpins 1 
[Amblyomma cajennense] 




604800744 putative heat shock protein, 
partial [Amblyomma 
cajennense] 




604826011 putative serine 
carboxypeptidase lysosomal 
cathepsin a [Amblyomma 
triste] 




604819279 putative extracellular matrix 
glycoprotein laminin subunit 
alpha and gamma, partial 
[Amblyomma triste] 
















604804137 putative vitellogenin-2 
[Amblyomma cajennense] 









604804135 putative vitellogenin-2, 
partial [Amblyomma 
cajennense] 









604801011 putative vitellogenin-2, 
partial [Amblyomma 
cajennense] 







604808137 putative vitellogenin-2 
[Amblyomma parvum] 
5574.11 22.14 1 8 37 224 1545 177.4 
604825322 putative vitellogenin-2, 
partial [Amblyomma triste] 
2722.91 12.35 1 1 15 114 1239 141.9 
604809419 putative vitellogenin-2 
[Amblyomma parvum] 




1747.28 38.34 1 36 36 67 1557 169.7 
604817817 putative vitellogenin-2, 
partial [Amblyomma triste] 
1162.51 15.65 1 2 8 67 377 43.1 
604799854 hypothetical protein, partial 
[Amblyomma cajennense] 
704.76 35.66 1 8 19 26 760 82.8 
604794253 hypothetical protein 
[Amblyomma cajennense] 
629.84 22.28 1 19 19 28 1324 151.0 
604799986 putative actin-binding 
cytoskeleton protein 
filamin, partial [Amblyomma 
cajennense] 












604804122 putative tick 
metalloprotease 1, partial 
[Amblyomma cajennense] 
202.20 5.36 1 1 2 4 541 61.1 
604799748 putative conserved 
membrane protein, partial 
[Amblyomma cajennense] 
197.98 14.65 2 4 4 16 662 64.4 
604798634 putative actin [Amblyomma 
cajennense] 
181.84 22.07 2 5 5 6 376 41.8 
604796863 putative serine proteinase 
inhibitor, partial 
[Amblyomma cajennense] 
160.76 25.45 1 5 5 6 220 24.7 
604825176 putative vitellogenin-3, 
partial [Amblyomma triste] 
130.81 4.82 1 3 3 3 830 92.9 
604824253 putative alpha tubulin, 
partial [Amblyomma triste] 
96.00 6.78 1 2 2 3 487 53.6 
MOA purified protein 
604804137 putative vitellogenin-2 
[Amblyomma cajennense] 
1836.56 31.57 1 12 46 71 1546 177.1 
604804135 putative vitellogenin-2, 
partial [Amblyomma 
cajennense] 
1443.91 30.46 1 29 40 50 1543 177.1 
604800820 putative vitellogenin-2 
[Amblyomma cajennense] 
1336.40 41.55 1 5 25 47 698 79.2 
604808137 putative vitellogenin-2 
[Amblyomma parvum] 
885.84 15.34 1 3 23 35 1545 177.4 
604798634 putative actin [Amblyomma 
cajennense] 
779.64 48.14 2 17 17 24 376 41.8 
604809419 putative vitellogenin-2 
[Amblyomma parvum] 
523.43 5.61 1 2 10 16 1552 177.8 
604825322 putative vitellogenin-2, 
partial [Amblyomma triste] 
496.02 11.06 1 1 15 22 1239 141.9 
604800196 putative tick serpins 1 
[Amblyomma cajennense] 
214.20 22.68 1 2 2 4 194 21.4 
604799854 hypothetical protein, partial 
[Amblyomma cajennense] 
181.96 9.08 1 2 4 5 760 82.8 
604796863 putative serine proteinase 
inhibitor, partial 
[Amblyomma cajennense] 
103.78 25.00 1 4 4 4 220 24.7 
604826011 putative serine 
carboxypeptidase lysosomal 
cathepsin a [Amblyomma 
triste] 
50.11 4.53 2 2 2 2 486 54.1 
 
 
Considering the possibility that vitellogenin may have been misidentified due to high 





the sequence was blasted against Arthropoda proteins on the NCBI database. This 
resulted in the identification of heme lipoprotein precursor of Amblyomma 
americanum, which has 91% identity with vitellogenin (Figure 4.3). Both proteins 
have four potential glycosylation sites.  
 
 
Figure 4.3. Aminoacid sequence of A. sculptum vitellogen. (A) Vitellogenin, the top hit from 
initial proteomic analysis, has four glycosylation sites (sequons in red and blue). (B) With a 
similar sequence (91% identity), heme lipoprotein has the same glycosylation sites.  
 
4.4.2.  a-galactosylated glycans in A. cajennense saliva samples do not 
appear to originate from the vertebrate host  
Blood feeding the ticks before saliva collection is unavoidable, since ticks are 
obligate bloodfeeders throughout all life stages. Therefore, we considered the 
possibility that the α-galactosylated glycans detected in tick saliva originated 
from the vertebrate host (in this case the mice normally used to feed the 
colony). To investigate this, we tested for the recognition of α-Gal residues in the 
saliva of ticks fed on alpha-1,3-galactosyltransferase gene knockout (α-Gal KO) 





versus the α-Gal KO showed a marked decrease in secreted proteins, which was 
not detectable by Coomassie blue stain (Figure 4.4).  
 
 
Figure 4.4. Coomassie blue stained SDS-PAGE analysis of tick saliva proteins. Asterisk indicates 
band corresponding to PNGase F enzyme. Ticks were fed either on C57BL/6 or a-1,3-
galactosyltransferase gene knockout (α-gal KO) mice. Saliva from both groups was treated 
with PNGase F (+) to remove N-glycans or left untreated (-). Samples were run through SDS 
PAGE (10%). Lanes 1-2 and 3-4 correspond to two different salivary dissections on normal 
mice.  
 
Loading in the gel was normalized by protein concentration, which was measured 
using a BCA protein concentration kit (data not shown). However, once stained with 
Coomassie blue, it is possible to observe that the quantities of individual proteins 
differ between the samples. This is possibly due to the KO mice themselves, which 
exhibit a deleterious phenotype; ticks fed on them take longer to feed, engorge less 
(Araujo, pers.comm.), and lower ammounts or total saliva are recovered (compared 
to ticks feeding on normal mice). Next, proteins were transferred onto a PVDF 
membrane and used the IB4 lectin to detect α-gal epitope in the saliva of ticks fed 





















binds to several salivary bands, and this recognition is decreased (Figure 4.5A) or 
disappears (Figure 4.5B) after treatment with PNGase F. 
 
 
Figure 4.5. IB4 lectin detection of α-gal in A. sculptum salivary glycoproteins. Ticks were fed 
either on C57BL/6 or alpha-1,3-galactosyltransferase gene knockout (α-gal KO) mice. Saliva 
from both groups was treated with PNGase F (+) to remove N-glycans or left untreated (-). 
Samples were run through SDS PAGE (10%) and transferred onto a PVDF membrane. (A) IB4 
lectin blot for detection of mannose in saliva before (-) and after (+) treatment with PNGase 
F to remove all N-glycans. Bovine Serum Albumin (BSA) and Dextra neoglycoprotein (NGP) 
were used as negative and positive controls, respectively. (B) Same membrane as A after 
washing and reblotting (C) Nigrosine stained membrane. Asterisk indicates band 
corresponding to PNGase F enzyme. 
 
 
4.4.3.  Tick salivary glycoproteins are modified with oligomannose and 
complex-type N-glycans 
To characterise the glycans in Amblyomma saliva, samples were treated with 
PNGase F, and the glycans then purified and procainamide-tagged as described in 
Materials and Methods. Analysis by HILIC-UHPLC revealed a high number of 
oligomannose structures ranging from Man3GlcNAc2 to Man9GlcNAc2 (Figure 
4.6Figure 4.6 top panel). In addition, more than half are complex-type glycans, 
containing from one to three terminal GlcNAc ressidues to one or possibly both 
mannose branches. Most oligomannose structures and all complex-type glycans are 
fucosylated; the fucose modification is likely to be in the innermost GlcNAc of the 





around half of these complex-type glycans have several terminal hexoses, which 
could potentially correspond to galactose residues. The bottom panel of Figure 4.6 
shows the average mass spectrum of released glycans, supporting the diversity of 




Figure 4.6. Analysis of released glycans from Amblyomma sculptum saliva. Top panel: HILIC-
UHPLC chromatogram; major structures are shown with corresponding GU values. Bottom 
panel: Positive-ion MS profile, showing m/z values with potential corresponding structures 
as assigned by Proteinscape software. Glycan symbols: GlcNAc (blue square), Man (green 
circle), Gal (yellow circle), Fuc (red triangle), Sia (purple diamond); empty circles represent 
unconfirmed hexose residues. 







































































































































































































































































































Assignment of structures by the Proteinscape software based on the resulting ions 
suggests once again the presence of several glycans with terminal hexose 
monosaccharides, which could potentially correspond to galactose residues. It 
additionally suggests the existence of a possible sialylated sugar. Although all 
proteins appear to have similar abundance, the largest peaks correspond to Proc-
HexNAc2Hex5Fuc1 (8.5%) of m/z 800.87 [M+H]2+ and Proc-HexNAc5Hex3Fuc1 (6.3%) at 
m/z 943.47 [M+H]2+.  
 
Table 4.2 Characteritics of the glycan structures of A. sculptum saliva detected by HILIC-
UHPLC and MS analysis. Asterisks indicate structures eluted at the same retention time. 
Glycan symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red 




















































































































































































































































































































































4.4.4.  Enzymatic treatment of tick salivary glycans confirms the presence 
of galactosylated structures 
To further confirm the glycan structures found, samples were subjected to 
enzymatic treatments with JBAM (Figure 4.7) or with b-galactosidase 1-4 and a-
galactosidase 1-3 (Figure 4.8). As expected, treatment with JBAM causes the 
disappearance of fractions corresponding to the oligomannose structures; as 
expected, some glycans with terminal GlcNAc modifications remain undigested.  
 
 
Figure 4.7 HILIC-UHPLC chromatogram of A. sculptum saliva before (top panel) and after 
(bottom panel) treatment with Jack Bean a-mannosidase. 
 
Two enzymes where used for galactosidase treatment, to help provide additional 
information on the type of linkage (Figure 4.8). Peak 28, of composition 
Hex5HexNAc3dHex, was not susceptible to either galactosidase and is possibly a 
hybrid-type glycan. Peak 33, containing the glycan Hex5HexNAc4dHex, was 













































































































































susceptible to β-galactosidase only. Peak 44, containing the sugar Hex5HexNAc5dHex 
umnderwent partial digestion with β-galactosidase, but was then fully digested by α-
galactosidase, indicative of the presence of terminal α-galactosylated residues; this 
peak also contains the structure Hex5HexNAc4dHex in a small proportion, which was 
also fully digested when both enzymes were used. The same was observed for peaks 
41 and 42, which contain glycans Hex7HexNAc4dHex and Hex7HexNAc5dHex. Peak 39, 
containing Hex6HexNAc4dHex, was only slightly digested; however, the MS spectrum 
indicates this peak has completely disappeared (not shown). In all, these results 
suggest that at least five of the complex-type structures detected in Amblyomma 
saliva appear to contain either terminal alpha- or beta-galactosyl residues or both.  
 
 
Figure 4.8. HILIC-UHPLC chromatogram of A. sculptum saliva. (A) undigested; (B) after 
treatment with α-1,3 galactosidase, and (C) after treatment with both α-1,3 galactosidase 
and β-1,4 galactosidase. Red lines indicate peaks modified by enzymatic treatment. Red 









































































































































































































4.4.5.  A. sculptum saliva contains mannosylated glycoproteins.  
To show evidence of the presence of mannose, Concanavalin A (Con A) was used to 
probe tick saliva before and after treatment with PNGase F (Figure 4.8). Con A 
positively recognised multiple salivary glycoproteins, indicating the other salivary 
proteins are in extremely low quantities and higher sensitivity methods are required 
to observe them. Considering previous results obtained with the saliva of other 
vector species, we tested whether any tick salivary proteins are recognised by the C-
type lectin receptors such as MR. Using a recombinant fragment of the MR, we show 
positive recognition of the major salivary band at ~100kDa (Figure 4.9).   
 
Figure 4.9 Detection of mannosylated glycoproteins in A. sculptum saliva. Saliva was 
extracted from female ticks and treated with PNGase F (+) to remove N-glycans or left 
untreated (-). Samples were fractionated on SDS PAGE (10%) and transferred onto a PVDF 
membrane. (A) Lectin blot with ConA for detection of mannose; (B) Overlay assay using 
CTLD4-7Fc, a recombinant fragment of the mannose receptor. Lanes 1-5: blots, lanes 6-7: 
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In recent years, an alarming increase in the distribution of various tick species 
around the world has raised serious public health concerns. Among all arthropods, 
ticks are responsible for the transmission of the widest variety of human and animal 
pathogens viruses42. Furthermore, their bites cause local tissue damage, paralysis, 
and increasingly, allergy to red-meat allergy. The latter is caused by an increase in 
the production of IgE antibodies against glycans containing terminal α-galactose 
residues, most likely as the linear epitope Gala1-3Galβ1-4GlcNAc-R. Different tick 
species around the world are responsible for triggering this allergic response, with 
Amblyomma sculptum being the main suspect in Brazil. In 2015, Araujo et al.185 used 
α-galactosyltransferase knockout mice to study the source of the α-gal antigen in 
ticks. They found that when these mice were exposed to virus particles carrying the 
Gala1-3Galβ1-4GlcNAc glycans, they produced anti α-Gal antibodies; this was also 
the case when the mice were challenged with tick saliva and when they were 
subjected to tick bites. This proposed the first strong evidence that that the source 
of the antigen responsible for causing the red meat allergy might be the tick saliva. 
In this work, we studied the salivary glycoproteins of the tick A. sculptum, with a 
focus on the α-Gal epitopes.  
 
Analysis by HILIC-UHPLC and mass spectrometry of tick saliva extracted from blood-
fed females revealed the high abundance and diversity of salivary glycans. Apart 
from the common oligomannose structures found in arthropods, it appears ticks 
have the biosynthetically machinery for producing complex-type glycans in higher 
abundance compared to other arthropods like sandflies, tsetse flies and mosquitoes. 
Interestingly, there is also extensive fucosylation with 70% of the major tick glycans 
modified by this sugar. Fucose can be recognised by several receptors of the 
immune system, including C-type lectins such as the DC-SIGN and mannose receptor 
69. It is unlikely that these would be of an α1-3 configuration, which is known to be 





requires them to remain attached to their hosts for long periods of time. Although 
the existence of a possible sialylated glycan is interesting it remains unconfirmed, it 
is important to keep in mind ticks are obligate bloodfeeders, and contamination 
from the blood host is always a possibility. In fact, some researchers suggest that the 
α-Gal epitope is obtained by ticks from other mammals and expose to humans 
during a next feeding. Likewise, the capacity of making sialic acids remains a matter 
of debate for insects and arthropods in general. The function of these complex 
sugars in bloodfeeding, disease transmission and allergic syndromes remain to be 
studied. This could include glycopeptides analysis (which would allow the 
identification of glycosylation sites and the understanding of what glycans are 
modifying each glycoprotein); in vitro immunological assays stimulating C-type lectin 
receptor bearing cells; and using serum from patients suffering from meat allergy.  
 
Identification of the protein bands susceptible to digestion with PNGase F (indicative 
of N-linked glycosylation), showed vitellogenin 2 as the main glycoprotein candidate 
carrying α-galactosylated glycans. Initially this seems counterintuitive, as vitellogenin 
is a precursor of vitellin, which is an important component in egg development189. 
Thus, its presence in saliva sample was initially thought to be a contamination, as has 
been suspected in other cases190. However, this protein has a role in the conversion 
of bloodmeal to yolk; both precursor and product have been shown to have heme-
binding characteristics191 and can exhibit antioxidant properties that protect the tick 
from heme-induced toxicity192. The association of vitellin and heme is what gives 
eggs their dark colour, and in fact it is also the source of heme required for the 
development of the embryo (as ticks are not able to produce heme on their own 
unlike other arthropods). When Esteves et al193 compared the sialotranscriptomes of 
unfed versus fed A. sculptum, they found six vitellogenins in the saliva of fed ticks. 
Vitellogenin was also found in the saliva of Rhipicephalus (Boophilus) microplus 
(Vitellogenin I)194, and one study looking at the sialome of A. americanum found that 





vitellogenin or vitellogenin-like proteins have been reported in the saliva of 
mosquitoes (with functions in the endocrinal pathway)196,197.  
 
Considering the possibility that the protein has been incorrectly identified, we 
blasted the sequence on NCBI in search of other salivary proteins with closely 
related sequences. In this case the closest match (91% identity) was heme 
lipoprotein (HeLp) precursor of another species of the same genus, A. americanum. 
Although this protein has not been described in the salivary transcriptome of A. 
sculptum193, HeLp and vitellogenin are actually very similar in distribution and 
function. Heme lipoprotein is also known as carrier protein (CP), and it is the most 
abundant protein in tick haemolymph and saliva198 and is highly conserved among 
Ixodid ticks (which include the Amblyomma genus).  
 
Characterization of the A. americanum HeLp198 revealed this protein composed of 
two b subunits of ~90kDa each (with the latter being highly glycosylated). This work 
discusses the similarity between HeLp and vitellogenin, including the fact that they 
are both lipid carriers and can bind heme; additionally, tick (and arthropod) 
vitellogenin homologues from different organisms (like vertebrates and other 
invertebrates like nematodes) share similar domain structures. HeLp has also been 
hypothesised to be part of the tick cement cone that is formed so it can remain 
attached for long periods of time but has not been proved yet. Later work done on 
the Dermacentor variabilis tick also showed an abundance of heme lipoprotein in the 
saliva of this species199.  
 
In fact, a proteomic analysis of R. microplus saliva of salivary proteins fractionated on 
SDS-PAGE, identified several bands as containing vitellogenin and heme lipoprotein 
peptides194; interestingly, even though they show a much larger number of bands, 
some of these appear to have the same molecular weights of those observed in our 





control, by injecting sheep with anti-vitellogenin antibodies200 which resulted in 
smaller ticks that laid less eggs. Curiously, when the sheep were challenged with a 
recombinant version of the protein (which was not glycosylated) there was no 
significant effect. This demonstrates how important it is to understand the 
glycosylation of salivary proteins like vitellogenin. Importantly, glycosylation can vary 
across tick species so even though the proteins are highly similar, posttranslational 
modifications might vary.  
 
Several studies by Commins and collaborators were the first to show the link 
between tick bites, increased the production of anti-α-Gal antibodies and allergy to 
red-meat182,201,202. Others have suggested the presence of α-Gal in the saliva of other 
tick species184.  
 
Mateos-Hernández et al203 identified tick salivary proteins of Rhipicephalus bursa or 
Hyalomma marginatum that were recgonised by the serum of two patients that 
were red-meat tolerant but had significant titres of anti α-Gal antibodies. Although 
patient serum seemed to recognize more tick salivary proteins than control serum, 
results varied greatly between both individuals. When one of the patients was 
exposed to a tick bite, they developed anaphylactic shock, but neither patient 
developed red-meat allergy during the time of follow-up. Analysis of salivary proteins 
recognised by both patient serum as well as an anti-α-Gal antibody showed several 
candidates, none of which is vitellogenin. Their list does include heat shock protein 
90, which out proteomic analysis yielded as a possible identification for our protein, 
but it was not the top hit, and coverage of this protein was very. It cannot be 
discarded, however, that there could be several glycoproteins carrying the 
modification; our blot using IB4 seemed to detect additional glycoproteins in A. 
sculptum saliva, but the major one ~ 100kDa still remains as our main candidate. In 







Other sources have been proposed as the origin of the α-Gal epitope. Hamsten et 
al204 did immunohistochemical staining of Ixodes ricinus, using monoclonal and 
polyclonal antibodies to detect the sugar epitope in the tick midgut. They also 
probed whole-tick extracts with the serum of patients with red meat allergy, 
although the western blot inhibition assay is not entirely convincing; their use of the 
whole-tick homogenate would only show that patients have IgE antibodies that bind 
to various Ixodes proteins, and not necessarily to the α-Gal epitopes, and adds a lot 
of background noise that difficults analysis of the results. While it is true that during 
feeding ticks may egest contents from their gut as well as their salivary glands, the 
presence of the α-Gal sugar alone is not enough to establish a connection with the 
development of red-meat allergy. They need to show that the glycan structures 
carrying this modification are effectively eggested into the host; exposure could be 
induced mechanically by the manner of tick removal, which could damage the tick 
and release fragments of it into the site of the bite. The potential recognition of 
patient serum to the α1,3-galactosylated sugars in the midgut is an interesting 
finding, but specificity of the binding is not clear. However, it a valuable study in the 
sense that very few experiments have been carried out with patient serum, which 
can be difficult to find, possibly due to the underreporting of the allergic condition. 
Importantly, this could be an indication that there are several sources for the allergy-
inducing epitope, which would increase the amount of it that the host is exposed to 
during feeding. If this is true, the conditions under which the degree of this exposure 
might vary are an interesting aspect to explore, especially since it might also help to 
partly explain the intensity and/or delay in the development of their allergy.  
 
The allergy induced by α-Gal residues, which results in a significant rise of IgE levels 
in humans can trigger severe reactions that can go all the way to anaphylactic shock. 
Worryingly, the α-Gal antigen can be found in several commercial products, 





identified through the exposure of patients to the cancer drug Cetuximab45, which is 
galactosylated as the antibodies are produced in mice205. The epitope has been 
historically recognised as the main barrier to xenotransplantation, as it is present in 
all mammals except humans, Old World monkeys and apes180. In some cases, the 
ingestion of cow or pig derived products such as milk or gelatine can also trigger a 
reaction in susceptible individuals. It should be considered that exposure to the α-
Gal antigen might increase sensitivity in all these situations and therefore exacerbate 
allergic reactions to it.  
 
A rise in the reports of allergy to red meat can be due to two factors. The first, is the 
increasing awareness of the condition, were both literature reports and the media 
have played a role. The second is the growing exposure of people to tick bites as 
urbanization increases, and human populations move into previously uninhabited 
ecosystems. In this context, tick salivary glycans could be exploited as markers to 
confirm exposure to tick bites and further understand the epidemiology of this 
condition. In the case of A. sculptum, and the whole A. cajennense complex, the wide 
distribution of these closely related species in Brazil increases the population at risk 
of developing red meat allergy, in a country well known for its high consumption of 
meat. Furthermore, A. sculptum is the vector of Brazilian spotted fever (Rickettsia 
rickettsia); A. cajennense has been found naturally infected with a non-pathogenic 
Rickettsia species8. How the induction of anti-α-Gal IgE levels could potentially 
modulate the transmission of tick-borne pathogens also remains to be investigated.  
 
In summary, we have confirmed the presence of α-Gal carrying sugars in the saliva of 
the tick A. sculptum and identified a potential candidate that could be carrying the 
epitope responsible for causing meat allergy in Brazil. Glycopeptide analysis of the 
tick salivary glycoproteins will help to confirm the presence of the α-galatosylated 
structures and their location within the proteins. Overall, this work constitutes the 





especially relevant in the context of the α-Gal allergy, but the discovery of multiple 








Chapter 5.  Comparison of N-linked 





Glycosylation, the posttranslational modification where sugars are attached to 
proteins, is a relatively conserved process across eukaryotic organisms. This 
modification plays important roles in protein folding and conformation, biological 
function and cell communication. Mutations in this pathway can have multiple 
implications in all life stages, from embryonic development to reproduction. In N-
linked glycosylation, a basic structure is formed by all organisms, consisting of a 
chitobiose core of two N-acetylglucosamine plus three mannose residues. However, 
further modifications to this core are dependent on the type of cells and the 
organism they take place in, and arthropods will produce different structures to 
plants and vertebrate animals.  
 
Currently, most knowledge on insect glycosylation comes from studies done in the 
model organism Drosophila, as well as some insect cell lines used to express 
recombinant proteins. In general, arthropods are known to produce mainly 
paucimannose and high mannose structures, with a few complex-type ones, which 
carry mostly terminal GlcNAc residues and/or can have core fucosylation. So far, we 
have confirmed here that the salivary glycoproteins of sandflies, tsetse flies and ticks 
produce these expected glycans; however, ticks in particular seem to additionally 
synthesize more complex-type ones not present in insects. In this work, we look at 
the salivary glycoproteins of three other insect species: Aedes aegypti, Anopheles 





capacity across bloodfeeding arthropods. Furthermore, we look at the genes 
encoding for glycosidases and glycosyltransferases of the N-linked biosynthetic 
pathway and compare this to what we have found experimentally.  
 
We show that triatomines produce very simple structures consisting mainly of 
oligomannose sugars, while mosquitoes are capable of synthesizing more complex-
type glycans than sandflies and tsetse flies; however, collectively insects still produce 
less complex-type structures than ticks, confirming the capacity of Acari for higher 
processing and modification of N-linked glycans. We found mainly differences in the 
presence of genes encoding putative Golgi glycosyltransferases, where for instance a 
gene expansion of fucosyltransferases was observed in the genome of Ixodes ricinus. 
Additionally, a comparison of the genes between different species of Glossina 
showed high variability within the genus, but it is unknown how this reflects in vivo 
and if it influences vectorial capacity in any way. Together, our results show that in 
vivo within arthropods, ticks (and potentially acarines in general) are capable of 
producing more complex type structures than insects. Glycosyltransferases and 
glycosidases appear to be relatively conserved, with some variations observed 





Structural glycans are not encoded into the genome. Instead, instead they are made 
by a group of enzymes in charge of glycan syntheis processing and metabolism; i.e. 
glycosyltransferases (GT) that create glycosidic bonds, and glycosyl hydrolases (GH) 
that hydrolyse or rearrange these bonds. The process of transcription, splicing, 
translation and posttranslational modification is influenced by the physiological 
conditions of a cell (ref). Although the pathways are relatively conserved, the 





and regulation of these enzymes. The numbers of GTs or GHs do not necessarily 
correspond to the perceived “complexity” of an organism. 
 
Biosynthesis of asparagine-linked glycans happens in four stages, the first three of 
which are conserved across different organisms206. In the first stage, a 14-sugar 
oligosaccharide precursor is synthesized and then transferred by an oligosaccharide 
transferase complex from the carrier Dol-P onto nascent proteins with the Asn-X-
Ser/Thr sequon (were X ¹ Pro)50. The next stages involve the trimming of the glycan 
structure,  and the removal of all Glc residues within the calnexin/calreticulin 
cycle207, which is important in protein quality control and are usually conserved 
among eukaryotes. The glycoprotein can then enter the secretory pathway in the 
Golgi complex, where either the glycan does not suffer much modification (leading 
to the formation of oligomanose structures) or several of the a-Man residues are 
trimmed off and new sugars are added to the glycan structure, to form either 
hybrid- or complex-type glycans; this is where the most diversity is observed 
between cells, tissues and organisms. Glycosylation is further influenced by the 
capacity of the cell type to make specific subsets of sugar nucleotide donors.  
 
GTs are classified according to sequence similarity and based on this grouped into 
families, which can be found in the CAZy database208. The finding that these families 
contain enzymes with varying substrate specificities indicates, among other things, 
that the development of new substrate specificities by both GTs and GHs are 
common evolutionary events and that the substrate affinity is largely due to specific 
characteristics of their three-dimensional structure. Therefore, assignment of 
function based solely on sequence relatedness can often be erroneous in the 
absence of experimental evidence.  
 
Insect N-glycosylation is expected yield mainly oligomannosidic structures, with very 





supported this finding, with the highest diversity of sugars found in the saliva of a 
tick species (arachnid). Importantly, we have yet to study the glycosylation capacity 
of mosquitoes. Mosquito-borne pathogens have a lifecycle that takes them to the 
salivary glands as a necessary step before reaching maturity, and from there are 
transmitted into the vertebrate host. As such, they are exposed to the insect’s saliva 
for long periods of time, and what’s more, in the case of viruses they can influence 
the type of posttranslational modifications they carry (e.g. glycosylation). Even 
though some works have hinted at the possible glycosylation in mosquitoes like 
Aedes, the structures of the sugars in saliva have yet to be studied.  
 
Here, we characterise the salivary glycan structures of Aedes aegypti, Anopheles 
gambiae and Rhodnius prolixus. Furthermore, the collective knowledge of the glycan 
structures in the six vector species studies allows us to draw some conclusions on 
the capacity of N-linked glycosylation insects and arachnids. We also looked at the 
genomes of these species in other to look at the presence/absence of the enzymes 
involved in the biosynthesis of glycans and discuss this according to our 
experimental findings.  
 
5.3 Methods 
5.3.1.  Search for genes of the N-glycan biosynthesis pathway 
The Kyoto Encyclopaedia of Genes and Genomes (KEGG) database was used to find 
the enzymes involved N-glycan biosynthesis reference pathway. Using the 
Drosophila melanogaster genome, we searched for the amino acid sequences of all 
enzymes in the pathway, and then performed a BLAST analysis using VectorBase 
genome data of the following arthropod species: Aedes aegypti, Anopheles gambiae, 
Glossina austeni, G. brevipalpis, G. fuscipes, G. morsitans, G. pallidipes, G. palpalis, 
Ixodes scapularis, Lutzomyia longipalpis, Musca domestica, Phlebotomus papatasi 






5.3.2.  Saliva extraction 
5.3.2.1. Mosquito saliva 
Saliva was extracted from sugar-fed females of Aedes aegypti and Anopheles 
gambiae, obtained from the colonies at the LITE facility of the Liverpool School of 
Tropical Medicine. Saliva was collected in filtered PBS and stored at -20C until use.  
 
5.3.2.2. Triatomine saliva 
Saliva samples of blood-fed Rhodnius prolixus, Triatoma infestans and Triatoma 
braziliensis were obtained through a collaboration with researchers at the 
Laboratório de Fisiologia de Insetos Hematófagos at the Universidade Federal de 
Minas Gerais in Brazil.  
 
5.3.3.  Prediction of glycosylation sites 
Published amino acid sequences for the salivary proteins of mosquitoes and 
triatomines were searched for N- and O-linked glycosylation sites using the online 
servers NetNGlyc 1.0118 and NetOGlyc209 (www.cbs.dtu.dk/services/NetOGlyc). 
SignalP 4.1was used for signal peptide/non-signal peptide predictions. 
 
5.3.4.  Lectin blotting 
Saliva samples, before and after treatment with PNGase F (New England Biolabs, US) 
were run on a polyacrylamide gel under standard conditions, transferred onto a 
PVDF membrane, and blocked with 1% BSA in PBS-Tw 20 overnight at 4°C. 
Membranes were incubated at room temperature with 1µg/ml biotinylated 
Concanavalin A (ConA) lectin (Vector Labs, Peterborough, UK) for 30 min, or with 
Aleuria aurantia lectin (AAL) for one hour. After washing, the membrane was 
incubated with 1:100000 streptavidin-HRP (Vector Labs, Peterborough, UK). 






For the detection of galactosylated glycans, membranes were incubated with 
0.3µg/ml of HRP-conjugated IB4 lectin (Sigma L5391) diluted in blocking buffer (1% 
BSA + PBS-Tween20) for 3 hours. After washing, SuperSignal West Dura 
Chemiluminescent substrate was used.  
 
5.3.5.  Chromatography and mass spectrometry analysis of glycan 
structures HILIC-HPLC-MS analysis on a Dionex Ultimate 3000 and 
Bruker Amazon Speed 
The samples were analysed by HILIC-UHPLC using a Dionex Ultimate 3000 UHPLC 
using a BEH-Glycan 1.7 µm, 2.1 x 150 mm column at 40°C on a Dionex UltiMate 3000 
instrument with a fluorescence detector ( ex = 310 nm,  em = 370 nm), controlled 
by Bruker HyStar 3.2. Buffer A was 50 mM ammonium formate made from 
LudgerSep N Buffer stock solution, pH4.4 [LS-N-BUFFX40]; Buffer B was acetonitrile 
(Acetonitrile 190 far UV/gradient quality; Romil #H049). 25 µL of sample was were 
injected in 24% aqueous/76% acetonitrile. Chromeleon data software version 7.2 
with a cubic spline fit was used to allocate GU (glucose units) values to peaks. 
Procainamide labelled glucose homopolymer was used as a system suitability 
standard as well as an external calibration standard for GU allocation for the system. 
 
Mass spectrometry (MS) analysis was performed by a Bruker AmaZon Speed ETD 
electrospray mass spectrometer which was coupled directly after the UHPLC 
fluorescence detector without splitting. The instrument scanned samples in 
maximum resolution mode, positive ion setting, MS scan + three MS/MS scans, 
nebuliser pressure 14.5 psi, nitrogen flow 10 litres/min, capillary voltage 4500 Volts. 









Saliva from three vector species, Aedes aegypti, Anopheles gambiae and Rhodnius 
prolixus was treated with PNGase and the glycans isolated and purified for analysis 
by HILIC-UHPLC and mass spectrometry. Below, I summarise the suggested N-
glycosylation pathways for each of the aforementioned insects based on 
bioinformatic searches and mass spectrometry/structural data.  
 
5.4.1.  Ae. aegypti 
5.4.1.1. Glycosylation predictions 
The published amino acid sequences of secreted salivary proteins of Ae. aegypti197 
were searched for potential glycosylation sites. The NetNGlyc 1.0 server118 searches 
for the Asn-X-Ser/Thr sequons (x ¹ Pro) in the protein, to predict sites where N-
linked glycans could be attached to the protein. Out of 69 proteins, 64% were 
predicted to have this sequon, carrying up to 9 glycosylation sites (e.g. putative 
41kDa secreted salivary protein) (Table 5.1). Of the 25 proteins suspected to be 
enriched or only present in the salivary glands, 68% are potentially glycosylated.  
The prediction of O-glycosylation sites must be considered carefully since it only 
considers the presence of either a Ser or Thr amino acid in the protein, without the 
need for a specific accompanying sequence. Analysis of Aedes salivary proteins using 
the NetOGlyc 4.0 server suggested ~64% had a potential O-linked glycosylation site. 
In some cases, up to 65 and 143 sites were observed, corresponding to protease 
inhibitor and PAN/APPLE domain-containing domains (respectively); these 
ubiquitous mosquito proteins were also predicted to have N-linked glycosylation 
sites. All but three of the 69 proteins had a signal peptide (SignalP 4.1187); the 
DeepLoc 1.0 server244, which predicts the protein’s subcellular localization, 
suggested 88% of the sequences corresponded to were likely to be extracellular 
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5.4.1.2. Salivary glycan structures in Aedes 
To examine the N-glycan structures in Ae. aegypti, glycans were cleaved from the 
proteins using PNGase F, purified and labelled with procainamide. 





allocate GU values to the peaks, and further analysed by mass spectrometry to 
confirm structure composition (Figure 5.1). The resulting chromatogram shows 
21 major peaks which correspond mainly to oligomannose glycans, from the core 
Man3GlcNAc2 to Man9GlcNAc2. We observed fucosylation of the innermost 
GlcNAc of the chitobiose core in glycans of m/z 1276, 1479 [M+H]1+ and 841 
[M+H]2+; the latter two in addition to glycans of m/z 768 and 841 [M+H]2+ are 
modified with one or two terminal GlcNAc residues. The most abundant peak is 
the Man3GlcNAc2 (18.8%), followed by the Man3GlcNAc3Fuc1 (18.2%) and 
Man3GlcNAc2Fuc1 (16%). Composition of all major peaks was confirmed by the 
MS/MS fragmentation spectra (see supplementary Figures S4.5 to S4.15 ). The 
peak of lowest relative abundance was also the most interesting structure found 
among the salivary glycans; with a GU value of 8.2, it corresponds to the 
composition Proc-HexNAc5Hex6. Analysis of the MS/MS fragmentation suggests 
this could be a galactosylated structure, with three potential conformations of a 
Gal3GlcNAc3Man3GlcNAc2, (Table 5.2).  
 
Saliva samples were treated with JBAM to confirm these structures () peaks 
corresponding to Man3 to Man5 disappear after treatment with the enzyme, 
resulting in peaks of H1N2 and H2N2. Peak at RT 15.9 corresponding to a Man4 
was not completely digested, possibly because the GU units also match a H6 
contaminant found in the processed samples. The peak assigned as H3N3 after 
JBAM treatment could be the result of an incomplete digestion, as the enzyme 
might be slower in cleaving Man α1,2 linkages.  
 
For various structures, action of the JBAM was impeded by GlcNAc modifications 
of one or both terminal mannose residues. The digestion of the peak at RT 16.8 
(5.22 GU) resulted in a peak of H2N3F1, suggesting a GlcNAc residue is modifying 
one of the mannose branches. Similarly, this was the case of H3N3 (RT 15,0) 





(H3N4F1) do not appear to be altered by the JBM, and together with the MS/MS 
analysis are a strong indication that two of the GlcNAc structures are modifying 





Figure 5.1 Analysis of procainamide-labelled N-glycans released from Aedes saliva by HILIC 
(top panel) and ESI-MS (bottom panel). » indicates peaks corresponding to the structure to 
their immediate left + a Na2+ adduct. Asterisk indicates structure missing an m/z of 73, 
corresponding to a loss of procainamide fragment125. Glycan symbols: GlcNAc (blue square), 
Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia (red diamond). 
 
































































































































Table 5.2 Details of the major N-linked glycans found in Ae. aegypti saliva. Glycan symbols: 
GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia (red 














1 4.2 1130.51 1130.68 565.84 Proc-HexNAc2Hex3 18.84 
 
  







3 4.8 1333.57 1333.76 666.84 Proc-HexNAc3Hex3 5.50 
 
  
5 5.0 1292.56 646  Proc-HexNAc2Hex4 1.00 
 
 






5 5.3 1536.63 n/a 768.94 Proc-HexNAc4Hex3 2.38 
 
  






7 6.0 1454.61 1454.74 727.9 Proc-HexNAc2Hex5 1.85 
 
  




9 7.8 1778.72 n/a 889.94 Proc-HexNAc2Hex7 2.64 
 
  




11 8.7 1940.77 n/a 970.97 (4) Proc-HexNAc2Hex8 1.85 
 
  



























5.4.1.3. Confirmation of mannosylated and fucosylated structures by 
lectin blotting 
Probing of saliva samples with ConA which indicated most salivary proteins in Aedes 
have mannosylated N-linked glycans, shown by the disappearance of signal after 
treatment with PNGase F. AAL bound only to glycans at ~57kDa, ~49kDa, ~39kDa 




Figure 5.2 Aedes aegypti saliva N-linked glycoproteins are mannosylated. Salivary glands 
were dissected from Ae. aegypti sugar-fed females and centrifuged to extract saliva. 2.5ug of 
saliva were run on SDS PAGE (12.5%) and transferred onto a PVDF membrane. (A) 
Membrane was blotted with ConA (lanes 1-5), and AAL (lanes 6-8), before (-) and after (+) 
treatment with PNGase F to remove all N-linked glycans. OVA= ovalbumin, positive control; 
BSA= bovine serum albumin, negative control. (B) Nigrosine stained membrane. Asterisk 
indicates band corresponding to PNGase F enzyme.  
 
Specificity of AAL was verified in a parallel experiment by preincubating the lectin 







Figure 5.3 Aedes aegypti saliva fucosylated glycoproteins. Salivary glands were dissected 
from Ae. aegypti sugar-fed females and centrifuged to extract saliva. (A) Membrane was 
blotted with AAL (lanes 1-5), and AAL pre-incubated with 100nM L-fucose (lanes 6-7), before 
(-) and after (+) treatment with PNGase F to remove all N-linked glycans. OVA= ovalbumin, 
enzyme positive control; BSA: bovine serum albumin, negative control. (B) Nigrosine stained 
membrane. Asterisk indicates band corresponding to PNGase F enzyme. 
 
 
5.4.2.  Anopheles gambiae 
5.4.2.1. Glycosylation predictions 
Predictions of the potential glycosylation sites were done with published amino acid 
sequences of An. gambiae saliva245. Analysis with the NetNGlyc 1.0 server showed 
90% of the main salivary proteins have between 1 and 8 potential glycosylation sites 
(Table 5.3). NetOGlyc indicated 85% had Ser or Thr in their sequences, with an 
anopheline antiplatelet protein having up to 26 potential O-linked glycosylation sites. 
As with Aedes, analysis of Anopheles salivary proteins with the DeepLoc 1.0 server 
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5.4.2.2. Salivary glycan structures in Anopheles 
HILIC-UHPLC analysis of glycan structures released from An. gambiae saliva showed 
12 major peaks of GU values between 4.20 and 9.38. The composition of glycan 
structures was highly similar to that of Ae. aegypti, including the Man3GlcNAc2 to 
Man9GlcNAc2 oligomannose sugars. Treatment of salivary glycans with JBAM 
confirmed these glycans. The structure of 5.21 GU at RT ~16.7 remains undigested 
after treatment with JBAM, indicating a GlcNAc modifying one of the terminal 
mannoses and preventing digestion by the enzyme.  
 
The most abundant peak is the Man3GlcNAc2Fuc1 (31.3%), making this the only 
species analysed in this work where a fucosylated structure is the majoritarian 
glycan. Four structures show the modification of a terminal GlcNAc, at m/z 1333.71, 
1479 [M+H]1+ and m/z 748 and 828 [M+H]2+. All other fractions are of relatively 
lower and similar abundance (Figure 5.4, Table 5.4).  
 
The UHPLC chromatogram before and after treatment with JBAM showed all 
mannosylated structures Man4 to Man9 were digested, which can be seen with the 
appearance of H1N2 (RT 5.51), H2N2 (RT 8.31) and H3N2 (RT 11.84). Peaks 
corresponding to the structures H3N3 and H3N3F1 were not susceptible to the 
enzyme, supporting a structure assignment where the chitobiose core is modified by 
GlcNAc residues on one of the mannose branches (as was also found in Ae. aegypti). 
The fraction with the lowest relative abundance is that of RT 22.1, corresponding to 
a H5N2 assignment (6.5 GU); MS/MS fragmentation supports a structure 
configuration Gal1GlcNAc1Man3GlcNAc2. All peaks were confirmed by MS/MS (see 
supplementary figures S4.16 to S4.26. 
 
The peak of lowest abundance at RT 22.07 is of 6.5 GU, corresponding to the 
structure Proc-HexNAc3Hex5, with the MS/MS fragmentation suggesting this could 







Figure 5.4 Procainamide-labelled N-glycans released from Anopheles saliva, analysed by 
positive-ion ESI-MS. Glycan symbols: GlcNAc (blue square), Man (green circle), Gal (yellow 

































































































































Table 5.4 Details on the major N-linked glycans found in An. gambiae saliva. Glycan symbols: 
GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia (red 





























4 5.0 1292.56   Proc-HexNAc2Hex4 1.17 
 











7 6.0 1454.61 1454.73 727.83 Proc-HexNAc2Hex5 3.97 
 
  








10 7.8 1778.72 n/a 889.86 Proc-HexNAc2Hex7 0.90 
 
  




























5.4.3.  Rhodnius prolixus 
5.4.3.1. Salivary glycan structures in Rhodnius 
Rhodnius salivary glycans appear to have the simplest structures of all species 
studied in this work. Analysis by HILIC-UHPLC revealed they are mostly 
paucimannose glycans, ranging from Man3 to Man9 (Figure 5.5, top panel). The most 
abundant peak corresponded to the Man6GlcNAc2 structure of 6.9GU at RT 24.31 
(~17%,); this was followed by the Man3GlcNAc2F1 at RT 14.76 (4.6 GU). The 
Man2GlcNAc2F1 is likely an artefact caused during sample analysis. Only one of the 
structures presented a modification to one of the branches MS average spectra 
confirmed the presence of these oligomannose structures (Figure 5.5, bottom panel) 






















Figure 5.5 Procainamide-labelled N-glycans released from Rhodnius prolixus saliva, analysed 
by HILIC-UHLPC (top panel) and positive-ion ESI-MS (bottom panel). Structures in blue are 
sodiated molecular ions. Glycan symbols: GlcNAc (blue square), Man (green circle), Gal 
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Table 5.5 Details on the major N-linked glycans found in Rh. prolixus saliva. Glycan symbols: 
GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia (purple 






















2 5.0 1292.56 1282.60 646.85 Proc-HexNAc2Hex4 2.88  
 






4 6.0 1454.61 n/a 727.85 Proc-HexNAc2Hex5 9.18 
 
 
5 6.9 1616.67 n/a 808.86 Proc-HexNAc2Hex6 16.97 
  
6 7.8 1778.72 n/a 889.87 Proc-HexNAc2Hex7 3.49 
  
7 8.7 1940.77 n/a 970.89 Proc-HexNAc2Hex8 2.18 
  






























Figure 5.6 Coomassie staining of saliva from several triatomine species: Rhodnius prolixus, 
Triatoma infestans and Triatoma braziliensis before (-) and after (+) treatment with PNGase 
F. OVA: positive control for PNGase F. Asterisk indicates PNGaseF enzyme.  
 
We looked at N-linked glycosylation in the salivary glycoproteins of three triatomine 
species: Rh. prolixus, T. infestans and T. braziliensis. Staining by Coomassie blue 
showed an electrophoretic shift of several glycans, while others remain unchanged 
(Figure 5.6). Probing of Rh. prolixus glycans reveals extensive mannosylation of the 
glycoproteins, which was observed in the characterised glycan structures.  
 
5.4.4.  Genes involved in the N-glycan biosynthesis pathway  
To look at the glycosylation machinery and compare with the experimental data we 
have obtained so far in this work, we used the genome of Drosophila melanogaster 
as a model organism to searched for all the enzymes involved in the N-glycosylation 
pathway. Table  shows a list of D. melanogaster gene orthologues identified from the 
genomes available in VectorBase, for Ae. aegypti, An. gambiae, G. austeni, G. 
brevipalpis, G. fuscipes, G. morsitans, G. pallidipes, G. palpalis, I. scapularis, L. 
longipalpis, M. domestica (non-haematophagous), Phlebotomus papatasi and 
Rhodnius prolixus. As expected, the N-glycosylation pathway is highly conserved for 
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Several gene duplications and some expansions were found. In the tsetse fly G. 
austeni we saw 11 copies of the ManI whose product hydrolyses the terminal 1-2 
linked  -mannoses of Man9; in the tick species Ix. scapularis MGAT4 and 
FucTA/TB/TC showed considerable expansion; hydrolysis by MGAT4 protein results 
in the production of sugar chains with three/four antennae in the Golgi apparatus 
allowing the formation of long complex-type glycans, while FucTA/TB/TC catalyses 
the addition of fucose residues in an a1-3 linkage. MGAT4 also had a minor 
expansion in Lu. longipalpis. In addition to these, minor gene duplications can be 
observed in Table S5.1. Various gene absences were also noted: ALG1 (Lu. 
longipalpis, Ph. papatasi), ALG13 (G. pallidipes), ALG14 (Rh. prolixus), DPM3 (G. 
brevipalpis and G. fuscipes), OST epsilon (Lu. longipalpis, all Glossina except G. 
austeni), OST beta (Ph. papatasi, G. palpalis and G. fuscipes), GCS1 (Lu. longipalpis 
and G. palpalis), MGAT3 (Lu. longipalpis, Ph. papatasi, G. brevipalpis, G. pallidipes, G. 









Table 5.6 Summary table indicating the presence (green) or absence (light yellow) of N-glycan biosynthesis genes in the genome of vector 
arthropods. Dmel: Drosophila melanogaster; AAE: Aedes aegypti; AGA: Anopheles gambiae; ISC: Ixodes scapularis; LLO: Lutzomyia longipalpis; 
MDO: Musca domestica; PPA: Phlebotomus papatasi; RP: Rhodnius prolixus; GA: Glossina austeni; GBR: G. brevipalpis; GFU: G. fuscipes; GMO: 
G. morsitans; GPA: G. palpalis; GPP: G. pallidipes. 
    Dmel AAE AGA ISC LLO MDO PPA RP GA GBR GFU GMO GPA GPP 
Dolichol kinase                               
UDP-N-acetylglucosamine--dolichyl-phosphate 
N-acetylglucosaminephosphotransferase 
ALG7   
    
  
                    
beta-1,4-N-acetylglucosaminyltransferase ALG13                             
beta-1,4-N-acetylglucosaminyltransferase ALG14                             
dolichol-phosphate mannosyltransferase DPM1                             
dolichyl-phosphate mannosyltransferase 
polypeptide 2, regulatory subunit 
DPM2   
    
  
      
          
    
dolichyl-phosphate mannosyltransferase 
polypeptide 3 
DPM3   
                
    
      
beta-1,4-mannosyltransferase ALG1                             
alpha-1,3/alpha-1,6-mannosyltransferase ALG2                             
alpha-1,2-mannosyltransferase ALG11                             
Phospholipid-translocating ATPase RFT1                             





    Dmel AAE AGA ISC LLO MDO PPA RP GA GBR GFU GMO GPA GPP 
alpha-1,2-mannosyltransferase ALG9                             
alpha-1,6-mannosyltransferase ALG12                             
dolichyl-phosphate beta-glucosyltransferase ALG5                             
alpha-1,3-glucosyltransferase ALG6                             
alpha-1,3-glucosyltransferase ALG8                             
alpha-1,2-glucosyltransferase ALG10                             
dolichyl-diphosphooligosaccharide---protein 
glycosyltransferase 
STT3   
                          
dolichyl-diphosphooligosaccharide---protein 
glycosyltransferase 
STT3   
                          
oligosaccharyltransferase complex subunit 
epsilon 
OST   
      
  
        
          
oligosaccharyltransferase complex subunit 
alpha (ribophorin I) 
OST   
      
  
              
  
  
oligosaccharyltransferase complex subunit 
delta (ribophorin II) 
OST   
                          
oligosaccharyltransferase complex subunit 
gamma 
OST   
                      
  
  
oligosaccharyltransferase complex subunit 
beta 
OST   
          
  
      
  






    Dmel AAE AGA ISC LLO MDO PPA RP GA GBR GFU GMO GPA GPP 
mannosyl-oligosaccharide glucosidase GCS1                             
alpha 1,3-glucosidase GANAB                             
mannosyl-oligosaccharide alpha-1,2-
mannosidase  
MAN1   
                          
alpha-1,3-mannosyl-glycoprotein beta-1,2-N-
acetylglucosaminyltransferase 
MGAT1   
          
  
              
alpha-mannosidase II MAN2                             
alpha-1,6-mannosyl-glycoprotein beta-1,2-N-
acetylglucosaminyltransferase 
MGAT2   
                          
beta-1,4-mannosyl-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase 
MGAT3           
  
    
  






MGAT4   
                          
glycoprotein 6-alpha-L-fucosyltransferase FUT8                             
glycoprotein 3-alpha-L-fucosyltransferase A FucTA                             
alpha-1,3-fucosyltransferase B FucTB                             
alpha-1,3-fucosyltransferase C FucTC                             
alpha1,3-fucosyltransferase D FucTD                             








Although studies on protein glycosylation in arthropods have been increasing in 
recent years, little is known about it in species responsible for the transmission of 
pathogens important for humans and other animals. The glycosylation of salivary 
proteins in mosquitoes is of great interest, considering these are vectors to some of 
the most important pathogens in the world; it becomes more relevant in this case as 
all parasites and viruses they transmit must first reach the salivary glands and 
mature to their infectious stage to then be transmitted. 
 
From what we could observe experimentally, all vectors produce oligomannose 
structures from the core Man3GlcNAc2 to the high-mannose Man9GlcNAc2. In both 
mosquito species as well as tsetse fly saliva, glycans showed higher processing, with 
the Man3 GlcNAc2 species being the most abundant; the Man3 GlcNAc2Fuc1 was 
equally abundant in A. aegypti. In sandfly saliva on the other hand, the Man5GlcNAc2 
structures were most abundant, indicating incomplete processing in these species. A 
search of the genome for the enzymes involved in N-glycosylation biosynthesis 
showed the high conservation of the pathway; where certain genes appear to be 
absent, alternative routes of mannosidases and mannosyltransferases are expected 
to be in place210. Oligomannose structures are normally associated with the 
recognition of foreign organisms into the human body. As such, one of the most 
important implications for the terminal mannosylated glycans is in their interactions 
with the vertebrate host cells, particularly those carrying C-type lectin receptors; 
these have roles in pathogen recognition either to facilitate the invasion host cells or 
to promote their destruction211. For most vector-borne pathogens, dendritic cells 
and macrophages constitute the very first line of defence (usually at the site of the 







On the other hand, in Amblyomma the complex-type structure GlcNAc3(Fuc1)Man5 
was the tallest peak in the chromatogram. The differences could be related to the 
type of feeding behaviour seen in ticks, as their attachment to the host for hours or 
days at a time requires more complex adaptations than the other vectors (which 
feed in only minutes). In the tick Ix. scapularis we found a significant gene expansion 
of two genes. The first is the MGAT4, which catalyses the addition of a terminal 
GlcNAc in the Golgi that allows for the creation of tri and tetra antennal branches in 
the Golgi. The second, FucT, catalyses the addition of an a1,3-fucosyl residue to the 
chitobiose core; it has nearly four times more copies in Ixodes than the FUT8 which 
catalyses the addition of a1,6-fucosyl residues also to the chitobiose core. Both of 
these expansions seem to match what was found experimentally in the salivary 
glycans of Am. cajennense, with a higher number of complex-type glycans and the 
majority of structures fucosylated. MGAT4 was also slightly expanded in Lu. 
longipalpis, although only one short complex-type structure was found.  
 
In 1984, studies of recombinant proteins produced in Aedes cell lines showed that 
they were able to produce paucimannose and high mannose-type sugars249. This 
type of glycosylation affects, for instance, arbovirus particles in two ways: during 
viral assembly as glycosylation is important for the folding of most glycoproteins, and 
in the selective recognition of the glycan structures by immune receptors in different 
hosts. Therefore, it can affect aspects like viral infectivity, tropism and evasion of 
immune defences.  
 
 Viral evolution results in constant addition and deletion of genetic materials, 
altering, for instance, their potential glycosylation sites and increasing both in 
complexity and diversity. Dengue virus (DENV) is a member of the Flaviviridae family, 
together with other pathogens like West Nile virus (WNV), Japanese encephalitis 
virus and yellow fever virus (among others)32. It is transmitted mainly by female 





salivary glands, when it becomes ready for transmission during the next bloodmeal. 
In DENV viral particles protein E is the main membrane glycoprotein present on the 
surface of the particle; protein E interacts with host cells like DCs to initiate 
endocytosis81. As with other viruses, DENV exploits the host cell machinery to 
replicate itself, including its glycosylation pathways; when infecting insect cells, they 
will acquire paucimannose-type structures, while if derived from mammalian host 
cells viral glycoprotein will likely express complex-type glycans. It has been shown 
that DC-SIGN, the receptor that initially encounters many viral infections, 
preferentially binds alphaviruses derived from mosquito cells rather than human 
ones212. A similar observation was made in WNV213. In addition, Hacker et al214 
looked at the differences in the glycosylation of mammalian versus insect-grown 
DENV. They showed through lectin work that of the two N-glycans carried by 
glycoprotein E, one was a permanent high mannose sugar while the other depended 
on whether it was derived from mosquitoes (paucimannose) or from mammalian 
cells (complex-type). Interestingly, unlike previous observations with other viruses, in 
DENV efficiency of DC invasion was the same independent of the origin of the viral 
particles, possibly due to the presence of the ‘permanent’ high-mannose glycan. 
They also suggested that incomplete glycan processing in all DENV serotypes was 
responsible for the high-mannose glycan that facilitates their invasion of DCs. Later 
in 2015, Lei et al215 looked at the structural composition of the DENV N-glycans from 
viruses produced in C6/36 Ae. albopictus cells. MALDI-TOF/TOF-MS/MS showed 19 
N-linked glycans species, the most abundant of which corresponds to the 
assignment HexNAc4Hex7dHex1. They also detected a high abundance of glycans 
with terminal hexoses, which together with the lectin array data (which suggested 
the presence of terminal α-gal, oligomannose, fucose, sialic acid and N-
acetylglucosamine residues) seems to suggest that some N-glycans may contain 
terminal (though unconfirmed) galactosylation. In our work, we show Aedes aegypti 
saliva has an abundance of oligomannose glycans, including the high-mannose Man9 





additionally appear to be complex-type with one or two GlcNAc modifications, and 
an interesting potentially a-galactosylated sugar. During infection of the mosquito, 
DENV invades the salivary glands last in preparation for transmission to the 
vertebrate host; here we show the capacity for N-linked glycans produced in the 
salivary glands, whose pathways are also used by the virus. The glycosylation found 
agrees with the glycans reported for DENV, except for the presence of sialic acid in 
the latter, which is likely produced in mammalian host cells.   
 
We did not find any evidence of sialic acids in the saliva of any of the insects studied 
in this work. However, there is a suggested sialylated sugar in the saliva of ticks, 
which our work shows are capable of producing more complex-type glycans. In 
Drosophila only one sialyltransferase gene has been reported, which is a homolog of 
the ST6Gal found in vertebrate organisms216, with an important role in the 
functioning of the fly’s central nervous system. Some studies have suggested Aedes 
have the capacity to produce complex-type structures with sialic acid modifications, 
but this still remains a matter of controversy. Interestingly, Rendic et al156 showed 
that when S. frugiperda and T. ni cells are grown in serum free media, they lacked 
the nucleotide donors to produce sialylated glycans. Insterestingly, we found the b-
galactoside a-2,6-sialyltransferase enzyme (ST6GalI) in the available genome of all 
our vector species, except G. morsitans, and so tsetse flies are not able to produce 
them even in the presence of donors. Furthermore, ST6GalI only uses b-
galactosylated structures as substrates, which were conspicuously absent from the 
triatomine N-glycan profile. The enzyme is also present in the genome of I. 
scapularis, and several galactosylated structures were detected in the saliva of A. 
cajennense; furthermore, HPLC/MS analyses suggested the presence of a sialylated 
structure with very low abundance (m/z 815 [M+Proc+H]3+). It is possible that this 
could be a contamination from dissections (after a bloodmeal) and glycoproteins 
obtained from the host. However, in mammals the sialylated N-glycan has a core a1-





obtains nucleotide donors from the vertebrate host and after bloodfeeding can 
produce these sialylated structures. The finding and localization of the active enzyme 
in ticks could help confirm this. Interestingly, we also found the enzyme in the 
genomes of A. aegypti and A. gambiae, which can also produce galactosylated 
glycans. However, for purposes of this project, and precisely to avoid contamination 
originated from the host, we only worked with saliva of sugar fed mosquitoes; it 
would be interesting therefore to look at the sugar structures produced by bloodfed 
mosquitoes. Humans also possess ST6GalI and glycans with the 2-6 linked sialic 
acid217. However, the implications of sialylated N-linked glycans in the saliva of 
vectors remain to be studied. 
 
Mendes et al218 looked at how the saliva of several triatomine species affected the 
differentiation, maturation and cytokine production of dendritic cells. They found 
that saliva significantly inhibited all these aspects in a dose-dependent manner; 
furthermore, different species varied in the level of inhibition caused, with Rh. 
prolixus causing the ‘mildest’ effect. It is possible that some of part of this effect may 
have been caused by the interaction of mannosylated glycoproteins in triatomine 
saliva. Interestingly, the addition of saliva increased invasion of DCs by T. cruzi; 
however, once again Rh. prolixus did not induce the same effects as the other 
species. Rh. prolixus salivary proteins are unique due to the presence of nitrophorin, 
a vasodilator that gives the saliva of this species a bright red colour. Further analyses 
looking at the salivary glycan structures of other triatomine vectors could show if 
differences extend to the types of glycosylations and their possible roles in these 
might have in the observed effect of Rhodnius saliva. This is also a good example of 
how extrapolations of results between different species should be regarded with 
care. It would be interesting to explore, however, how the salivary glycans might 
affect invasion of host cells by pathogens like Leishmania and Plasmodium. It is well 
known that sandfly saliva affects infection with Leishmania, and although one report 





during infection219, recent studies indicate it actually has a significant effect acting 
against malaria infection247, 248.  
 
The structure with a potential composition of Gal1GlcNAc1Man4GlcNAc2 in An. 
gambiae saliva, has been found in the glycans from a royal jelly mixture, and lists the 
glycoprotein apisin as the first discovery of an insect glycoprotein with a Galb1–
3GlcNAcb1–4Man220. Aspisin, which also contains high mannose type 
oligosaccharides, was shown to stimulate the proliferation of human monocytes220. 
Anopheles showed a similar salivary N-glycan profile with mostly mannosylated 
glycans, with a fucosylated structure for the first time being the most abundant 
species. One of the few complex-type structures possibly carries an a-linked 
galactose. 
 
Insect cells have been commonly used to express recombinant proteins (e.g. 
Spodoptera frugiperda line or Trichoplusia ni), one of the reasons being their 
capacity for eukaryotic PTM, unlike bacterial organisms such as E. coli156. In fact, this 
resulted in many of the first works on the capacity of insect N-linked glycosylation, 
finding they produce mainly high-mannose type glycans, leading to believe 
oligomannose structures were the dominant sugars in these organisms. Eventually, 
the variability in core mono- and double-fucosylation was discovered158,221. As 
glycosylation can be dependent on cell and tissue type, it is important to understand 
not only what kind of glycosylation an organism produces, but also how it can vary 
between tissue types, which will affect the final product. The production of drugs is 
one of the most closely regulated processes, any alterations to the glycosylation of 
recombinant proteins can cause anywhere from mild allergic responses up to life-
threatening conditions. An example of the use of insect cells to produce proteins can 
be seen in the creation of a Chikungunya virus-like particle which will be used as a 







Recently, clinical trials are being carried out using Ae. aegypti saliva in the form of a 
vaccine called AGS-v223, with the idea of tackling the many viral pathogens 
transmitted by this vector species. It contains recombinant versions of mosquito 
salivary peptides; in cases like these, its important to understand how glycosylation 
of the vaccine candidate varies compared to native proteins in the mosquito, as 
immune responses can also change according to this.  
 
With this work, we have characterised the salivary N-glycome of six vector species, 
responsible for the transmission of several pathogens of public health importance 
worldwide. Additionally, we have contributed to the knowledge of the capacity of 













Chapter 6.  Discussion and Conclusions 
 
Many researchers have looked at the salivary proteins, and their characteristics and 
biological roles have been described. As these are secreted proteins, many of them 
are glycosylated, but to date few papers have addressed the glycosylation of salivary 
molecules. Glycosylation can affect many properties of the protein, but importantly 
it influences its interaction with the vertebrate immune system. Considering the 
importance of this saliva for pathogen transmission in all the vectors analyzed in this 
thesis, knowledge of the glycan structures can shed more light on the biological 
interactions of vector bites.  
  
Some cell lines of immune cells can be modified to overexpress a specific receptor 
and carry out assays to determine its role in immune responses. This is the case of 
the ATCC® mutant U937-DC-SIGN (CRL-3253)155, a monocytic cell line that 
overexpresses human DC-SIGN protein on the surface and has been exploited to 
study its recognition and internalization of Dengue viruses224. Stimulation 
experiments with saliva to compare the immune responses of U937-DC-SIGN cells 
versus the U937 wild type line could provide hints of the responses due specifically 
to DC-SIGN. In fact, we have carried out preliminary experiments stimulating these 
cells with different concentrations of G. morsitans saliva, using LPS as a positive 
control. In endemic areas, people are mostly exposed to uninfected saliva bites, and 
so we were interested in seeing the effects of saliva alone. Cytokine levels measured 
after stimulation suggest that tsetse salivary glycans interaction with DC-SIGN could 
be responsible for a pro-inflammatory response, evidenced by a higher TNFa/IL10 
ratio in the U937-DC-SIGN cells; this effect seems to be dose-dependent, as at high 
saliva concentrations, there were no significant differences between the lines. We 
also wondered whether saliva could modulate an existing response, so we 





this resulted in a reduction of TNFa compared to LPS alone, but replicates are 
needed to verify this. In a third condition, we wanted to mimic saliva stimulation of 
the cells by using a highly mannosylated glycoprotein, as mannose is the main ligand 
of the DC-SIGN CRL. By using egg albumin, we observed a slight production of TNFa, 
lower compared to LPS. Again, replicates are needed to confirm this effect (K. 
Mondragon-Shem, J. Reiné and A. Acosta-Serrano, unpublished). 
 
More experiments are needed to confirm these findings and ascertain the role of 
mannosylated glycoproteins in saliva-DC-SIGN interactions. These would involve 
using a wider range of saliva concentrations to see dose-response effects. 
Paucimannose glycans are the main types of glycans found in all arthropod saliva 
characterized in this work. However, they are present in different ratios depending 
on the species, and together with stimulation produced by the proteins themselves, 
means the effects of exposure to each vector can be significantly different. Further 
in vitro assays using the saliva of different vectors will shed light on their specific 
relevance to disease transmission, while common effects could hint at their role in 
haematophagy. Other cell lines expressing CLRs exist such as CHO-MMR expressing 
mannose receptor and K562 expressing DC-SIGN225; however, the advantage of the 
monocytic U937 cells is that they can be differentiated to macrophages or dendritic 
cells, both of which form part of the first line of defense against many vector-borne 
pathogens.  
 
Saliva has many components, and the modifying glycans are not all oligomannose. As 
it is difficult to ascertain the effects of glycans specifically, an additional experiment 
would involve the enrichment of the sample for oligomannose glycans by using a 
concanavalin A column, followed by deglycosylation to compare with the effects of 
proteins alone. Fluorescent dyes such as Oregon Green or Alexa Fluor can be used to 
label salivary glycoproteins and visualize by confocal microscopy the binding to the 





that although both mannosylated glycoproteins and deglycosylated ones can reach 
endocytic compartments (where MHC II molecules reside) once they are 
endocytosed, mannosylated antigens stimulate stronger T-cell proliferation. In fact, 
some studies found that mannosylated antigens can increase antigen presentation 
and stimulation of T-cells by up to 200-fold 226,227, with important relevance for 
vaccine and drug development. This enhanced antigen presentation could explain 
the effects observed with the saliva of some vectors, where it can help clear 
pathogens in the vertebrate host. Additionally, mannosylation could be masking the 
antigenicity of some of the salivary proteins, which is exposed once protein is 
degraded in the endocytic compartment of cells. All of these interactions influence 
the stability of these proteins in blood, and the glycans in particular could be the 
main determinants of how long salivary proteins remain in circulation or certain 
tissues. Mannosylation of proteins has been explored for the administration of 
certain drugs, particularly to increase their immunogenicity. In the case of vector 
salivary proteins, their use for the creation of transmission blocking vaccines could 
greatly help prime the immune response. The production of recombinant proteins 
for this purpose should therefore be tailored to be made in insect cells that result in 
similar N-linked glycosylation.   
 
It would be interesting to understand, together with all of these aspects, how the 
timing of exposure affects this observed effect of mannosylated glycoproteins, 
considering the different transmission dynamics of vector-borne diseases analyzed in 
this work. In general, in endemic areas people and other animals are exposed to 
non-infected bites. Then, different vectors vary in their mode of pathogen 
transmission. For instance, T. brucei resides in the salivary glands of G. morsitans 
until the moment of transmission, when the metacyclic trypomastigotes are likely 
‘coated’ by the salivary glycoproteins at during immune recognition at these first 
stages of infection. Here, saliva is reported to have an anti-inflammatory effect106. 





malaria and certain arboviruses. In this case, mannosylated glycoproteins could favor 
invasion of certain immune cells, which is necessary in the life cycle of these 
pathogens. Dengue virus, for example, is well known to use DC-SIGN as a main point 
of entry into dendritic cells. On the other hand, sandflies inject saliva first, prior to 
regurgitating the parasites. Saliva from different sandfly species varies in its effects 
on infection success of different Leishmania species. It sometimes favors infection by 
recruiting certain immune cells to the site of infection near the skin; in other cases, 
saliva glycoproteins could be increasing antigen presentation both of the salivary 
molecules as well as well as the parasites, or it could be favoring invasion of 
neutrophils and macrophages, which Leishmania needs to survive. In ticks, where 
constant injection of saliva (and pathogens) occurs, the greatest diversity of glycans 
was found; the role of this variety of fucosylated and galactosylated sugars is 
unknown. In all cases, oligomannose glycans could be acting as ‘decoys’ for cells 
bearing C-type lectin receptors.  
 
Another aspect to explore is the affinity of glycan binding, through techniques like 
surface plasmon resonance (SPR). SPR measures the association between ligands 
and their receptors, providing a result in resonance units (RUs). During this process, 
the glycoprotein can be exposed to a series of glycosidases allowing us to obtain 
detailed structural information about the glycoprotein interaction with a receptor228. 
This method can provide a type of glycan profiling using lectins or the fragments of 
the C-type lectins that bear the carbohydrate-binding domains229. Alternatively, 
nuclear magnetic resonance spectroscopy allows the measurement of binding 
kinetics in solution (normally works better with low-affinity interactions), while 
atomic force microscopy can provide remarkably detailed information not only 
about binding affinity at a single-molecule level, but also about the nature of the 
molecular bond228. While several other options to study glycan-receptor interactions 
exist, election of the best one will depend on aspect such as amounts of sample 






Binding inhibition can also help understand glycan-lectin interactions. Antagonists of 
mannose binding like α-methyl-D-mannopyranoside have been shown to inhibit 
interaction with carbohydrate receptors230, and their addition simultaneous to the 
mannosylated glycoproteins could provide clues as to whether effects are CLR-
specific. C-type lectins constitute a superfamily of proteins with multiple roles in 
immune responses and other physiological roles69. DC-SIGN and MR have major 
functions in the recognition of saliva and vector-borne pathogens, and so should be 
the focus of follow-up experiments. However, the role of other carbohydrate 
receptors in the processing of salivary glycoproteins also needs to be considered. 
Toll-like receptors for example, are also expressed on the surface of macrophages 
and dendritic cells, can also recognize and bind mannosylated carbohydrates, and 
sometimes there can be simultaneous stimulation of various receptors at the same 
time. Receptors for other glycan structures can produce immune responses specific 
to certain species and could also be interesting to explore; an example of this is 
galectin, which binds galactosylated sugars246. 
 
The generation of recombinant proteins expressing specific glycan structures could 
help discern which sugars are stimulating these responses; in some studies, 
glycosylation sites have been eliminated or altered in recombinant egg albumin for 
example, to study its interaction with DC-SIGN225. Nevertheless, it is important to 
keep in mind that the production of unglycosylated proteins can alter their 
conformation and thus affect conformational epitopes. OVA antigens could 
potentially be expressed in existing insect cell lines, such as Spodoptera frugiperda or 
Trichoplusia. ni, or ideally in cell lines isolated from their specific vectors and tissues. 
Having these cells would allow us to study species-specific gene expression, in 
addition to facilitating experiments to see how external activated sugar donors 






The stimulation of C-type lectin receptors (CLRs) can trigger signaling cascades that 
promote innate immune responses and the production of molecules such as 
cytokines and interferons. CLRs are also responsible for endocytosis and antigen 
presentation, providing a link to acquired immunity. Glycans bearing mannosylated, 
fucosylated or galactosylated structures for example are recognised by these 
receptors, and a combination of stimuli can lead to specific immune responses.  
 
Even though the majority of salivary glycoproteins are expected to be mannosylated, 
in some cases it will be particularly relevant to know exactly which proteins are 
carrying different glycan structures. For instance, we have found that saliva of the 
tick A. cajennense contains several galactosylated sugar structures, one of which 
potentially has a role in the induction of anti-a-gal IgE antibodies causing red-meat 
allergy around the world. The a-galactosylated antigen seems to be modifying one 
of the major salivary proteins, which proteomic analyses suggest could be 
vitellogenin or heme lipoprotein. However, in order to be certain, it is necessary to 
sequence the glycosylated sites in the protein and the composition of the glycan 
structures attached to these, often referred as glycopeptide mapping231. The 
identification of other galactosylated structures in ticks and mosquitoes, as well as 
fucosylated structures with antigenic potential, would contribute towards a more 
complete understanding of the roles played by specific salivary proteins that have 
been described elsewhere. Once identified, recombinant versions of the salivary 
proteins could be produced and used for overlaying and in vitro assays.  
 
Activation of the lectin complement pathway is another interesting aspect to 
explore. This pathway is activated by the pattern recognition molecule mannose-
binding lectin (MBL) and has a role as first line against pathogen invasion. However, 
lesser known is the role of this pathway in homeostasis, which involves aspects like 





glycans could interfere with this role of MBL, contributing to the well-known 
anticoagulant properties of the saliva of haematophagous species. 
 
Using the glycosylation enzyme sequences found for each of the vectors to generate 
complementary DNA sequences, functional activity can be evaluated by inserting 
these sequences into a cloning vector and transfecting them into mutant cell lines 
deficient specific enzymes; flow cytometry using fluorescent-labelled lectins could be 
used to evaluate the production of specific monosaccharide and potential linkages. 
As an example, this was done to test for the functionality of sialyltransferases in 
different tissues of Ae. aegypti 233. Sialylation in particular is one of the most 
interesting areas to explore, considering it has been a subject of controversy in 
arthropod glycosylation; this has been mainly due to weaknesses found in some of 
the experiments carried out for its detection (e.g. lack of controls). Sialic acid 
glycosylation has been genetically and biochemically described in D. melanogaster, 
with special relevance in embryonic development and the nervous system216, 
suggesting it is limited to certain tissues and life stages. Mertsalov et al234 described 
the activity of the CMP-N-acetylneuraminic acid synthase, which is the sugar 
nucleotide donor necessary for the Golgi sialylation of glycan structures. BLAST 
search on VectorBase indicated that homologous sequences for this enzyme exist in 
G. fuscipes, G. brevipalpis, I. scapularis, A. gambiae (and a few Anopheles species), 
Ae. aegypti and Ae. albopictus (data not shown). The presence of the CMP-Neu5Ac 
donor has yet to be demonstrated in these species, except for Aedes233. Although 
sialylation capacities have not been found to be significant in insect cells used for in 
culturing assays like viral studies and protein expression235, it is important to keep in 
mind that generalizations about protein glycosylation pathways are difficult 
considering the diversity observed in arthropods. Analysis not only the 
glycosyltransferase but also the availability of the activated sugar donors is necessary 
in the process of confirming sialylation in these arthropods. It might be that this 





more sensitive techniques will allow their study. Furthermore, the capacity to 
produce Neu5Gc, which is antigenic in humans236 and has been suggested in 
Drosophila, also remains to be studied.  
 
Expression of the different enzymes such as fucosyltransferases, 
galactosyltransferases, and sialyltransferases in different tissues can be detected by 
conventional immunohistochemistry or by fluorescent microscopy using 
fluorescently labelled antibodies or lectins. This would help understand their 
potential relevance for both arthropod biology as well as for pathogen transmission 
(e.g. in areas like midgut and salivary glands).  
 
An alternative to study this glycosylation is through mutations or alterations of the 
pathway. In Drosophila, mutations of various enzymes such as mannosidases have 
revealed alternatives paths the fly uses to produce glycosylation, but this is limited 
to certain tissues in the body and a deleterious phenotype is still observed117. The 
creation of glycosylation mutants using techniques such as the Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system can provide in vivo 
evidence of the effects of glycosylation impairment not only in the biology of the 
organism, but also on pathogen transmission. An initial approach could be to alter 
the glycosylation capacity of existing insect cell lines or to create cell lines from these 
vectors to study their glycosylation. These insect cell lines could also be used to 
explore the capacity for O-linked glycosylation. We did not find O-linked glycans in 
tsetse flies or sandflies but have yet to look at the rest of the vectors. However, the 
absence of O-linked glycans is curious, since saliva-type fluids found in many other 
organisms usually exhibit this type of glycosylation.  
 
The generation of novel glycosylation mutant cell lines, directly derived from vector 
cells, could be used to study the importance of glycosylation in the assembly and 





Flaviviruses, the envelope has one glycosylation site, which is essential for 
virulence237; a mutant lacking this modification (and therefore un-glycosylated) not 
only resulted in lower viremia, but also decreased infectivity by mosquito 
transmission. Interestingly, antibodies produced against this mutant showed 
protection against the wild type virus. Alterations of the biosynthesis pathways could 
shed light on where glycosylation of the viral particles takes place in the mosquito. 
However, this has to be regarded with care because glycosylation is reported to be 
fundamental for several aspects of arthropod biology; in Drosophila for instance, it 
has roles in embryo development and the side effects of these alteration might be 
deleterious117.  
 
However, results with one species cannot be extrapolated to others, and might vary 
depending on factors such as diet intake or other physiological conditions, such as 
including infection. Studies have found that infection with T. brucei affects protein 
concentrations in the salivary gland, and that this deficiency may favor parasite 
transmission by forcing the fly to take repeated bloodmeals. However, salivary 
glycosylation did not appear to be affected by infection with T. brucei. An effect of 
infection in the other vector species remains to be seen.  
 
In this work I have only looked at the glycosylation of salivary proteins in 
bloodfeeding insects, which are important because they transmit human and animal 
diseases worldwide. Nevertheless, plant-feeders can cause millions of dollars in 
losses by destroying fields of crops. Many of these herbivores can transmit viruses 
117, whose glycosylation would be influenced by the host. Plants use lectins as 
protection measures against certain predators; in this case these glycans could be 
recognizing the saliva of the herbivore to neutralize it. Additionally, it could be useful 
to study an herbivore as an outgroup to all bloodfeeders studied here, particularly as 






Furthermore, the sugar structures modifying salivary proteins represent only a 
snapshot of the arthropod’s glycosylation, and it would be necessary to study 
different parts of the vectors (e.g. midgut) in more detail to understand the extent of 
glycosylation in other tissues and their relevance for disease transmission.  
 
In summary, this work provides for the first time a structural characterization of the 
salivary glycans in arthropod vectors of disease. Together, the salivary glycans 
studied in this work give us a very good idea of the glycosylation capacity of these 
vectors (and possibly other arthropods). More functional studies are needed to fully 
understand the biological roles these sugar structures on hematophagy and 
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Table S2.1. Prediction of potential N-linked glycosylation sites in Lu. longipalpis salivary proteins Protein sequences were searched on the 
NetNGlyc server to find N-X-S/T sequon. Signal Peptide was predicted using the SignalP server. Prediction of N-glycosylation sites of the major 





 Name VectorBase NCBI Protein name Class Predicted sequon 
1 LJL04 LLOJ004915-PA AAS16906 29.2 kDa salivary protein PpSP32-like 38 NKSS 
2 LJL08 LLOJ005746-PA* AAA29288 Maxadilan* Maxadilan no sites 








5 LJL124 LLOJ008400-PA AAS16915 6kDa salivary protein  no sites 
6 LJL13 LLOJ009780-PA AAL16051 D7 salivary protein d7 related no sites 






8 LJL143 LLOJ001514-PA AAS05319 32kDa salivary protein 33kDa 
63 NQTH 
262 NKTC 
9 LJL15 LLOJ004397-PA ABA39525 16.5 kDa salivary protein anticoagulant 53 NLTL 





11 LJL18 LLOJ004397-PA ABA39526 16.2 kDa salivary protein anticoagulant no sites 
12 LJL23 LLOJ003550-PA AAD33513 putative apyrase apyrase no sites 
13 LJL34 LLOJ002578-PA AAD32191 antigen 5 related protein antigen 5 related 151 NLRT 
14 LJL35 LLOJ007566-PA AAD32196 
putative RGD containing 
peptide 
RGD no sites 
15 LJL38 LLOJ005673-PA AAR99723 2.5kDa salivary protein  no sites 
16 LJL91 LLOJ004397-PA AAS05317 16.3 kDa salivary protein anticoagulant no sites 
17 LJM10 LLOJ004397-PA ABB00902 16.7kDa salivary protein anticoagulant no sites 
18 LJM11* LLOJ001468-PA AAS05318 43.2kDa salivary protein* yellow-related 
33 NVTP 
213 NVTH 
19 LJM111 LLOJ001468-PA ABB00904 43kDa salivary protein yellow-related 141 NPTL 
20 LJM114 LLOJ009498-PA AAS16907 14.2kDa salivary protein  no sites 
21 LJM17* LLOJ001469-PA AAD32198 putative yellow protein* yellow-related 29 NITF 
22 LJM19* LLOJ006680-PA AAR99725 10.7 kDa salivary protein*  no sites 
23 LJM26 LLOJ006962-PA AAS16913 49kDa salivary protein SERPIN 83 NLSK 









25 LJS03 LLOJ003729-PA AAS16914 15kDa salivary protein  
64 NSSV 
75 NETL 
26 LJS105 LLOJ007883-PA AAS16910 7.3kDa salivary protein  44 NQSG 
27 LJS138 LLOJ006038-PA AAS16917 16.1kDa salivary protein  no sites 
28 LJS142 LLOJ004397-PA ABB00903 16.6kDa salivary protein anticoagulant no sites 
29 LJS169 LLOJ005853-PA AAS16912 11.6kDa salivary protein  53 NLTK 
30 LJS192 LLOJ006680-PA AAR99724 9.6kDa salivary protein  no sites 
31 LJS193 LLOJ007302-PA AAS16918 32.2kDa salivary protein hyaluronidase 
25 NESA 
233 NDSM 
32 LJS201 LLOJ003106-PA AAS16919 9kDa salivary protein  no sites 
33 LJS238 LLOJ007029-PA AAS16909 4.6kDa salivary protein  no sites 
34 LuloAC LLOJ004397-PA AAD33512 anticoagulant anticoagulant no sites 
35 LuloAMY LLOJ004838-PA AAD32192 putative alpha-amylase amylase 
179 NQTI 
414 NGSN 



























37 LuloSL1 LLOJ000181-PA AAD32197 SL1 protein PpSP15-like no sites 
41 Lon LLOJ004398-PA AAS17937 16.4kDa salivary protein anticoagulant no sites 






































4 4.87 718.8 1436.58 1436.48 (Hex)4 (HexNAc)2  0.41 
 
5 4.95 





748.79 1436.58 1436.48 











7 5.15 718.8 - 1436.48 (Hex)4 (HexNAc)2  3.87 
 
8 5.88 819.31 - 1639.56 
(HexNAc)1 + 144 + Hexose + 





727.8 1454.59 1454.61 (Hex)2 + (Man)3(GlcNAc)2 
41.43 
 
646.79 1292.58 1292.56 (Hex)4 (HexNAc)2 
 
10 6.83 808.82 1616.64 1616.67 (Hex)3 + (Man)3(GlcNAc)2 9.84 
 
11 7.10 767.76 - 1534.57 (Hex)4 (HexNAc)2 0.37 ? 
12 7.25 767.76 - 1534.57 (Hex)4 (HexNAc)2 0.35 ? 
13 7.44 727.23 - 1454.61 (Hex)2 + (Man)3(GlcNAc)2 0.38 
 
14 7.72 889.83 - 1778.72 (Hex)4 + (Man)3(GlcNAc)2 2.77 
 





















Figure S2.1. MS/MS fragmentation of Lu. longipalpis glycan observed at m/z 1276.58 
[M+H]1+ Glycan symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc 






Figure S2.2. MS/MS fragmentation of Lu. longipalpis glycan observed at m/z 1436.58 
[M+H]1+ Glycan symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc 
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Figure S2.3. MS/MS fragmentation of Lu. longipalpis glycan observed at m/z 1292.58 
[M+H]1+ Glycan symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc 





Figure S2.4. MS/MS fragmentation of Lu. longipalpis glycan observed at m/z 1454.61 
[M+H]1+ Glycan symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc 
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Figure S2.5. MS/MS fragmentation of Lu. longipalpis glycan observed at m/z 1292.58 
[M+H]1+ Glycan symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc 






Figure S2.6. MS/MS fragmentation of Lu. longipalpis glycan observed at m/z 1616.64 
[M+H]1+ Glycan symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc 
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Figure S2.7. MS/MS fragmentation of Lu. longipalpis glycan observed at m/z 1534.57 
[M+H]1+ Glycan symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc 





Figure S2.8. MS/MS fragmentation of Lu. longipalpis glycan observed at m/z 1534.57 
[M+H]1+ Glycan symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc 
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Figure S2.9. MS/MS fragmentation of Lu. longipalpis glycan observed at m/z 1454.61 
[M+H]1+ Glycan symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc 





Figure S2.10. MS/MS fragmentation of Lu. longipalpis glycan observed at m/z 1778.72 
[M+H]1+ Glycan symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc 
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Figure S2.11. MS/MS fragmentation of Lu. longipalpis glycan observed at m/z 1940.77 
[M+H]1+ Glycan symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc 





Figure S2.12. MS/MS fragmentation of Lu. longipalpis glycan observed at m/z 2102.82 
[M+H]1+ Glycan symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc 
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Figure S2.13 MALDI-TOF analysis of the m/z [718.89]2+ isomer at minute 25.0, (a) untreated, 




Figure S2.14 MALDI-TOF analysis of the m/z [718.89]2+ isomer at minute 26.5, (a) untreated, 




























Table S3.1 Prediction of N-linked glycosylation sites in G. morsitans salivary proteins. Protein 
sequences were searched on the NetNGlyc server to find N-X-S/T sequon that marks 
possible glycosylation sites. NCBI accession number and VectorBase. Signal Peptide was 
predicted using the SignalP server.  






deoxyribonuclease i |Tsal2 form 
A [Glossina morsitans 
morsitans] 
N 1 347 NMTQ 
gi:125901748 GMOY012361-PA 
deoxyribonuclease i |Tsal2 form 
A [Glossina morsitans 
morsitans] 
Y 1 229 NMTQ 
gi:8927464 GMOY012071-PA 
deoxyribonuclease i |Tsal1 
protein precursor [Glossina 
morsitans morsitans] 
Y 1 268 NITR 
gi:195450783 GMOY005442-PA 
retinoid- and fatty acid-binding 











isoform b | 15'-nucleotidase-








isoform b | 5' nucleotidase 









venom allergen 3-like | 1antigen 
5 precursor [Glossina morsitans 
morsitans] 
Y 0 n/a n/a 
gi:89112793 GMOY000466-PA 
lectin subunit alpha-like | lectin 























































tubulin alpha-1 chain | alpha-
Tubulin at 84B [Drosophila 
melanogaster]  
N 1 380 NTTA 
gi:557765473 GMOY006173-PA 14-3-3 zeta N 2 
176 NFSV 
227 NLTL 
gi:557763622 GMOY009591-PA disulfide isomerase Y 0 n/a n/a 
gi:24645350 GMOY002487-PA beta 2c N 2 
184 NATL 
370 NSTA 
gi:557763388 GMOY011657-PA 14-3-3 protein epsilon-like N* 2 
176 NFSV 
227 NLTL 






transferrin precursor | 
1transferrin [Glossina morsitans 
morsitans] 
Y 0 n/a n/a 
gi:17530805 GMOY007085-PA actin-4 N 1 66 NGSG 















gi:557765833 GMOY011870-PA isoform c N 0 n/a n/a 
gi:17975545 GMOY008458-PA actin N 1 13 NGSG 




glyceraldehyde 3 phosphate 






















gi:20129309 GMOY005869-PA cg3652 N 1 89 NVTY 
gi:557758542 GMOY001776-PA actin N* 1 13 NGSG 









Gmfb8 | Gmfb8 [Glossina 
morsitans morsitans] 
Y 1 161 NVSN 
gi:157132376 GMOY000148-PA tubulin beta-1 chain N 2 
184 NATL 
370 NSTA 
gi:498950702 GMOY006365-PA tubulin beta chain N* 2 
166 NATL 
352 NTTA 
gi:557761720 GMOY003315-PA actin N* 1 13 NGSG 














































gi:557780372 GMOY000743-PA vacuolar h N* 2 
180 NYTV 
310 NTSN 






































gi:157131457 GMOY002613-PA tubulin alpha-1a chain N* 1 380 NTTA 
gi:557754077 GMOY001525-PA 
atp synthase subunit 
mitochondrial-like 
N* 0 n/a n/a 
gi:557768424 GMOY005920-PA alpha 8 like N 2 
127 NVTT 
390 NTTA 


















serpin 4 | serine protease 










N 1 233 NVSV 
gi:195457222 GMOY003216-PA 
heat shock 70 kda protein 
cognate 3 isoform x1 
Y 0 n/a n/a 


























gi:557767527 GMOY005837-PA calcium-binding protein N 0 n/a n/a 

























protein lethal essential for life-
like isoform x1 









gi:557768079 GMOY001238-PA isoform b Y 1 201 NLSV 





























gi:557762438 GMOY004732-PA isoform a N 0 n/a n/a 
gi:150416150 GMOY012268-PA 
sgp1_glomm ame: full=glycine 
glutamate-rich protein sgp1 
flags: precursor | 
SGP1_GLOMMRecName: 
Full=Glycine/glutamate-rich 
protein sgp1; Flags: Precursor 
[Glossina morsitans morsitans] 
Y 0 n/a n/a 
gi:1346214 GMOY002000-PA glutathione s-transferase d1 N 0 n/a n/a 








rich protein sgp2 flags: 
precursor | 
SGP2_GLOMMRecName: 
Full=Proline-rich protein sgp2; 
Flags: Precursor [Glossina 
morsitans morsitans] 


















gi:195112292 GMOY006777-PA pyruvate kinase N 1 140 NETI 
gi:557784231 GMOY002913-PA 
t-complex protein 1 subunit 
beta-like 











citrate synthase | 
CISY_GLOMMRecName: 
Full=Probable citrate synthase, 
mitochondrial; Flags: Precursor 
[Glossina morsitans morsitans] 
N* 1 271 NVSA 
gi:195429230 GMOY001282-PA calbindin isoform a N* 1 90 NATD 
gi:50897523 GMOY008040-PA 
peroxiredoxin 1-like |putative 
thioredoxin peroxidase 1 
[Glossina morsitans morsitans] 
N* 0 n/a n/a 
gi:557772845 GMOY005539-PA adenylosuccinate synthetase N 1 72 NGTE 
gi:557762793 GMOY012116-PA yellow- isoform a Y 0 n/a n/a 
gi:558515932 GMOY004864-PA 

















gi:557760037 GMOY003684-PA enolase N 2 
37 NKSN 
142 NKSK 
gi:218526911 GMOY003765-PA moesin ezrin radixin N* 1 160 NKSV 
gi:122001617 GMOY005519-PA 
imaginal disc growth factor 4 | 
IDGF4_GLOMMRecName: 
Full=Chitinase-like protein 
Idgf4; AltName: Full=Imaginal 
disk growth factor protein 4; 
Flags: Precursor [Glossina 
morsitans morsitans] 
Y 1 225 NSSL 





gi:557759958 GMOY011561-PA 40s ribosomal protein s7-like N* 0 n/a n/a 
gi:557756536 GMOY001946-PA leucyl aminopeptidase N 1 146 NLSV 


































spermine oxidase-like N 2 
177 NLSL 
488 NLTI 
gi:557783817 GMOY009975-PA annexin isoform b N* 0 n/a n/a 
gi:557753635 GMOY008764-PA 
atp synthase subunit 
mitochondrial-like 
N* 0 n/a n/a 
gi:498984678 GMOY009575-PA annexin isoform a N 1 293 NRTL 
gi:557755420 GMOY006832-PA 














tsep_glomm ame: full=protein 
ame: full=ep-repeat protein 




protein; Flags: Precursor 
[Glossina morsitans morsitans]  
Y 0 n/a n/a 







calcium-binding protein isoform 
a 
Y 0 n/a n/a 





















gi:557777303 GMOY002792-PA yippee interacting protein 2 N* 2 
178 NMSQ 
198 NYSL 
gi:557755691 GMOY009907-PA cytochrome c N* 0 n/a n/a 
gi:498999942 GMOY007346-PA 
electron transfer flavoprotein 
subunit beta 
N 0 n/a n/a 
gi:557764171 GMOY011989-PA cg12262-pa N* 0 n/a n/a 





































gi:195456794 GMOY007078-PA isoform a N* 0 n/a n/a 



















eukaryotic translation initiation 
factor 4 gamma-like isoform x3 
N* 0 n/a n/a 




odorant-binding protein 99b 
|odorant binding protein 2 
[Glossina morsitans morsitans] 
Y 0 n/a n/a 
gi:557759734 GMOY000211-PA 







gi:195451659 GMOY002605-PA isoform a N 1 544 NCSI 





























gi:558515948 GMOY000497-PA heat shock protein N* 1 63 NASR 
gi:125811503 GMOY000487-PA 
nad dependent epimerase 
dehydratase 
N 0 n/a n/a 
gi:118777462 GMOY002110-PA aldo-keto reductase N 0 n/a n/a 


















gi:195037353 GMOY006255-PA 60s ribosomal protein l4 N 0 n/a 
n/
a 











Gmfb8 | Gmfb8 [Glossina 
morsitans morsitans] 
Y 0 n/a n/a 
gi:557775125 GMOY000979-PA 60s acidic ribosomal protein p0 N 0 n/a n/a 
gi:498979583 GMOY002461-PA adenylosuccinate lyase N 1 354 NVSQ 











gi:194769104 GMOY011744-PA adp-ribosylation factor 2-like N* 0 n/a n/a 
gi:194904751 GMOY000747-PA nucleoside diphosphate kinase N* 1 3 NFSE 






hypothetical protein | succinate 
dehydrogenase [ubiquinone] 
flavoprotein 
            subunit, mitochondrial-
like 
N 0 n/a n/a 


























N 0 n/a n/a 





















gi:6707288 GMOY007385-PA isoform a N* 1 77 NVSV 
gi:19168450 GMOY001239-PA 
Gmfb8 | Gmfb8 [Glossina 
morsitans morsitans] 
Y 1 66 NFSS 
gi:557766460 GMOY000825-PA 
adenylate kinase isoenzyme 1-








































transcription factor btf3-like 
protein 4 
N 0 n/a n/a 
gi:557774634 GMOY009071-PA 
protein transport protein 






ubiquitin carboxyl terminal 
hydrolase 












gi:557754781 GMOY010862-PA glutamate carboxypeptidase N 1 17 NKSQ 





gi:17136866 GMOY003850-PA adp-ribosylation factor 1 N 1 60 NISF 
gi:194903336 GMOY005635-PA tryptophanyl-trna synthetase N 2 
2 NDTE 
196 NLTF 




gi:557780962 GMOY007807-PA heat shock protein 23-like N 0 n/a n/a 
gi:498960712 GMOY010573-PA rab gdp-dissociation inhibitor N 0 n/a n/a 
gi:557756446 GMOY008484-PA 
camp-dependent protein kinase 






t-complex protein 1 subunit 
epsilon 




















gi:38564653 GMOY005926-PA superoxide dismutase N* 2 
89 NGSG 
97 NISD 
gi:557773470 GMOY002660-PA chloride intracellular channel N 0 n/a n/a 
gi:557780840 GMOY001589-PA enoyl- mitochondrial N 1 87 NESD 
gi:557774964 GMOY010107-PA ribonuclease uk114 N* 0 n/a n/a 


























































gi:557782505 GMOY004027-PA aspartate aminotransferase N 0 n/a n/a 
gi:24581506 GMOY004726-PA 
male accessory gland serine 
protease inhibitor-like 
Y 0 n/a n/a 
gi:82408370 GMOY008503-PA 
ferritin 2 light chain isoform a | 
1ferritin light-chain [Glossina 
morsitans morsitans] 
Y 0 n/a n/a 
gi:195445040 GMOY007954-PA phosphoglyceromutase Y 1 249 NMSE 
















translationally controlled tumor 
protein 
N 1 6 NTTS 
gi:83595253 GMOY003656-PA 
serpin 43ab |serine protease 
inhibitor 43Ab [Glossina 
morsitans morsitans] 
Y 0 n/a n/a 
gi:557775017 GMOY006029-PA 
ubiquitin carboxyl terminal 
hydrolase 
N 0 n/a n/a 






























gi:557752290 GMOY001033-PA phosphoglycerate kinase N 0 n/a n/a 
















gi:557762554 GMOY009585-PA annexin isoform a N 0 n/a n/a 
gi:557767205 GMOY004289-PA isoleucyl trna synthetase N 0 n/a n/a 



















like isoform x2 
N 0 n/a n/a 
gi:557754727 GMOY010851-PA 
































eukaryotic translation initiation 
factor 2 alpha subunit 








0 n/a n/a 





















reticulum atpase ter94-like 
N 1 838 NATQ 
gi:498926571 GMOY003371-PA elongation factor 1-alpha N 1 284 NLTT 
gi:195165108 GMOY003773-PB 40s ribosomal protein s5 N* 0 n/a n/a 
gi:195426868 GMOY009102-PA fk506-binding protein N 2 
33 NGTK 
95 NSTL 































eukaryotic translation initiation 
factor 5a 
N* 0 n/a n/a 
gi:24659604 GMOY003037-PA cg2867 N* 1 392 NKTV 
gi:83595251 GMOY002262-PA 
serpin b3-like |serine protease 







bifunctional purine biosynthesis 
protein purh 




















gi:8980621 GMOY009534-PA partial Y 1 45 NETM 
gi:391348549 GMOY007655-PA calmodulin N* 1 70 NGTI 
gi:395513211 GMOY005690-PA 
ubiquitin-60s ribosomal protein 
l40-like 
N* 1 35 NLSK 




gi:557760664 GMOY011752-PA isoform a N 1 75 NRSQ 















odorant-binding protein 99c 
|odorant binding protein 21 
[Glossina morsitans morsitans] 
N* 1 101 NSSV 




gi:557760515 GMOY012179-PA acetyl- mitochondrial N* 1 258 NGTV 








like | 1salivary gland growth 
factor-1 precursor [Glossina 
morsitans morsitans] 
N 1 359 NTTR 












































N 1 290 NGTA 
gi:557768444 GMOY002255-PA 












citrate synthase | 
CISY_GLOMMRecName: 
Full=Probable citrate synthase, 
mitochondrial; Flags: Precursor 
[Glossina morsitans morsitans]  
Y 1 268 NVSA 
gi:557775163 GMOY000886-PA wd-repeat protein N 0 n/a n/a 
gi:498927294 GMOY009874-PA 
t-complex protein 1 subunit eta-
like 
N 0 n/a n/a 
gi:557752418 GMOY006110-PA leucine--trna cytoplasmic-like N 1 337 NMSY 
gi:498943240 GMOY010979-PA rab5 N 2 
22 NGTS 
27 NKSC 






gi:557770076 GMOY002902-PA succinyl- :3-ketoacid isoform a N 1 82 NLTA 
gi:17933672 GMOY011554-PA myosin light chain 2 N 1 154 NFTQ 
gi:557775282 GMOY004791-PA calponin transgelin N 0 n/a n/a 
gi:498963712 GMOY004070-PA ribosomal protein l14 N* 0 n/a n/a 





gi:557766884 GMOY011640-PA isoform b N* 1 153 NATG 
gi:195123945 GMOY008696-PA aspartyl-trna synthetase Y 1 240 NTSK 
gi:557762442 GMOY009851-PA 
proteasome subunit alpha type-
3-like 











imaginal disc growth factor 3 | 
DGF1_GLOMMRecName: 
Full=Chitinase-like protein 
Idgf1; AltName: Full=Imaginal 
disk growth factor protein 1; 









ribonucleoprotein at isoform a 
N 1 181 NKTL 






































gi:557766326 GMOY000946-PA lethal 72dr N* 0 n/a n/a 
gi:557772282 GMOY011451-PA probable fatty acid-binding N* 0 n/a n/a 
gi:557756350 GMOY002522-PA 
eukaryotic initiation factor 4a-iii-
like 













carboxylate reductase 2 
[Glossina morsitans morsitans] 
N 0 n/a n/a 
gi:195046570 GMOY004611-PA 









ejaculatory bulb-specific protein 
3-like |chemosensory protein 3 
[Glossina morsitans morsitans] 
y 0 n/a n/a 
gi:194757828 GMOY004175-PA 
camp-dependent protein kinase 
isoform d 




N 1 119 NVTE 
gi:156371481 GMOY009985-PA histone h2b N 1 123 NITK 
gi:557750019 GMOY005787-PA 
fk506-binding protein 14 
isoform a 
Y 1 125 NISN 








gi:285026355 GMOY010075-PA 60s acidic ribosomal protein p2 N 0 n/a n/a 
gi:498927699 GMOY011979-PA vacuolar h N 0 n/a n/a 






poly -specific endoribonuclease 
homolog 
Y 1 497 NGTI 
gi:194764334 GMOY008078-PA calcineurin a at isoform a N 2 
30 NGTH 
40 NKTG 
gi:557768944 GMOY011770-PA hydroxyacyl dehydrogenase N 1 98 NKST 
















atp synthase subunit 
mitochondrial-like isoform x1 
N* 1 85 NVTS 
gi:601036656 GMOY010873-PA ribosomal protein l19 N 0 n/a n/a 
gi:557778795 GMOY010121-PA 
venom dipeptidyl peptidase 4-












N* 1 292 NITL 













gi:83944690 GMOY008502-PA ferritin 1 heavy chain isoform a Y 0 n/a n/a 
gi:557767237 GMOY006884-PA 
atp-binding cassette sub-family 




gi:557773707 GMOY005803-PA protein dj-1-like N 0 n/a n/a 
gi:588480884 GMOY002642-PA 
protein lethal essential for life-
like isoform x1 
N 0 n/a n/a 

























eukaryotic translation initiation 
factor 3 subunit 6 
N 1 46 NKTN 
gi:557756536 GMOY006859-PA aminopeptidase -like N 0 n/a n/a 
gi:557758407 GMOY006894-PA selenium-binding protein 1-like N* 1 166 NVTA 
gi:557758677 GMOY009666-PA 
nucleolar mif4g domain-























gi:498980663 GMOY002421-PA heat shock protein 60 N 1 422 NATR 
gi:557775851 GMOY001423-PA 60s ribosomal protein l9 Y 0 n/a n/a 
















gi:557759313 GMOY002766-PA cg16916 protein N* 1 344 NLSE 
gi:499008051 GMOY004813-PA 
dihydrolipoamide 
acetyltransferase component of 
pyruvate dehydrogenase 










gi:195443866 GMOY009915-PA isoform a Y 1 81 NGTK 
gi:557778327 GMOY006412-PA isoform a Y 0 n/a n/a 
gi:557763493 GMOY007591-PA 
26s protease regulatory subunit 
8-like 
N 1 116 NESY 
gi:498931806 GMOY007323-PB 







eukaryotic translation initiation 
factor 3 subunit b-like 
N 1 466 NVSF 
gi:557764735 GMOY005546-PA adenosylhomocysteinase 3-like N* 2 
263 NDSV 
440 NLSC 
gi:195449447 GMOY001920-PA isoform a N 1 161 NGSV 














gi:557772677 GMOY005979-PA cysteine synthase N* 1 178 NKSD 
gi:557772010 GMOY001361-PA 40s ribosomal protein s8-like N* 1 111 NASN 









gi:557760618 GMOY009457-PA atp synthase subunit d N* 1 86 NVTK 
gi:498966686 GMOY003041-PA coatomer subunit delta-like N 0 n/a n/a 
gi:498956168 GMOY001340-PA isoform i N 0 n/a n/a 
gi:557762258 GMOY009288-PA probable prefoldin subunit 4-like N* 1 131 NISL 
gi:557763196 GMOY002066-PA 
protein transport protein 


































gi:22024141 GMOY010846-PA 40s ribosomal protein s23-like N* 0 n/a n/a 
gi:89112791 GMOY003596-PA 
hsp70 hsp90 organizing protein 
homolog |Hsp70/Hsp90 
organizing protein-like protein 
[Glossina morsitans morsitans] 
N 1 43 NRSA 
























gi:557782495 GMOY004025-PA tyrosyl-trna synthetase N 0 n/a n/a 
gi:351709298 GMOY000268-PA histone partial N* 0 n/a n/a 
gi:351709298 GMOY002745-PA histone partial N 0 n/a n/a 










gi:351709298 GMOY007493-PA histone partial N 0 n/a n/a 




gi:195358314 GMOY000629-PA histone h2b N 1 17 NITK 
gi:498970418 GMOY011222-PA ribosomal protein s4e Y 1 176 NDTV 






gi:195066363 GMOY005739-PA histone h2b N 1 19 NITK 






gi:195457346 GMOY000522-PA isoform a N 0 n/a n/a 
gi:557785215 GMOY001529-PA isoform a N 0 n/a n/a 




vacuolar atp synthase subunit 
ac39 
N* 0 n/a n/a 







N* 0 n/a n/a 
gi:498940735 GMOY008253-PA 





gi:498926604 GMOY011901-PA isoform c N 1 156 NQTE 





eukaryotic translation initiation 
factor 3 subunit 4 
N* 1 193 NLSE 


















gi:357612924 GMOY007746-PA troponin i N 1 59 NLSD 
gi:498963817 GMOY004668-PA protein ergic-53-like N* 0 n/a n/a 
gi:498925918 GMOY008633-PA death-related protein N* 0 n/a n/a 





















gi:557775929 GMOY002168-PA ribosomal protein partial N* 0 n/a n/a 





gi:195428873 GMOY009595-PA ribosomal protein s17 N* 0 n/a n/a 
gi:557776960 GMOY000366-PA 60s ribosomal protein l5 N* 1 187 NKSF 
gi:557756098 GMOY004524-PA 
eukaryotic translation initiation 
















N 1 3 NMST 
















like |putative peroxiredoxin, 










mitochondrial-like isoform x2 
N 1 210 NVTS 
gi:557765691 GMOY002503-PA 
















gi:195117978 GMOY010016-PA gs1- isoform b N* 2 
46 NVSL 
158 NMTD 
gi:323319559 GMOY007805-PA heat shock protein 23-like N* 0 n/a n/a 
gi:498972154 GMOY002420-PA thymosin isoform 2 N 0 n/a n/a 
gi:557750309 GMOY000635-PA 
eukaryotic peptide chain 












































gi:195063737 GMOY002747-PA histone h2b N* 0 n/a n/a 
gi:557782445 GMOY004194-PA 




















proteasome subunit beta type-
1-like 
N 0 n/a n/a 
gi:557768609 GMOY010276-PA 
endoplasmic reticulum resident 
protein 44-like isoform x2 




N 1 18 NTSH 




gi:557757593 GMOY001332-PA ribosomal protein s25 N 0 n/a n/a 
gi:50897519 GMOY009173-PA 
peroxiredoxin 2540-1 |putative 
peroxiredoxin [Glossina 
morsitans morsitans] 
N 0 n/a n/a 
gi:19921950 GMOY001757-PA 
eukaryotic translation initiation 
factor 3 subunit j 










gi:498964568 GMOY002115-PA signal sequence receptor beta Y 2 
93 NYTH 
109 NFTA 
gi:557752269 GMOY009186-PA isoform a N* 1 113 NFTH 
gi:557782259 GMOY000656-PA spermine oxidase-like N 1 177 NLSL 
gi:498931349 GMOY011241-PA isoform a N 1 16 NMSS 
gi:195431275 GMOY006168-PA 






c3 and pzp-like alpha-2-
macroglobulin domain-
containing protein 8 
N* 0 n/a n/a 
gi:557779811 GMOY005336-PA 
mitochondrial processing 
peptidase beta subunit 
N 0 n/a n/a 
gi:498983172 GMOY002540-PA 
charged multivesicular body 
protein 3-like 
N 0 n/a n/a 
gi:557768137 GMOY001798-PA 







gi:505353758 GMOY001547-PA chaperonin N 1 414 NLSE 
gi:557772170 GMOY003579-PA 
sodium potassium-transporting 













gi:557759556 GMOY002594-PA cg8392 N 0 n/a n/a 
gi:498963911 GMOY004675-PA glutathione s-transferase N 0 n/a n/a 





gi:557754623 GMOY003678-PA prosalpha6 N 0 n/a n/a 
gi:557752148 GMOY005602-PA isoform a N* 1 86 NYTY 






N* 0 n/a n/a 
gi:557782279 GMOY004377-PA dihydropteridine reductase N 0 n/a n/a 



















peroxiredoxin 6005 |putative 
peroxiredoxin [Glossina 
morsitans morsitans] 
Y 0 n/a n/a 
















hemomucin |hemomucin protein 
[Glossina morsitans morsitans] 
Y 0 n/a n/a 
gi:557761360 GMOY011348-PA 
extended synaptotagmin-like 
protein 2 isoform b 
N* 1 558 NDTL 
gi:195445138 GMOY000582-PA atp synthase-gamma isoform a N 2 
298 NASK 
315 NRTR 
gi:557784738 GMOY002555-PA stromal cell-derived factor 2-like Y 0 n/a n/a 






gi:557772402 GMOY002010-PA udp-glucose pyrophosphatase N 1 50 NTTR 





gi:195107527 GMOY006235-PA ribosomal protein s13 N* 0 n/a n/a 
gi:499003444 GMOY008615-PA 
probable nuclear transport 
factor 2-like isoform x2 
N* 0 n/a n/a 
gi:557783667 GMOY008699-PA 
er protein with rdel retention 
signal 
Y 1 132 NKSL 
gi:557765634 GMOY000803-PA 
adp-ribosylation factor gtpase-















































gi:557765119 GMOY010879-PA adenylate kinase N* 0 n/a n/a 
gi:281426821 GMOY002859-PA 
odorant-binding protein 56h 
|odorant binding protein 13 
[Glossina morsitans morsitans] 
Y 0 n/a n/a 













gi:557751145 GMOY008552-PA cg10562- partial N* 1 180 NYSQ 
gi:195116545 GMOY004967-PA translocation protein isoform d N 2 
157 NGSN 
284 NLTE 
gi:566559895 GMOY010776-PA cyt-b5-pb N* 0 n/a n/a 
gi:195135380 GMOY011965-PA ribosomal protein l23a N 1 170 NNTL 











ribonucleoprotein at isoform a 
13 NNSQ 
gi:498941911 GMOY008310-PA isoform a Y 0 n/a n/a 
gi:557761736 GMOY007075-PA dnaj chaperone N 0 n/a n/a 





gi:498935661 GMOY004614-PA 60s ribosomal protein l36 N* 0 n/a n/a 
gi:557768944 GMOY008251-PA hydroxyacyl dehydrogenase N 0 n/a n/a 
gi:195495938 GMOY000932-PA 
eukaryotic peptide chain 





gi:557775671 GMOY002750-PA dopamine n acetyltransferase N 1 29 NCSY 






























proteasome subunit beta type-
4-like 
N 1 34 NTSD 
gi:557764583 GMOY009906-PA vacuolar h N* 0 n/a n/a 
gi:557772461 GMOY008072-PA 
atp synthase delta 
mitochondrial 





















gi:557773400 GMOY006900-PA rer1 protein N 0 n/a n/a 













N* 0 n/a n/a 
gi:557772851 GMOY005535-PA alcohol dehydrogenase N 1 176 NCTI 
gi:6942136 GMOY006034-PB adp atp translocase N 1 6 NTSR 








gi:557757048 GMOY001290-PA alpha4 proteasome subunit N 1 160 NATG 
gi:557780254 GMOY007301-PA 
signal recognition particle 54 
kda protein 



























26s protease regulatory subunit 
s10b 
N 1 128 NMSH 
gi:557762644 GMOY003285-PA 60s ribosomal protein l7a-like N* 0 n/a n/a 
























gi:557770512 GMOY009725-PA isoform a Y 0 n/a n/a 





Idgf5; AltName: Full=Imaginal 
disk growth factor protein 5; 
Flags: Precursor [Glossina 






containing protein family 






















associated protein vta1 
homolog isoform x2 
N 0 n/a n/a 
gi:557757018 GMOY006055-PA xaa-pro dipeptidase N* 1 53 NDTD 
gi:557757775 GMOY003508-PA mitochondrial cytochrome c1 N* 1 27 NLST 
gi:498946176 GMOY000980-PA 
26s proteasome non-atpase 






























dehydrogenase 1 [Glossina 
morsitans morsitans] 
N 0 n/a n/a 
gi:557766350 GMOY006765-PA isoform a Y 1 173 NETA 
gi:557767072 GMOY005499-PA 40s ribosomal protein s2 N* 0 n/a n/a 
gi:498940498 GMOY009818-PA 
probable 26s proteasome non-
atpase regulatory subunit 3-like 




(NAD+) 1 [Glossina morsitans 
morsitans] 
N* 0 n/a n/a 
gi:557756737 GMOY001220-PA 
cdgsh iron-sulfur domain-
containing protein 2 homolog 



















N 1 229 NSSK 
gi:557762733 GMOY004957-PA tropomyosin isoform p N* 1 80 NVSI 
gi:557768887 GMOY008928-PA isoform b N* 0 n/a n/a 
gi:557756470 GMOY008302-PA proteasome subunit alpha type N 1 211 NSTN 
gi:499011432 GMOY011646-PA 
26s proteasome non-atpase 










gi:557761793 GMOY004246-PA zinc carboxypeptidase a 1-like Y 0 n/a n/a 
gi:557769171 GMOY004839-PA 
26s proteasome non-atpase 
regulatory subunit 6-like 
N 1 62 NWTV 







gi:557778016 GMOY005676-PA atp-dependent rna helicase N 2 
296 NATY 
1833 NLSK 
gi:557762206 GMOY010017-PA nadh dehydrogenase N* 0 n/a n/a 
gi:499007739 GMOY000905-PA gtp-binding nuclear protein ran N* 0 n/a n/a 
gi:195442210 GMOY009727-PA 



































ejaculatory bulb-specific protein 
3-like | hypothetical protein 
[Glossina morsitans] 
>gi|281426841|emb|CBA11327.
1| chemosensory protein 1 
[Glossina morsitans morsitans] 
Y 0 n/a n/a 
gi:557753139 GMOY002098-PA 













trifunctional enzyme beta 
subunit 
N 1 220 NVTR 





























26s proteasome non-atpase 
regulatory subunit 8 
N 1 29 NYTY 
gi:498995808 GMOY009860-PA 
26s proteasome non-atpase 











gi:557771429 GMOY010676-PA cuticular protein isoform a Y 0 n/a n/a 

















gi:557784403 GMOY004626-PA ribosomal protein s20 N* 0 n/a n/a 
gi:17737907 GMOY008332-PA ribosomal protein isoform a N 0 n/a n/a 
gi:557764561 GMOY003541-PA 
mitochondrial cytochrome c 
oxidase subunit 5a 




N* 1 205 NATL 
gi:557770165 GMOY001806-PA ribosomal protein l27 N* 0 n/a n/a 
gi:195384223 GMOY004579-PA isoform a N* 0 n/a n/a 
gi:28574010 GMOY009569-PA 
histidine triad nucleotide-
binding protein 1 
N* 0 n/a n/a 
gi:557754294 GMOY012189-PA 
phosphatidylethanolamine-
binding protein homolog -like 
Y 0 n/a n/a 














v-type proton atpase 116 kda 
subunit a isoform 1-like 
N 1 367 NRTN 
gi:557757773 GMOY011173-PA 
ubiquitin-conjugating enzyme 
e2 variant 2-like 
N* 1 3 NQST 
gi:557762904 GMOY004902-PA isoform b N 2 
22 NNTS 
23 NTSQ 
gi:557757593 GMOY001333-PA ribosomal protein s25 N* 0 n/a n/a 











Table S3.2 Details of the glycan structures in G. morsitans saliva analysed by HILIC-MS. Glycan symbols: GlcNAc (blue square), Man (green 



























2 2 0 968.46 484.73 968.47 nd 









3 2 0 1130.51 565.76 1130.49 565.74 







968.46 (H2N2-PROC)     
3 4.62 
  
3 2 1 1276.57 638.79 1276.52 638.77 
441.25 (N-PROC) 806.39 (H1N2-PROC) 1130.51 (H3N2-PROC) 
587.34 (N1F1-PROC) 952.48 (H1N2F-PROC)   
644.38 (N2-PROC) 968.50 (H2N2-PROC)   




3 3 0 1333.59 667.30 1333.57 667.29 
441.21 (N-PROC) 1130.51 (H3N2-PROC)   















































PROC)   
644.36 (N2-PROC) 
1171.57 (H2N3-








PROC)   











PROC)   
644.37 (N2-PROC) 
1292.62 (H4N2-






PROC)     
          
   
          





       
   






















6 2 0 1616.67 808.84 1616.61 808.81 
441.26 (N-PROC) 
1292.62 (H4N2-
PROC)   
644.36 (N2-PROC) 
1454.70 (H5N2-


















7 2 0 1778.72 889.86 1778.68 889.84 
441.25 (N-PROC) 
1292.62 (H4N2-
PROC)   
644.36 (N2-PROC) 
1454.70 (H5N2-














8 2 0 1940.77 970.89 nd 970.87 
441.23 (N-PROC) 1014.35 (H1N6) 1500.54 (H1N8) 
644.29 (N2-PROC) 
1130.45 (H3N2-
PROC)   
806.49 (H1N2-
PROC) 1176.41 (H1N5)   
852.27 (H1N4) 
1292.62 (H4N2-
PROC)   
968.54 (H2N2-




8 2 0 1940.77 970.89 nd 970.87 





PROC) 1500.44 (H1N8) 
806.38 (H1N2-
PROC) 1176.42 (H1N5)   
852.31 (H1N4) 
1292.50 (H4N2-
PROC)   
968.44 (H2N2-
PROC) 1338.42 (H1N7)   
13 9.35   9 2 0 2102.83 1051.92 nd 1051.90 





PROC) 1500.49 (H1N8) 
806.39 (H1N2-
PROC) 1176.40 (H1N5) 1662.53 (H1N9) 
852.25 (H1N4) 
1292.53 (H4N2-
PROC)   
970.86 (H2N2-





































Figure S4.1. UHPLC chromatogram of procainamide-labelled N-glycans from Aedes aegypti. 
Before (A) and after (B) treatment with JBAM. Peaks were annotated with monosaccharide 
composition assigned from the MS base peak chromatogram. Red text: possible structures; 
purple: partially digested structures; blue: new structures after JBAM; grey: contaminants. 
GU value each peak is shown. 
 
 
Figure S4.2. UHPLC chromatogram of procainamide-labelled N-glycans from Anopheles 
gambiae. Before (A) and after (B) treatment with JBAM. Peaks were annotated with 
monosaccharide composition assigned from the MS base peak chromatogram. Red text: 
possible structures; blue: new structures after JBAM; grey: contaminants. GU value each 




































































































































Figure S4.3. UHPLC chromatogram of procainamide-labelled N-glycans from Rhodnius 
prolixus. Before (A) and after (B) treatment with JBAM. Peaks were annotated with 
monosaccharide composition assigned from the MS base peak chromatogram. Red text: 
possible structures; blue: new structures after JBAM; grey: contaminants. GU value each 
peak is shown. 
 
 
Figure S4.4.  HPCL chromatogram of Rhodnius saliva samples, treated with α-galactosidase 
































































































































































































Figure S4.5. MS/MS fragmentation of Ae. aegypti glycan observed at m/z 1130.66 [M+H]1+ 
Fragmentation of the procainamide results in a loss of m/z 73 (labelled in light grey). Glycan 
symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia 
(red diamond); empty circles represent unconfirmed hexose residues. 
 
 
Figure S4.6. MS/MS fragmentation of Ae. aegypti glycan observed at m/z 1276.67 [M+H]1+ 
Fragmentation of the procainamide results in a loss of m/z 73 (labelled in light grey). Glycan 
symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia 
(red diamond); empty circles represent unconfirmed hexose residues. 
343.25
469.24 1+



































































































































Figure S4.7. MS/MS fragmentation of Ae. aegypti glycan observed at m/z 1333.79 [M+H]1+ 
Fragmentation of the procainamide results in a loss of m/z 73 (labelled in light grey). Glycan 
symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia 
(red diamond); empty circles represent unconfirmed hexose residues. 
 
Figure S4.8. MS/MS fragmentation of Ae. aegypti glycan observed at m/z 740.55 [M+H]2+ 
Fragmentation of the procainamide results in a loss of m/z 73 (labelled in light grey). Glycan 
symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia 











































































































Figure S4.9. MS/MS fragmentation of Ae. aegypti glycan observed at m/z 768.93 [M+H]2+ 
Fragmentation of the procainamide results in a loss of m/z 73 (labelled in light grey). Glycan 
symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia 
(red diamond); empty circles represent unconfirmed hexose residues. 
 
 
Figure S4.10 MS/MS fragmentation of Ae. aegypti glycan observed at m/z 842.17 [M+H]2+ 
Fragmentation of the procainamide results in a loss of m/z 73 (labelled in light grey). Glycan 
symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia 




























































































Figure S4.11. MS/MS fragmentation of Ae. aegypti glycan observed at m/z 1454.83 [M+H]1+ 
Fragmentation of the procainamide results in a loss of m/z 73 (labelled in light grey). Glycan 
symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia 
(red diamond); empty circles represent unconfirmed hexose residues. 
 
 
Figure S4.12. MS/MS fragmentation of Ae. aegypti glycan observed at m/z 1113.46 [M+H]2+ 
Fragmentation of the procainamide results in a loss of m/z 73 (labelled in light grey). Glycan 
symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia 




























































































































Figure S4.13. MS/MS fragmentation of Ae. aegypti glycan observed at m/z 808.92 [M+H]2+ 
Fragmentation of the procainamide results in a loss of m/z 73 (labelled in light grey). Glycan 
symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia 
(red diamond); empty circles represent unconfirmed hexose residues. 
 
 
Figure S4.14. MS/MS fragmentation of Ae. aegypti glycan observed at m/z 889.96 [M+H]2+ 
Fragmentation of the procainamide results in a loss of m/z 73 (labelled in light grey). Glycan 
symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia 

























































































































Figure S4.15. MS/MS fragmentation of Ae. aegypti glycan observed at m/z 971.00 [M+H]2+ 
Fragmentation of the procainamide results in a loss of m/z 73 (labelled in light grey). Glycan 
symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia 




Figure S4.16. MS/MS fragmentation of An. gambiae glycan observed at m/z 1130.70 [M+H]1+ 
Fragmentation of the procainamide results in a loss of m/z 73 (labelled in light grey). Glycan 
symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia 
































































































































































Figure S4.17. MS/MS fragmentation of An. gambiae glycan observed at m/z 1276.73 [M+H]1+ 
Fragmentation of the procainamide results in a loss of m/z 73 (labelled in light grey). Glycan 
symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia 
(red diamond); empty circles represent unconfirmed hexose residues. 
 
Figure S4.18 MS/MS fragmentation of An. gambiae glycan observed at m/z 1333.77 [M+H]1+ 
Fragmentation of the procainamide results in a loss of m/z 73 (labelled in light grey). Glycan 
symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia 











































































































































Figure S4.19 MS/MS fragmentation of An. gambiae glycan observed at m/z 740.43 [M+H]1+ 
Fragmentation of the procainamide results in a loss of m/z 73 (labelled in light grey). Glycan 
symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia 
(red diamond); empty circles represent unconfirmed hexose residues. 
 
 
Figure S4.20 MS/MS fragmentation of An. gambiae glycan observed at m/z 748.41 [M+H]1+ 
Fragmentation of the procainamide results in a loss of m/z 73 (labelled in light grey). Glycan 
symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia 



















































































Figure S4.21 MS/MS fragmentation of An. gambiae glycan observed at m/z 727.92 [M+H]1+ 
Fragmentation of the procainamide results in a loss of m/z 73 (labelled in light grey). Glycan 
symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia 
(red diamond); empty circles represent unconfirmed hexose residues. 
 
Figure S4.22 MS/MS fragmentation of An. gambiae glycan observed at m/z 1657.67 [M+H]1+ 
Fragmentation of the procainamide results in a loss of m/z 73 (labelled in light grey). Glycan 
symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia 

























































































Figure S4.23 MS/MS fragmentation of An. gambiae glycan observed at m/z 1616.67 [M+H]1+ 
Fragmentation of the procainamide results in a loss of m/z 73 (labelled in light grey). Glycan 
symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia 
(red diamond); empty circles represent unconfirmed hexose residues. 
 
Figure S4.24 MS/MS fragmentation of An. gambiae glycan observed at m/z 889.94 [M+H]2+ 
Fragmentation of the procainamide results in a loss of m/z 73 (labelled in light grey). Glycan 
symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia 

















































































































































































Figure S4.25 MS/MS fragmentation of An. gambiae glycan observed at m/z 970.98 [M+H]2+ 
Fragmentation of the procainamide results in a loss of m/z 73 (labelled in light grey). Glycan 
symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia 
(red diamond); empty circles represent unconfirmed hexose residues. 
 
 
Figure S4.26 MS/MS fragmentation of An. gambiae glycan observed at m/z 1052.01 [M+H]2+ 
Fragmentation of the procainamide results in a loss of m/z 73 (labelled in light grey). Glycan 
symbols: GlcNAc (blue square), Man (green circle), Gal (yellow circle), Fuc (red triangle), Sia 
























































































Table S5.1 Search for glycosyltransferase and glycosidase genes involved in the biosynthesis pathway. Top hits are shown for different 
hematophagous species, and Musca domestica as a non-bloodfeeder outgroup. Table indicates enzyme name, accession numbers and e-
values. 
    Drosophila melanogaster Ae. aegypti An. gambiae Ix. scapularis Lu. longipalpis M. domestica Ph. papatasi Rh. prolixus 






















































































































                                




















































    Drosophila melanogaster Ae. aegypti An. gambiae Ix. scapularis Lu. longipalpis M. domestica Ph. papatasi Rh. prolixus 






































































































































































































































































































    Drosophila melanogaster Ae. aegypti An. gambiae Ix. scapularis Lu. longipalpis M. domestica Ph. papatasi Rh. prolixus 






































































































































































































































































































    Drosophila melanogaster Ae. aegypti An. gambiae Ix. scapularis Lu. longipalpis M. domestica Ph. papatasi Rh. prolixus 













































































































































































            








































































































    Drosophila melanogaster Ae. aegypti An. gambiae Ix. scapularis Lu. longipalpis M. domestica Ph. papatasi Rh. prolixus 
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    Drosophila melanogaster Ae. aegypti An. gambiae Ix. scapularis Lu. longipalpis M. domestica Ph. papatasi Rh. prolixus 
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    Drosophila melanogaster Ae. aegypti An. gambiae Ix. scapularis Lu. longipalpis M. domestica Ph. papatasi Rh. prolixus 
































































































































































































































































                





                
                                





    Drosophila melanogaster Ae. aegypti An. gambiae Ix. scapularis Lu. longipalpis M. domestica Ph. papatasi Rh. prolixus 


















































































































































































































                    





































































    Drosophila melanogaster Ae. aegypti An. gambiae Ix. scapularis Lu. longipalpis M. domestica Ph. papatasi Rh. prolixus 

























































































































































                





                










    Drosophila melanogaster Ae. aegypti An. gambiae Ix. scapularis Lu. longipalpis M. domestica Ph. papatasi Rh. prolixus 


















































































        










        










        





                





                





















































    Drosophila melanogaster Ae. aegypti An. gambiae Ix. scapularis Lu. longipalpis M. domestica Ph. papatasi Rh. prolixus 
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    Drosophila melanogaster Ae. aegypti An. gambiae Ix. scapularis Lu. longipalpis M. domestica Ph. papatasi Rh. prolixus 
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Table 6.1 Search for glycosyltransferase and glycosidase genes involved in the biosynthesis pathway. Here details are shown for Glossina species, 
indicating enzyme name, accession numbers and e-values. 
    Drosophila melanogaster G. austeni G. brevipalpis G. fuscipes G. morsitans G. pallidipes G. palpalis 










































































































    Drosophila melanogaster G. austeni G. brevipalpis G. fuscipes G. morsitans G. pallidipes G. palpalis 


























































































































































    































































    Drosophila melanogaster G. austeni G. brevipalpis G. fuscipes G. morsitans G. pallidipes G. palpalis 


















































































































































































































































































































    Drosophila melanogaster G. austeni G. brevipalpis G. fuscipes G. morsitans G. pallidipes G. palpalis 













































































































































































































































    Drosophila melanogaster G. austeni G. brevipalpis G. fuscipes G. morsitans G. pallidipes G. palpalis 
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    Drosophila melanogaster G. austeni G. brevipalpis G. fuscipes G. morsitans G. pallidipes G. palpalis 
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    Drosophila melanogaster G. austeni G. brevipalpis G. fuscipes G. morsitans G. pallidipes G. palpalis 


























































































































































































        














        










        










    Drosophila melanogaster G. austeni G. brevipalpis G. fuscipes G. morsitans G. pallidipes G. palpalis 




















































































































































































                










































































    Drosophila melanogaster G. austeni G. brevipalpis G. fuscipes G. morsitans G. pallidipes G. palpalis 



































    










    






















































































































































    Drosophila melanogaster G. austeni G. brevipalpis G. fuscipes G. morsitans G. pallidipes G. palpalis 
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The sandfly Phlebotomus papatasi is the vector of Leishmania major, the main causative
agent of Old World cutaneous leishmaniasis (CL) in Saudi Arabia. Sandflies inject saliva
while feeding and the salivary protein PpSP32 was previously shown to be a biomarker
for bite exposure. Here we used recombinant PpSP32 to evaluate human exposure to
Ph. papatasi bites, and study the association between antibody response to saliva and CL
in endemic areas in Saudi Arabia.
Methodology/Principal Findings
In this observational study, anti-PpSP32 antibodies, as indicators of exposure to sandfly
bites, were measured in sera from healthy individuals and patients from endemic regions in
Saudi Arabia with active and cured CL. Ph. papatasi was identified as the primary CL vector
in the study area. Anti-PpSP32 antibody levels were significantly higher in CL patients
presenting active infections from all geographical regions compared to CL cured and
healthy individuals. Furthermore, higher anti-PpSP32 antibody levels correlated with the
prevalence and type of CL lesions (nodular vs. papular) observed in patients, especially
non-local construction workers.
Conclusions
Our findings suggest a possible correlation between the type of immunity generated by the
exposure to sandfly bites and disease outcome.
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Author Summary
Leishmania is transmitted by the bite of infected female sandflies. When a sandfly bites a
vertebrate host, it injects a cocktail of salivary proteins meant to facilitate blood feeding.
The constant exposure to sandfly bites in endemic areas triggers a humoral response
against the major antigenic components in the saliva. These antibodies can be then
exploited to measure exposure to vector sandflies, which is useful for surveillance in leish-
maniasis control programmes. In Saudi Arabia, cutaneous leishmaniasis (CL) is mainly
transmitted by the Phlebotomus papatasi sandfly. Here we study the recognition of the
main antigenic salivary protein from Ph. papatasi, PpSP32, in leishmaniasis patients and
healthy individuals from three CL endemic areas in Saudi Arabia. Anti-PpSP32 antibody
levels were significantly higher in CL patients presenting active infections from all
geographical regions compared to the CL-cured and healthy individuals. Furthermore,
higher anti-PpSP32 antibody levels correlated with the prevalence and type of CL lesions
observed in patients. Our results suggest that previous long-term exposure to sandfly saliva
can have a role in modulating the severity of leishmaniasis infection, resulting in a milder
form of the disease.
Introduction
Cutaneous leishmaniasis (CL) in Saudi Arabia is an increasing public health problem due to
rapid urbanization, intensive agriculture and human migration [1]. Zoonotic CL (ZCL) is the
most prevalent form of leishmaniasis in the country, which is caused by Leishmania major and
transmitted by the sandfly Phlebotomus papatasi. Leishmania tropica on the other hand is
exclusively endemic to the South Western region [2], where it is transmitted by Ph. sergenti
and causes anthroponotic CL (ACL).
The saliva that sandflies inject into their vertebrate host impairs the haemostatic and
inflammatory systems allowing the insects to efficiently take a blood meal [3]. These salivary
components were also shown to promote or inhibit the development of Leishmania in the
vertebrate host [4]. Increased sandfly-host contact translates into an increased risk of being in-
fected. Repeated exposure to sandfly bites produces antibodies against its salivary components
in the host, providing an indirect measure of exposure to vectors [5]. The presence of IgG
antibodies against Ph. papatasi saliva has been associated with a higher risk of being infected
with L. major [4,6]. The transient nature of the antibody response to sandfly bites [6–10] allows
for the study of temporal changes in transmission risk and the efficacy of vector control pro-
grammes [11].
Biomarkers used to evaluate sandfly exposure need to be species-specific in order to differ-
entiate between antibody responses to vector and non-vector species, or between sandflies and
other blood-feeding insects including mosquitoes. The sandfly salivary protein PpSP32 has
been described as a 30 kDa immunodominant target of the host antibody response against
Ph. papatasi saliva [12,13], and was highly specific when tested against individuals living in a
region with high prevalence of Ph. perniciosus. Additionally, expression of the PpSP32 salivary
transcript is not influenced by age or diet of the sandfly [14]. B-cell epitope prediction analysis
showed six epitopes were identical between the Tunisian PpSP32 and the PpSP32 protein de-
posited in GenBank (Israeli strain), indicating it is a good candidate to assess biting exposure
in different ZCL foci [13]. Furthermore, the production of rPpSP32, a recombinant form of the
Ph. papatasi PpSP32 protein, overcomes the difficulty of obtaining large quantities of salivary
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glands, and facilitates the use of salivary biomarkers for large scale epidemiological studies in
endemic areas.
To better understand the correlation between sandfly biting exposure and leishmaniasis
infection, we determined the level of exposure to Ph. papatasi bites in individuals from several
CL endemic areas in Saudi Arabia by measuring the levels of anti-PpSP32 antibodies present in
the sera of patients and healthy volunteers.
Materials and Methods
Ethics statement
The study was approved by the Liverpool School of Tropical Medicine Ethics Committee UK
(12.03RS). All participants provided written informed consent for the collection of blood sam-
ples and subsequent analyses. All research was conducted according to Declaration of Helsinki
principles.
Study samples
Peripheral blood samples were obtained from 411 individuals (106 females and 305 males,
aged 18–60 years, median of 36 years) living in two ZCL (Al Ahsa and Al Madinah) and one
ACL (Asir) endemic areas in Saudi Arabia (S1 Table). Study sites were chosen to include areas
were patients would be exposed to the bite of Ph. papatasi (ZCL transmission) or Ph. sergenti
(ACL transmission) (Al Salem et al, 2014. Submitted) to test the specificity of the biomarker.
Samples were collected during the months of April and December 2012. Cases were diagnosed
through parasitological confirmation of Leishmania by a trained clinician, and the infecting
Leishmania species was confirmed in patients with both active and cured infections (through
clinical history). Clinical cure was signified by successful re-epithelialisation of the lesion(s)
after treatment.
Donor sera were classified as healthy (no history of leishmaniasis infection), ZCL (L. major)
or ACL (L. tropica) patients with either active or cured CL. An additional 80 serum samples of
patients with active infection from Al Ahsa were used for the analysis of local versus non-local
exposure; although these were likely to be infections with L. major, they are unconfirmed and
therefore considered separately. We used sera from five United Kingdom residents as non-
endemic controls. These healthy volunteer donors have no history of leishmaniasis or travelling
to sandfly endemic areas.
Expression and purification of PpSP32 recombinant protein
Mammalian VR-2001 plasmid coding the PpSP32 protein with 6 histidine tag was sent to the
Protein Expression Laboratory at the Frederick National Laboratory for Cancer Research
(Frederick, Maryland). Expression was performed by transfecting HEK-293F cells. The
supernatant was collected after 72 hours, filtered and concentrated from 1 litre to 300 ml using
an Amicon concentrator device (Millipore, Billerica, MA, USA) in the presence of NaCl
500mM. The volume was returned to 1 litre at a final concentration of 10 mM Tris, pH 8.0.
The expressed protein was purified by an HPLC system (DIONEX, CA, USA) using two 5 ml
HiTrap Chelating HP columns (GE Healthcare, Buckinghamshire, UK) in tandem and charged
with 0.1 M NiSO4. The protein was detected at 280 nm and eluted by an imidazole gradient
as described by Teixeira et al. [15]. Eluted proteins were collected every minute in a 96-well
microtiter plate using a Foxy 200 fraction collector (Teledyne ISCO, Lincoln, NE, USA).
Fractions corresponding to eluted proteins peaks were selected and run on a NuPage Bis-Tris
4–12% Gel (Novex, Life Technologies, Carlsbad, CA, USA) with MES running buffer under
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reducing conditions as per manufacturer’s instructions. Appropriate fractions, as determined
by molecular weight were pooled and concentrated to 1 ml using an Amicon Ultra Centrifugal
Filter (Millipore, Billerica, MA, USA). Protein concentration was measured using a NanoDrop
ND-1000 (Thermo Scientific, Waltham, MA, USA) spectrophotometer at 280 nm and
calculated using the extinction coefficient of the protein.
Detection of human anti-PpSP32 antibodies
Exposure to sandfly bites was measured through the levels of anti-PpSP32 IgG antibodies in the
sera of participants. Anti-PpSP32 antibodies were measured by ELISA (Enzyme-Linked Immu-
nosorbent Assay), as described by Marzouki et al. [13] with some modifications. Briefly, micro-
titer plates (Thermo-Scientific) were coated overnight with 50 ml of PpSP32 (2 mg/ml = 0.1 mg/
well) in 0.1M carbonate buffer (pH 9.6). Plates were blocked with PBS-BSA at 37°C for one
hour and then washed several times with PBS. Diluted sera (1:200) were added to the plates
and incubated at 37°C for 2 hours. After washing, plates were incubated with anti-human IgG
peroxidase-conjugated antibody (1:10000) (Jackson ImmunoResearch, Suffolk, UK) for one
hour at 37°C. Antibody binding was visualized using the substrate, 3,30,5,50 tetramethylbenzidine
(Biolegend, San Diego, CA, USA), and absorbance was read at 450 nm on a Fluorostar Omega
microplate reader (BMG Labtech, Ortenberg, Germany). Each serum was tested in triplicate.
Wells without serum were used as negative controls.
Sandfly vector species in CL endemic areas
To determine the relative abundance of vector species in each of the endemic areas, sandfly
collection was conducted between March and November of 2012. Adult sandflies were
collected using CDC light traps placed from 6:00pm to 6:00am in the peridomicile of houses,
including sheds harboring domestic animals such as chickens and rabbits. Sticky traps were
used to capture sandflies in rodent burrows. Sandflies were preserved in 70% alcohol and
identified to species [16].
Distribution maps
Software ArcGIS 10 (ESRI, Redlands CA) was used to show the presence of vector species.
Statistical analysis
The Kruskal-Wallis test was used to compare sets of groups. GraphPad Prism Software 5 was
used for all data analysis. Statistical significance was considered as P<0.05.
Results
Ph. papatasi was the only vector species found in Al Ahsa and Al
Madinah, while in Asir Ph. sergenti was the most common
In the regions of Al Ahsa and Al Madinah,*99% of sandflies were identified as Ph. papatasi,
with the additional presence of a few Ph. bergeroti (*1%) in Al Madinah (Table 1). The
Southern region of Asir showed the highest diversity of vector species; Ph. sergenti was the
most abundant (21%), followed by Ph. bergeroti (10%). Although Sergentomyia species (of
non-medical importance) represented only a small percentage (*1%) in Al Ahsa and Al
Madinah, they constituted over half of the specimens identified in Asir (67%). The predomi-
nant presence of Ph. papatasi in both Al Ahsa and Al Madinah, and of Ph. sergenti in Asir, is in
agreement with the prevalence of infections caused by L. major and L. tropica, respectively
(Fig. 1).
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PpSP32 is recognized by sera of individuals living in CL endemic areas
of Saudi Arabia where Ph. papatasi is prevalent
We found that the levels of anti-PpSP32 antibodies in the sera of healthy individuals from Saudi
Arabia were significantly higher (P0.01) (S1 Fig.) when compared to unexposed individuals
Table 1. Sandfly species in the cutaneous leishmaniasis endemic regions.
Species Al Ahsaa Al Madinaha,b Asirb
Ph. papatasi 99% 99% 1%
Ph. bergeroti 0 <1% 10%
Ph. sergenti 0 0 21%
Ph. alexandri 0 0 <1%
Ph. orientalis 0 0 <1%
Sergentomyia spp.c 1% <1% 67%
Sandflies were collected using CDC light traps around houses of leishmaniasis patients, and sticky traps
were used in rodent burrows Ph. papatasi was the most abundant species in Al Ahsa and Al Madinah.
However, in Asir Ph. sergenti was the dominant vector, followed by Ph. bergeroti.
a. Region with Zoonotic Cutaneous Leishmaniasis cases
b. Region with Anthroponotic Cutaneous Leishmaniasis cases
c. Genus with no Leishmania vector species
doi:10.1371/journal.pntd.0003449.t001
Figure 1. Map of Saudi Arabia indicating the presence of sandfly vector species in several areas
endemic for cutaneous leishmaniasis. Phlebotomus papatasi is prevalent in Al Ahsa and Al Madinah. In
Asir, Ph. sergenti is the most common vector species. Symbols are representative of sampling locations and
do not reflect species abundance. Filled triangle: Ph. papatasi; Open triangle: Ph. bergeroti; Open circle:
Ph. sergenti.
doi:10.1371/journal.pntd.0003449.g001
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from the UK. This indicates the biomarker is successfully recognized by Saudi individuals, and
furthermore agrees with the expected level of exposure to sandflies in CL-endemic areas.
In Al Ahsa and Al Madinah the levels of anti-PpSP32 antibodies are
higher in CL patients than healthy individuals
When we compared healthy individuals from the two ZCL endemic regions studied, there
was a significantly higher level of anti-PpSP32 antibodies in Al Ahsa compared to Al Madinah
(Fig. 2A). To test for a possible correlation between exposure to sandfly bites and leishmaniasis
infection, we compared healthy and infected individuals. In both Al Ahsa (Fig. 2B) and Al
Madinah (Fig. 2C), patients with an active infection (CL) showed significantly higher levels of
anti-PpSP32 antibodies compared to healthy residents (P<0.001). Overall, comparing the
Figure 2. Human antibody response to Phlebotomus papatasi salivary protein PpSP32. (a)
Comparison of anti-PpSP32 antibody levels in healthy individuals from the ZCL regions of Al Ahsa and Al
Madinah (b) Anti-PpSP32 antibody levels in ZCL patients with active and cured infections from Al Ahsa.
(c) Anti-PpSP32 antibody levels in ZCL patients with active and cured infections from the region of Al
Madinah. Control: healthy individuals; CL: active infection; CR: cured infection; OD: optical density. * P .05;
** P .01; *** P .001.
doi:10.1371/journal.pntd.0003449.g002
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groups from both Al Ahsa and Al Madinah, the levels of anti-PpSP32 in Al Ahsa individuals
appear to be higher than those from Al Madinah, suggesting that Al Ahsa populations are
more exposed to Ph. papatasi bites.
PpSP32 is recognized with less extent by individuals living where Ph.
sergenti is prevalent
In individuals from the region of Asir (endemic for ACL L. tropica infections), both the healthy
and cured groups showed very low levels of anti-PpSP32 antibodies (Fig. 3), which agrees with
the near absence of Ph. papatasi from this region (Table 1). Unexpectedly, the levels of anti-
PpSP32 antibodies were significantly higher (P<0.01) in individuals with an active L. tropica
infection, compared to healthy residents and cured patients (Fig. 3). Sequence alignment of the
Ph. papatasi PpSP32 [17] and the PpSP32-like protein from Ph. sergenti [18] confirmed a
significant level of similarity between these homologous proteins (S2 Fig.), suggesting cross-
reactivity. Although these patients were Saudi residents and their migration is uncommon,
we cannot discard either the possibility that these individuals might have been exposed to
Ph. papatasi bites while traveling outside this area, or the presence of Ph. papatasi in low num-
bers. In both cases, the anti-PpSP32 levels may reflect a low exposure to this sandfly species.
Evidence of an association between the levels of anti-PpSP32
antibodies and ZCL clinical presentation
To test for a correlation between exposure to sandfly bites and the clinical presentations of
L. major infection in human patients, we compared the levels of anti-PpSP32 antibodies in pa-
tients presenting nodular, papular or ulcerated-nodular lesions. Of the three, nodular lesions
and then papular are the least severe; both of these lesion types can progress to the more severe
ulcerated-nodular form. ZCL patients from Al Madinah with nodular and ulcerated nodular
type lesions have higher levels of anti-PpSP32 than those with papular type lesions (Fig. 4A),
but a statistical difference was only observed between papular and nodular lesions (P<0.01).
There were no significant differences in anti-PpSP32 levels between different types of lesions in
Al Ahsa patients (Fig. 4B).
We also looked at the levels of anti-PpSP32 in ZCL patients according to the lesion charac-
teristics. Lesion size was classified as being either 10–15mm or>15mm. Patients from Al Ahsa
with large lesions>15mm had significantly higher antibody levels (P<0.01) than individuals
Figure 3. Antibody response to PpSP32 from patients in Asir where L. tropica is prevalent. Sera of
individuals living in the ACL endemic area of Asir region were tested for anti-PpSP32 antibodies. Control:
healthy individuals; CL: active infection; CR: cured infection; OD: optical density. Significance: **P .01.
doi:10.1371/journal.pntd.0003449.g003
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Figure 4. Levels of anti-PpSP32 antibodies in patients with active ZCL vary according to the type and
size of the lesions. (a) Anti-SP32 antibody levels were measured in patients with nodular, papular and ulcer
type lesions in Al Madinah and (b) Al Ahsa. (c) Comparison of antibody levels according to ZCL lesion size in
patients from Al Ahsa (** p0.01) and Al Madinah. (d) Antibody levels according to lesion number in Al Ahsa
and Al Madinah. Control: healthy individuals; CL: active infection; CR: cured infection; OD: optical density.
* P .05; ** P .01; *** P .001.
doi:10.1371/journal.pntd.0003449.g004
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with lesions between 10–15mm (Fig. 4C). This difference was not observed in Al Madinah. Ad-
ditionally, when we compared the patients with different lesion numbers (< 3 or> 3 lesions)
(Fig. 4D), no significant differences in antibody levels were found within each region. However,
the same figure shows the difference in anti-PpSP32 levels was significant, with higher levels in
Al Ahsa than Al Madinah.
Visiting labour in Saudi Arabia exhibit a significantly higher antibody
response to PpSP32 compared to the residents in Al Ahsa
In Al Ahsa, we found that non-local patients (visiting labour) had significantly higher levels
(P<0.001) of anti-PpSP32 compared to the local residents (Fig. 5A). Interestingly, nearly three
quarters of the non-local patients developed more than three lesions compared to only 40% in
the local group (Fig. 5B). Although such differences did not correlate with the levels of anti-
PpSP32 (S3 Fig.), patients from the visiting labour group presented in general a higher number
of lesions compared to the residents (S2 Table).
Discussion
Antibodies to sandfly saliva can be used to indicate disease risk in endemic areas [4,6,12,19],
and the development of biomarkers for this purpose depends on the discovery of highly con-
served yet species-specific molecules. SP32-like proteins are unique to sandflies and occur in all
Figure 5. Differential antibody response to PpSP32 between local and non-local patients in Al Ahsa.
(A) Comparison of anti-PpSP32 antibody levels in local and nonlocal ZCL patients from Al Ahsa. (B)
Comparison of lesion numbers in local residents and non-local ZCL patients in Al Ahsa. OD: optical density.
*** P .001.
doi:10.1371/journal.pntd.0003449.g005
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species studied to date [18]. Among these, PpSP32 is a highly immunogenic protein isolated
from the saliva of Ph. papatasi that serves as a biomarker for vector exposure [13]. Data ob-
tained from a CL-endemic area in Tunisia showed that the human antibody response to
PpSP32 is representative of the humoral response against whole salivary gland extract [6].
Here, we used a recombinant form of this protein to evaluate the level of exposure to sandfly
saliva in three endemic areas in Saudi Arabia. Our results show that the severity of human CL
pathology appears to be influenced by previous exposure to sandfly bites.
The migration of non-immune people into leishmaniasis endemic areas has been well docu-
mented to affect groups such as civilian workers and military personnel [20,21], resulting in
leishmaniasis outbreaks [22]. Evaluation of biting exposure can be useful for assessing disease
risk of such populations in Saudi Arabia. The higher serum levels of anti-saliva antibodies in
the visiting workers compared to the long-term residents of Al Ahsa suggest the migrant popu-
lation is highly exposed to sandfly bites and less immune to CL. Residents have a lower (but
continuous and long-term) exposure to bites, which might induce desensitisation (tolerance)
to sandfly saliva, thus explaining their lower antibody levels compared to the non-locals. This
desensitization after long term exposure has been previously observed in mice models [23].
Moreover, the residents seem to suffer less severe leishmaniasis lesions. Exposure to uninfected
bites of Ph. papatasi has been shown to be protective against L. major in mice [24] and whether
the same level of protection is conferred to humans in CL-endemic areas remains to be deter-
mined. Non-locals typically work and dwell closer to sandfly habitats like the burrows of ro-
dents (reservoirs of disease) and are consequently plagued by biting sandflies. Previously
unexposed to this level of biting, they showed a more intense antibody response over a shorter
period of time. The high exposure to sandfly bites might increase susceptibility to infection and
severe clinical outcomes, as nearly three quarters of them developed multiple lesions. Other
factors such as genetic background can also influence susceptibility to disease [25]; however,
this is unlikely in this situation as the visitors originate from eight different countries, mainly
fromMiddle East, Southern Asia and Africa.
Interestingly, CL patients from both ZCL regions (Al Ahsa and Al Madinah) exhibited even
higher levels of anti-PpSP32 antibodies compared to healthy residents from their respective
areas. Marzouki et al. [6] previously investigated this relationship using whole salivary gland
extract and associated the significantly higher antibody levels in ZCL patients with increased
risk of developing CL. This difference was also reported for ACL [12], where exposure to
Ph. sergenti bites was evaluated in both healthy individuals and patients with L. tropica. Simi-
larly, ACL patients produced a significantly higher IgG response compared to healthy people
from the same area, likewise supporting the relationship between exposure and leishmaniasis
infection. B-cell clonal expansion, which increases production of non-specific antibodies in
some parasitic infections [26], could be an alternative explanation to an increased antibody
response in CL patients; however, this has only been reported in visceralizing forms of leish-
maniasis [27,28].
Our research identified the sandfly species inhabiting the three CL endemic areas in order
to complement the data obtained on bite exposure. In agreement with the anti-PpSP32 levels
in patient sera, the majority of sandflies found in Al Ahsa and Al Madinah were identified as
Ph. papatasi. Other sandfly species identified belong to the Sergentomyia genus, whose mem-
bers rarely bite humans (they are mostly zoophilic) and have been shown to be refractory to
Leishmania species pathogenic to humans [29] Ph. papatasi accounts for most, if not all, of
the bites sustained by individuals in the ZCL areas. This was further supported by finding
significant levels of anti-PpSP32 antibodies in healthy donors of these regions compared to UK
control sera. However, anti-PpSP32 antibodies were significantly higher in Al Ahsa, suggesting
a higher exposure to Ph. papatasi in this region.
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Unexpectedly, we found that sera of L. tropica patients from the Southwest region of
Asir (where Ph. sergenti is the predominant CL vector) also recognized PpSP32, although
levels were much lower compared to ZCL patients. This could be due to a cross reaction with
salivary proteins from Ph. sergenti. In fact, there is a high degree of similarity (52%) between
Ph. sergenti SP32-like protein and Ph. papatasi SP32. In mice exposed to Ph. sergenti bites,
a partial cross-reactivity to Ph. papatasi whole salivary gland homogenate was reported
[12,30]. A similar level of cross-reactivity could also be present between salivary proteins from
Ph. papatasi and Ph. bergeroti [31] (the second most abundant species in Asir).
Is there a correlation between CL clinical forms and exposure to sandfly bites? We detected
higher levels of anti-PpSP32 antibodies in patients with nodular-type lesions compared to
those with papular lesions in Al Madinah, but not in Al Ahsa. This differential response could
be attributed to a) the genetic background of the infected patients, b) a cumulative exposure to
sandfly bites or c) the parasite strains found in each area. It would be interesting to further
study how the interaction between these factors affects the immune responses to salivary
proteins and disease pathology.
The immune response elicited by sandfly salivary proteins and how it modulates the
Leishmania infection, varies depending on the vector species and vertebrate host [32]. Some
reports have shown that sandfly saliva is able to preferentially trigger a protective Type I de-
layed-type hypersensitivity response [33–35]. In animal models a Th1 response to salivary pro-
teins is correlated with protection against CL, and immunization with single proteins from
sandfly saliva conferred protection against a L. major infection when animals were challenged
with infectious Ph. papatasi bites [35–37]. On the other hand, a Th2 response (and antibodies
to salivary proteins) correlates with higher susceptibility and in some cases exacerbation of the
disease [38,39]. Furthermore, individuals living in a CL endemic region of Tunisia, where the
main vector is Ph. papatasi, developed a mixed response with a dominance of Type II immuni-
ty [40]. It may possible that subjects that develop antibodies (in a Th2 environment) to PpSP32
(and perhaps other salivary proteins) may be more susceptible to CL. It would be relevant to
characterize the immune response(s) in individuals with different clinical presentations and
from different geographical locations.
In summary, the use of recombinant salivary proteins can help us understand the impacts
of natural exposure to sandflies in leishmaniasis endemic areas [3]. Our results provide insights
into the relationship between the human antibody response to sandfly saliva and development
of cutaneous leishmaniasis in different transmission contexts. In addition, they support the use
of biomarkers as epidemiological tools to improve the surveillance of human-vector contact
and disease transmission.
Protein accession numbers (NCBI): Phlebotomus papatasi SP32 GI:449060662, Phlebotomus
sergenti SP44: GI:299829437
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This article considers the current public health perspective on cutaneous leishmaniasis (CL)
and its implications for incidence, prevalence, and global burden of disease calculations. CL is
the most common form of leishmaniasis and one of a small number of infectious diseases
increasing in incidence worldwide [1] due to conflict and environmental factors in the Middle
East (“Old World”) and the Americas (“New World”)—regions where it is most prevalent.
Recently, the disease has reached hyperendemic levels in the conflict zones of the Syrian Arab
Republic, Iraq, and Afghanistan while simultaneously affecting refugees from those regions
[2]. Nevertheless, CL is not seen as a priority for policymakers because it is not life limiting.
This is evidenced by a lack of commitment in recent years to preventive campaigns and patient
provision (limited diagnostic capacity, knowledge of treatment, drug availability) in a number
of endemic countries [3].
Expanding the spectrum of CL disease
Cutaneous leishmaniasis is characterized by the active infection of Leishmania spp. and its
accompanying lesions, which classically evolve from papules and nodules to plaques and
ulcers; we term this the active phase of CL. These lesions commonly self-heal in the absence of
treatment after a variable amount of time (usually months) [4]. Importantly, the residual scar-
ring that follows the resolution of active CL infection in all cases is not currently recognized as
part of the spectrum of CL disease. We term this scarring “inactive CL” to convey parasitologi-
cal inactivity of lesions rather than sterile immunity; indeed, in a small number of cases, lesions
may contain a focus of parasites [5], although it is yet to be demonstrated if these are involved
in further disease transmission [6].
Notably, while inactive CL is not currently recognized within the spectrum of CL disease,
other, less common sequelae of CL are. For example, the mutilating mucocutaneous leishman-
iasis (MCL) is widely considered a long-term sequela of CL, despite occurring almost exclu-
sively in the Americas region and in only a small proportion of overall CL cases [7]. We
therefore advocate for CL to be viewed as a disease of 2 phases (active and inactive) followed
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by a variable third phase (MCL) and wish to further discuss why this expanded view of CL dis-
ease is important.
In common with other neglected tropical diseases (NTDs) with prominent cutaneous man-
ifestations such as onchocerciasis, leprosy, yaws, scabies, and Buruli ulcer, CL is damaging
socially and deeply stigmatizing [8]. However, social stigma in leishmaniasis has also been
shown to reinforce poverty in affected individuals and thus is of great concern [9]. Notably, it
is the lasting aspect of inactive CL (scarring) that generates this considerable stigma; in this
sense, stigma in CL is independent of a patient’s microbiological status in endemic communi-
ties. This is evidenced by many local terms that equate CL specifically with its scarring form
(e.g., “the scar will remain forever” in the Kingdom of Saudi Arabia, “mountain leprosy” in the
Amazon region, “Aleppo evil” in Syria, and “trace” in Yemen) [3,10], underlining the impor-
tance placed on inactive CL by those affected by the disease.
Moreover, there is known to be a continuation of psychological morbidity with the scarring
that ensues post CL infection (both treated and self-healing). This is unsurprising, as epidemi-
ological studies show that approximately 50% of CL lesions are located on the face [1], and
lesion visibility is an important risk factor for depression in dermatological conditions. Indeed,
the rates of comorbid depression associated with inactive CL may equal if not exceed those of
active disease [11,12]. The quality of life of patients is also significantly impaired relative to
control groups, and in some cases, this is equivalent to the impairment found in active disease
[11,13]. Overall, inactive CL represents a substantial disease burden extending beyond active
CL infection. To recognize the extent of the impact of CL on the lives of patients, it is therefore
important to recognize that its burden of disease does not end upon resolution of active
infection.
Lastly, while both active and inactive forms of CL can be unsightly, the residual scar of inac-
tive CL is hard to remove cosmetically, and thus in the vast majority of cases, scarring is per-
manent and lifelong. As a result, there is a much greater number of “inactive” CL patients in
the world than “active” cases. How CL is viewed as a disease therefore has important and direct
implications for how incidence (number of new cases of CL per year) and prevalence (total
number of cases of CL) is both reported and estimated. In turn, this then impacts the overall
burden of disease as measured by Disability Adjusted Life Years (DALY) estimates for CL,
which are based upon prevalence. These aspects will now be further discussed in turn.
Discrepancies in incidence and prevalence figures
In Table 1, we display figures from various sources that provide information on the global inci-
dence and prevalence of CL, upon which, policy and burden of disease (DALY) estimates have
been based. Notably, some CL figures (including WHO and Global Burden of Disease [GBD])
include MCL cases, although these are likely to only represent a small proportion of the overall
CL case load (about 5%) [7].
Overall, estimates of CL incidence have increased from 1.1 to 1.2 million cases per year
from 2002–2009 [14,15], which is 6- to 10-fold higher than reported incidence data. Larger
increases in incidence have, however, been recently noted at regional levels [2]. On the other
hand, estimates of CL prevalence have almost doubled from 2.1 million cases in 2002 [14] to
nearly 4 million cases in the 2015 GBD study [20]. Whilst increases in CL prevalence are to be
expected in light of the lasting nature of CL sequelae and its increasing incidence, such esti-
mates seem unrealistically small. For example, this latter figure of 3.9 million prevalent cases
from the 2015 GBD study represents only twice the sum of 11 years of reported incidence
from WHO (2005–2015) [17] and only 3 times the previously estimated annual global inci-
dence [15].
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From these figures, it is clear that (1) only active disease has been included in incidence cal-
culations, and (2) scarring (inactive CL) is not factored into prevalence estimates. This is
apparent because, otherwise, CL prevalence estimates would be significantly higher. As CL is
not a life-limiting condition, we would also expect prevalence estimates to have increased con-
sistently throughout the study period. In the past 11 years (2005–2015) alone, 2 million new
cases have been reported by WHO [17]. Given that the number of estimated cases varies from
6- to 10-fold higher than reported cases [7,15,16], the actual numbers of inactive CL patients
could be between 12–20 million (assuming no deaths). However, the life expectancy of patients
with scarring CL is likely to exceed the 11 years represented by WHO’s figures. Applying a
highly conservative life expectancy of 20 years for affected individuals with inactive CL, it is
possible that upwards of 40 million inactive CL patients are currently living with the aforemen-
tioned psychosocial consequences of past infection.
Implications for global burden of disease (DALY) calculations
It is evident that CL is being viewed from a purely parasitological perspective in current preva-
lence estimates. However, as mentioned, prevalence is the major determinant of the Years of
Life with Disability (YLD) component of DALY calculations. This implies that when patients
are no longer positive for Leishmania spp., they are considered to not be affected by the disease
in such calculations. If the scarred CL patients were included in the prevalence estimates of
GBD studies (approximately 40 million cases) instead of simply those with active infection
(approximately 4 million cases) [20], then the estimated burden of CL disease would be
increased by a factor of 10. Such findings have important implications with respect to prioritiz-
ing CL for global disease control and research and development (R&D) needs, including CL
drugs, diagnostics, and vaccines [21].
Table 1. Reported and estimated incidence and prevalence of cutaneous leishmaniasis, 2002–2015.
Author Study year Reported Estimated
Incidence Prevalence Incidence Prevalence
Mathers et al. [14] 2002 - - 1,157,000 2,157,000
Alvar et al. [15] 2002–2009 214,036 - 1,213,300 -
WHO WER [16] 2014 154,649* - - -
WHO GHO [17] 2005–2015 187,855* (mean) 2,066,410* (11 years) - -
GBD 2010 [18] 2010 - - - 10,000,000
GBD 2013 [19] 2013 - - - 3,914,800*
GBD 2015 [20] 2015 - - - 3,895,900*
N.B. The studies below the dotted line (. . .) refer to Global Burden of Disease (GBD) studies conducted by the Institute of Health Metrics and Evaluation
(IHME)
*MCL included
Abbreviations: GBD, Global Burden of Disease; GHO, Global Health Observatory; WER, Weekly Epidemiological Record
https://doi.org/10.1371/journal.pntd.0005739.t001
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In the 2010 GBD study, leishmaniasis (CL, MCL, and visceral leishmaniasis [VL]) had the
largest single-cause disease burden of any NTD [18], yet less than 10% of the overall disease
burden was accounted for by CL, because inactive CL was not included in the study. This dem-
onstrates that it is not possible to understand the true burden of CL disease without first recog-
nizing its inactive scarring component. From this, we can extrapolate that the psychological
impact associated with other, less prevalent leishmaniases such as post-kala-azar dermal leish-
maniasis (PKDL) is equally unrecognized; for example, PKDL is by definition a sequela of VL
but has not been included in any estimate of the burden of VL disease to date.
Furthermore, the unlikely finding that leprosy and CL both had among the lowest YLDs of
any NTD in the 2015 GBD Study [20] raises questions about the ability of such estimates to
capture the important stigmatizing nature of such diseases. Overall, the purpose of the DALY
is to recognize and compare the morbidity and the mortality of patients with a range of condi-
tions. However, for a lifelong stigmatizing disease such as CL (as well as other chronic NTD
skin conditions), the current microbiological perspective to disease monitoring leads to a mas-
sive underrecognition of the true disease burden of affected individuals in GBD studies and
therefore calls into question the validity of such comparisons.
Conclusion
We conclude that the current view of CL neglects a large majority of patients living with con-
tinued stigma and psychological burden postinfection and show that this has major implica-
tions for the way global prevalence estimates are generated, which in turn directly impacts
burden of disease calculations. Of particular concern is the long-term impact of CL on
endemic and conflict-affected countries and especially the role of CL in promoting poverty in
such settings, which has not been addressed. The possibility that up to 40 million people suffer
from the long-term stigmatizing effects of inactive CL scarring suggests that the disease is a
large-scale global health problem. Appropriate revision of current CL estimates is therefore
critical in order to better prioritize this neglected skin disease for global efforts and R&D
needs.
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Abstract
Background
Major depressive disorder (MDD) associated with chronic neglected tropical diseases
(NTDs) has been identified as a significant and overlooked contributor to overall disease
burden. Cutaneous leishmaniasis (CL) is one of the most prevalent and stigmatising NTDs,
with an incidence of around 1 million new cases of active CL infection annually. However,
the characteristic residual scarring (inactive CL) following almost all cases of active CL has
only recently been recognised as part of the CL disease spectrum due to its lasting psycho-
social impact.
Methods and findings
We performed a multi-language systematic review of the psychosocial impact of active and
inactive CL. We estimated inactive CL (iCL) prevalence for the first time using reported
WHO active CL (aCL) incidence data that were adjusted for life expectancy and underre-
porting. We then quantified the disability (YLD) burden of co-morbid MDD in CL using MDD
disability weights at three severity levels. Overall, we identified 29 studies of CL psychologi-
cal impact from 5 WHO regions, representing 11 of the 50 highest burden countries for CL.
We conservatively calculated the disability burden of co-morbid MDD in CL to be 1.9 million
YLDs, which equalled the overall (DALY) disease burden (assuming no excess mortality in
depressed CL patients). Thus, upon inclusion of co-morbid MDD alone in both active and
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inactive CL, the DALY burden was seven times higher than the latest 2016 Global Burden of
Disease study estimates, which notably omitted both psychological impact and inactive CL.
Conclusions
Failure to include co-morbid MDD and the lasting sequelae of chronic NTDs, as exemplified
by CL, leads to large underestimates of overall disease burden.
Author summary
Cutaneous leishmaniasis is a highly prevalent vector-borne disease affecting large parts of
Latin America and the Middle East, as well as parts of Northern Africa. There are several
types of Cutaneous leishmaniasis, almost all of which have an active phase characterized
by a disfiguring lesion (typically on exposed parts of the body), which then becomes a per-
manent scar (the inactive phase). We recently published an article highlighting the impact
of the inactive scarring phase of CL on affected individuals, which is associated with high
levels of stigma. Nevertheless, this aspect of the disease is not considered in its own right
when calculating the overall disease burden by the Global Burden of Disease (GBD) Stud-
ies. In this article we estimate the prevalence of depression (major depressive disorder) in
cutaneous leishmaniasis, in both the active and inactive forms. We then show the contri-
bution of inactive CL to the overall disease burden estimates when included, which is due
to the large psychological impact it has on those affected by it. We also highlight the
importance of further similar efforts for other NTDs which have a chronic course, and
which are also not sufficiently included in disease burden calculations at present.
Introduction
Cutaneous leishmaniasis
Cutaneous leishmaniasis (CL) is the most prevalent form of leishmaniasis and 1 of 22 highly
prevalent neglected tropical diseases (NTD) [1]. Current disease classifications differentiate
aspects of the active (nodular, ulcerative or plaque) CL lesion in terms of its transmission route
(“zoonotic” vs “anthroponotic”), geographical location (“New World” vs “Old World”), and
extent of its dermatological manifestations (“diffuse” vs “localised”) [2]. However, none cap-
ture the characteristic stigmatisation and psychological sequelae of life-long residual CL scar-
ring that accompanies active infection in almost all cases. As such, we recently expanded the
spectrum of CL disease by introducing new terminology—active (aCL) and inactive (iCL) scar-
ring cutaneous leishmaniasis—to describe the dermatological changes of CL in relation to its
disease activity [3]. Such a classification is also inclusive of long-term sequelae such as muco-
cutaneous leishmaniasis (MCL), which develops in a minority of CL cases (~4%) [4] mainly in
the Americas and East African regions and which may represent a reactive form of CL [5].
The stigmatisation resulting from visible active and inactive CL lesions can be traced back
centuries and was probably a major driver in establishing the ancient practice of leishmanisa-
tion [6]. Nevertheless, this defining psychosocial aspect of cutaneous leishmaniasis has been
almost completely overlooked by successive disease burden studies [7–10]. Furthermore, the
prevalence of inactive CL has not previously been estimated and as such is not presently incor-
porated into burden estimates. This unfortunately underlines a habitual lack of consideration
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for the chronic sequelae of NTDs. Regrettably, as CL is not a life-limiting infection, policy-
makers often neglect CL as a priority disease [11–13] despite its importance to endemic com-
munities and its links to poverty [14]. This oversight is particularly problematic given the
increasing CL incidence in highly endemic conflict zones of Afghanistan, Iraq, the Syrian Arab
Republic, and Yemen, creating a major public health problem [15,16].
Major depressive disorder (“depression”)
Major Depressive Disorder (MDD) is the most prevalent form of mental disorder, affecting
4.4% of world’s population [17]. The diagnosis of MDD is symptom-based and follows the Dis-
ease Statistical Manual (DSM). MDD is one of two depressive disorders that account for the
fifth largest cause of disability (years of life lived with disability; YLD) in the latest 2016 Global
Burden of Disease (GBD) Study [18]. There is also a growing recognition by the global mental
health community of the importance of adopting a more inclusive approach to mental health
and disease, from wellness to subclinical distress to clinical “disorder”, known as the staged
model of depression [19].
The psychological impact of NTDs is an area that has only recently been emphasised in the
NTD community [20]. For example, mental ill health was not included in recent calculations
of disability-adjusted life years (DALYs) by NTD programmes, suggesting that the psychologi-
cal impact of these conditions is not a primary outcome of such programmes [21]. It is there-
fore unsurprising that previous global burden of depression studies appear to exclude NTDs
from their prevalence and burden estimates [17,22,23] This omission is highly significant for
two reasons: Many NTDs are uniquely stigmatizing [20], and collectively, WHO estimates that
NTDs affect over 1 billion (or 1 in 6) people worldwide [1].
In summary, CL is often ignored at the policy level due to its lack of mortality, and is there-
fore a prime example of a stigmatising, prevalent NTD whose associated mental illness is disre-
garded. The aims of the present study are two-fold: 1) To conduct a systematic review of the
psychological impact of cutaneous leishmaniasis; 2) To quantify the burden of co-morbid
major depressive disorder in this highly prevalent and stigmatising condition for the first time.
Methods
Our study reflects the current approach to disease burden estimates, which are based upon
MDD as classified by the DSM [22]. We have also adopted the staged model of depression to
use additional evidence from psychological and quality of life studies. These latter studies were
used to calculate stages of subclinical distress associated with CL and to quantify its overall psy-
chosocial impact.
There are four steps to calculating the burden of co-morbid depression (in DALYs) due to
CL. Firstly, we conducted a systematic review of the psychosocial impact of all forms of CL
(including MCL). To quantify the overall impact of iCL as part of the burden of CL, we also
had to generate estimates of iCL prevalence for the first time. Following these first two steps,
we then estimated the prevalence of MDD co-morbidity and its severity in aCL and iCL
patients. We did not calculate the burden of co-morbid MCL as the associated mortality rate is
not known and therefore prevalence estimates could not be reliably calculated. Finally, we
multiplied the prevalence of aCL and iCL with co-morbid MDD by the disability weight (DW)
for MDD at three severity levels (mild, moderate, and severe) following the methodology of
Ton et al (2015) [24] (see Fig 1).
The search strategy queried four Ovid databases–Medline [25], EMBASE [26], Global
Health [27], and PSYCInfo [28]–as well as LILACS [29], using English, French, Spanish, and
Portuguese search terms on 4th December 2017. Additional searches through Google Scholar
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[30] were performed in Arabic and English, along with back referencing of relevant articles
and a grey literature search. The search strategy accounted for common terms and abbrevia-
tions for cutaneous leishmaniasis (e.g. “CL” and “cutaneous leishmaniasis”), and combined
these with key words for major depressive disorder and its symptoms, as well as general psy-
chological impact (e.g. “psych�”, “major depressive disorder”, “distress”). We included all rele-
vant psychological studies in CL patients and those with reliable knowledge of their
experiences (i.e. their caregivers and their care providers) (Fig 2). As such, community studies
were excluded from our final analysis except to further contextualise our findings. Please see
S1 Appendix for further details of the search strategy and individual terms queried. Please see
S2 Appendix for our inclusion and exclusion criteria, and S3 Appendix for the reasons for
excluding studies from final analysis.
Results
Estimating major depressive disorder co-morbidity in cutaneous
leishmaniasis
Twenty-nine studies were included in the final analysis of the psychosocial impact of CL (see
S4 Appendix). The large majority (25/29) of studies were based in middle-income countries
(18/29 UMIC, 7/29 LMIC) [32]. Similarly, most studies took place in the highest burden world
regions (12/29 in the Eastern Mediterranean Region (EMR) and 11/29 in the Americas Region
(AMR)), and included 11 of the 50 highest burden countries for CL in the world [9].
Studies that quantified an MDD diagnosis or symptoms using both validated (e.g. SCID-1;
BDI) and unvalidated tools (e.g. self-reported depression symptoms) were used to determine
rates of co-morbid MDD in both aCL and iCL (See Table 1). Additional quality of life, stigma,
socioeconomic, and qualitative studies were used to generate an estimate of subclinical “dis-
tress” as per the staged model of depression (see Tables 2 and 3).
A diagnosis of MDD was consistently reached within the mean or one standard deviation
of the mean in CL patients [33,34,36,38], equating to MDD rates of 30–50%. Meanwhile, quan-
tification of symptoms of MDD mostly relied upon self-reporting. As such, symptoms of low
Fig 1. Modified disability-adjusted life years (DALY) model for calculating the burden of co-morbid conditions. Adapted from Ton et al (2015) [24].
https://doi.org/10.1371/journal.pntd.0007092.g001
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mood and depression in CL patients ranged from 12.5–90.9% [34,40–45] aCL patients had sig-
nificantly higher rates of MDD compared to controls in both children and adults [36] aCL was
also found on multivariate analysis to be an independent risk factor for mental disorder in the
primary care setting [33]. It is therefore unlikely that these results are a product of significant
selection bias.
Equally, whilst rates of MDD were not measured for children with iCL, significantly higher
rates of MDD were found in adults compared to controls. iCL patients were also at signifi-
cantly higher suicide risk than controls [34]. In the only study to measure co-morbid MDD in
both aCL and iCL, CL scarring was associated with non-statistically significantly higher MDD
scores [38]. These findings are important, as considerably more patients are in the inactive
(scarring) phase of CL than in the active phase. Although the data suggest that rates of MDD
in iCL are at least equal to those found in aCL patients, the majority of studies (16/29) focused
exclusively on aCL.
More broadly, quality of life was found to be significantly decreased in CL patients com-
pared with controls. Stigma was a characteristic feature of CL in most quantitative and qualita-
tive studies, whilst psychological distress was found to be between 50–90% [46,55]. Similarly,
issues of disfigurement and reduced capacity to work affected the majority of sufferers (see
Table 2). Interestingly, the psychological burden extended to CL caregivers, who were also
Fig 2. Prisma flowchart. [31].
https://doi.org/10.1371/journal.pntd.0007092.g002
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found to have significantly elevated depression rates [36] and diminished quality of life [36,49]
compared to controls.
Overall, CL is associated with a high degree of psychological morbidity irrespective of coun-
try, age, and disease activity. We present two other important patient- and disease-specific var-
iables considered during our analysis: patient sex and lesion location. These were chosen due
to multiple reports linking them with increased psychosocial impact. Indeed, despite findings
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BDI = Beck Depression Inventory; BSS = Beck Scale for Suicidal Ideation; CDI = Children’s Depression Inventory; EQ-5D = Euro-Qol-5 Dimensions;
HADS-D = Hospital Anxiety and Depression Scale–Depression; LIC = Low Income Country; LMIC = Lower-Middle Income Country; SCID-I = Systematic Clinical
Interview for Depression– 1st version; UMIC = Upper-Middle Income Country; WHO-QoL Bref = World Health Organization Quality of Life Short; UL = upper limbs
https://doi.org/10.1371/journal.pntd.0007092.t001
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none of the four quantitative studies [34,46,52,54] providing subgroup analysis demonstrated
a statistically significant association with facial lesions and worsening psychological outcomes.
Moreover, facial iCL scars were actually associated with lower rates of depression and suicidal-
ity than those located on other parts of the body [34]. Instead, it may be more appropriate to
differentiate the visibility of lesions in future studies.
A significant number of studies focused solely on women (5/29) on the basis that women
are generally at greater risk of depression [17]. It is therefore important to consider possible
sex differences in MDD rates given that men have more reported cases of CL than women in
most endemic countries [4] Interestingly, women-only studies were found to have comparable
MDD rates to mixed sex studies, although differences in self-reported symptoms of MDD
were noted in some countries [43,44]. The reasons for these findings could perhaps be
explained by community [68], socio-economic [62], and qualitative studies [67]. For example,
whilst women are commonly more concerned by bodily appearance and marital prospects, a
roughly equal impact is placed upon men through incapacity to work and perform leadership
responsibilities [52] due to the disease.
Based on the available evidence, we conservatively estimate that 70% of individuals with
both active and inactive CL will experience some degree of psychological morbidity. This
ranges from subclinical “distress” (50%) to clinical “disorder” (20%), in accordance with the
staged model of depression [19] As such, 30% of CL patients fall into the “wellness” category of
the model, in view of regional differences in psychosocial impact [55,65] and the small number
of countries and endemic communities in which CL is less stigmatizing [59] and perceived as
less severe [69] (see Table 4).
Calculating the prevalence of inactive CL
The 2016 GBD Study provides CL prevalence estimates that account solely for aCL and that
also include MCL within them unseparated. As such, the prevalence of inactive (scarring) CL
has not been previously estimated, and is not incorporated formally into the GBD burden esti-
mates for CL. The methodology for calculating the prevalence of inactive CL has been previ-



































































DLQI = Dermatology Life Quality Index; DQLI = Dermatology Quality of Life Index; FDLQI = Family Dermatology Life Quality Index; PedQoL = Pediatric Quality of
Life; PLSI = Psoriasis Life Severity Index; UL = upper limbs; LL = lower limbs
https://doi.org/10.1371/journal.pntd.0007092.t002
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(Continued)
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incidence data from WHO spanning 2006–2015 [70] that have been adjusted for underreport-
ing [10,71] and the presence of MCL within them [72–74] (see Table 5). We assume zero CL-
associated mortality and a life expectancy of 30 years with scarring; this is a conservative lon-
gevity estimate considering the life expectancy of at-risk populations in high burden countries
[74]. For further information on this methodology, please see S5 Appendix.
Estimating the severity of major depressive disorder co-morbidity in
cutaneous leishmaniasis
GBD Studies differentiate the severity of episodes of MDD at three levels—mild, moderate,
and severe–each with its own disability weight [22]. Therefore, it is necessary to calculate the
severity of co-morbid MDD in CL patients to calculate the disability burden (YLD) compo-
nent of the DALY.
In the studies we identified, the mean depression scores of CL patients equated to mild
MDD, with moderate MDD scores being reached within one standard deviation in most stud-
ies. Furthermore, in a study of depression in inactive CL using Beck’s Depression Inventory,
~70% of cases with depression scored in “mild” severity [34]. Due to the relatively small sample
sizes and difficulties in comparing MDD severity from different measurement tools, we used
data from the 2010 GBD study on depressive disorders to help inform our estimates (see
Table 6). In that study, the patient MDD cohort was classified accordingly: 72.7% withMild


















LIC 10 50% F 29.3 100% face aCL 30%
iCL 70%
MDD symptoms (low self-esteem,
hopelessness, sadness) very common;
Poor QoL due to CL impact on SES, and
lack of treatment services;
Main concern is aCL, yet all left disfigured
by iCL scar;
Commonly insulted with local terms for
both iCL and aCL;
Vast majority experienced stigma,
especially in aCL phase;
Unaffected people favoured for work,
especially if facial lesions;
Marital rejection common, though some
believe not a problem
AFR = African Region; AMR = Region of the Americas; EMR = Eastern Mediterranean Region; EUR = European Region; HIC = High Income Country; SEAR = South-
East Asian Region
https://doi.org/10.1371/journal.pntd.0007092.t003
Table 4. Estimating the psychological impact of CL using the staged model of depression adapted from Patel (2017) [19].
Stage Definition CL estimate References
Wellness Absence of any sustained, distressing, emotional experiences 30% [57–59, 61]
Distress Mild to moderate distressing emotional experiences of relatively short duration 50% [46, 47, 49, 51–55, 60,
62]
Major Depressive Disorder Severely distressing experiences, lasting at least two to four weeks, with impairment of
social functioning
20% [33, 34, 36, 38, 40–45]
Recurrent Major Depressive
Disorder
Unresponsive or relapsing depressive episodes
https://doi.org/10.1371/journal.pntd.0007092.t004
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Quantifying DALYs for major depressive disorder in cutaneous
leishmaniasis
Applying the estimate for MDD severity to our prevalence estimates for cutaneous leishmania-
sis, the following YLDs were calculated: 200,000 for active CL, and 1.7 million for inactive CL
(combined total 1.9 million YLDs for CL) (see Table 7 and Table 8). We assumed no mortality
burden associated with MDD co-morbid to cutaneous leishmaniasis, and as such our YLD fig-
ures equalled the overall DALY figures (see S6 Appendix for in-depth calculations). These fig-
ures only represent the impact of co-morbid MDD in this condition and do not account for
the impact of other mental disorders such as anxiety disorders or the subclinical state of dis-
tress as per the staged model of depression [19].
Discussion
The results presented here challenge the most recent GBD estimates for the overall burden
of CL given the prevalence of mental illness reported in the literature for the condition. We
highlight the lack of reliable prevalence estimates on which GBD figures are based. We fur-
ther emphasise that, despite the increased recognition of NTDs through their inclusion
within the UN Sustainable Development Goal (SDG) health targets, the burden of mental
health associated with stigmatising and chronically disabling NTDs is not appropriately fac-
tored into the calculations of overall global mental health estimates. We stress the impor-
tance of residual disease on the continuing suffering of those with NTDs using the example
of inactive CL.
Indeed, inclusion of iCL increases the CL prevalence estimate 10-fold, which substantially
increases the CL disease burden in itself. However, factoring in the burden of co-morbid
MDD for both aCL and iCL further increases its overall burden to 2.2 million DALYs. This is
approximately eight times greater than the previous DALY estimate reported in the 2016 GBD
study that accounted for aCL alone [76]; this is despite our conservative estimate of only a 30
years of life expectancy post-lesion acquisition (see Table 8). Significant increases in burden
estimates were calculated previously for lymphatic filariasis [24], indicating that mental illness
is grossly unaccounted for in the NTD GBD estimates.
These findings come at a crucial time for those affected by CL, a growing number of whom
continue to be affected by war and displacement in current conflict zones. The inclusion of
iCL into prevalence estimates for CL, we argue, is necessary to enact changes at the policy level
that reflect the importance of CL to affected individuals and their communities. Moreover, the




Ratio ~10 ~90 100
Prevalence 4,320,000 33,883,900 38,203,900
https://doi.org/10.1371/journal.pntd.0007092.t005
Table 6. Estimating the severity of co-morbid MDD in cutaneous leishmaniasis.
Severity of MDD Disability Weight75 Severity of MDD
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studies we have highlighted show a clear benefit for psychological as well as physical therapies
on quality of life [41,47,51] as well as rates of depression [41] in CL patients; sadly, inability to
access any form of treatment is a commonly cited major concern for patients [45,55,63,64]. As
such, there is a very clear opportunity for national NTD programmes and partner interna-
tional NGOs to incorporate mental health care into their activities and to provide appropriate
services to tackle this growing public health problem.
Overall, the stigma and depression linked to NTDs represent areas of global health that
have only recently been highlighted [21]. From our literature review, the previous GBD esti-
mates for depression (which predict depressive disorders as a leading cause of DALYs) do not
incorporate MDD (or any other mental illness) associated with NTDs. Omitting NTDs from
such consideration of global mental health burden is significant as NTDs have been estimated
by WHO to affect over 1 billion (1 in 6) people worldwide [1].
Implications for future GBD studies
In the latest 2016 iteration of the GBD study, the psychological impact of CL scarring has been
incorporated into the disease burden estimates for the first time via a modification of disability
weights (DW) (IHME personal communication). As such, the disability burden of CL has
increased from 41,500 [77] to 273,000 [18] YLDs. Despite this modification, relying upon
DWs to capture the unique psychosocial aspects of NTDs has unfortunately led to some of the
most stigmatising (namely CL and leprosy) diseases yielding some of the lowest disability
(YLD) estimates of all the NTDs in past iterations [18,77–79]. CL is currently viewed as a “level
two disfigurement”, meaning that its DW reflects “a visible physical deformity that causes others
to stare and comment. As a result, the person is worried and has trouble sleeping and concentrat-
ing”. This corresponds to a DW of 0.067 in GBD 2016, where 0 indicates perfect health and 1
Table 7. Estimating the burden of Major Depressive Disorder in cutaneous leishmaniasis.
Active CL� Inactive CL Total CL
Prevalence 4,320,000 [18] 33,883,900 38,203,900






















Table 8. Overall DALY estimates for cutaneous leishmaniasis (aCL and iCL).
Active CL Inactive CL Total
Physical health DALYs
(GBD 2016)76
273,000� - 273, 000




�GBD estimate includes MCL
https://doi.org/10.1371/journal.pntd.0007092.t008
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indicates death [75] Thus, we can be confident that our findings represent an unrecognized
mental disease burden of CL.
Instead, we strongly recommend that inactive (scarring) CL be included with active CL
infection in future CL prevalence estimates, and that MCL and aCL estimates be presented
separately for further information. We have shown that with inactive CL, such a large increase
in prevalence (10-fold higher) and burden of co-morbid MDD (8-fold increase) is not suffi-
ciently accounted for by simply altering the DWs for active CL given the evidence of mental ill-
ness in patients with residual scarring. As we have only included the “disorder” stage of
depressive burden in our YLD estimates, our estimate of CL-related distress (50%) using the
staged model approach to depression is not accounted for. Here adjustments to DWs for both
aCL and iCL would be justified, as a large proportion of affected individuals with both forms
of CL experience some degree of quantifiable distress or socially adverse consequences.
Finally, it is important to highlight that the 2016 GBD Study estimates of aCL incidence
[18] are almost half those of previously accepted incidence estimates published in 2012 [71].
This is despite the marked increase in CL incidence due to ongoing conflict and displacement
in the Middle East [15]. Similarly, our aCL burden estimates are based upon the 2016 GBD
Study estimates of aCL prevalence to allow for comparisons to be made. However, it is unclear
why these prevalence estimates are almost seven times lower than the annual incidence of aCL
[18] when the majority of cases of aCL self-heal within 6–12 months [2]. For these reasons, we
did not include GBD estimates in our calculations of iCL prevalence.
Study limitations
Although our study is the first to generate prevalence estimates of inactive (scarring) CL, we
were cautious of the life span of patients with iCL lesions, which is currently unknown. Whilst
the majority of CL infections occur in older children and young adults [4] we took a conserva-
tive approach to our iCL prevalence estimates by assuming just 30 years lived with residual
scars. Nevertheless, given that the majority of aCL cases occur in the young and working adult
populations, this figure could be significantly higher. We also conservatively assume no mor-
tality burden with CL, yet suicidal risk and ideation has been noted in both aCL and iCL
patients [34,63].
Secondly, we acknowledge our failure to include prevalence and isolated burden estimates for
co-morbid MDD in mucocutaneous leishmaniasis (MCL). As discussed, MCL prevalence (and
YLD burden) has not been separated from that of aCL in GBD Studies. A further complicating
factor is the mortality rate of MCL, which has not been established and consequently prevented
us from generating reliable MCL prevalence estimates from WHO incidence data. Nevertheless,
the experience of shame in CL patients [45,59] was surprisingly higher than that found in a
study of mixed MCL and CL patients [61]. However, in a study of MCL patients alone [80], nota-
bly those with severe disease, rates of social exclusion and reduced quality of life were compara-
ble to those found in CL patients [45,52,54,62]. It is possible that the prevalence of co-morbid
MDD in MCL patients is similar to that of aCL patients (~20% of cases), meaning that our aCL
burden estimates may be relatively unaffected by the presence of MCL cases within them.
This is the first study to estimate the burden of a co-morbid mental disorder in aCL and
iCL. One major limitation of our estimates is the evidence underpinning them. We recognize
that our 29 studies represent only a relatively small proportion of the global CL caseload. Nev-
ertheless, our systematic literature review has identified the most evidence of psychological
impact in CL patients to date, and doubled the evidence of previous recent attempts [81].
Moreover, these studies represent a range of geographically diverse populations across several
levels of economic development. In our analysis, studies quantifying MDD using robust and
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internationally recognised criteria (i.e. DSM) were given the most weight in generating our
final estimates of MDD co-morbid to CL. We were also selective and chose to only utilize stud-
ies of CL patients and their care providers. In order to minimize the effects of bias we
accounted for patient- and disease-specific variables such as sex, age, lesion location, and
country of study. As results for co-morbid MDD were comparable when these variables
changed, we were confident that none of these variables could have significantly biased our
overall estimates.
Finally, whilst depressive disorders represent the most prevalent form of mental disorder
worldwide, CL patients are affected by a range of other mental disorders, which have not been
included in our estimates. Indeed, CL patients may be at even greater risk of multiple mental
disorders [33]. These include generalised anxiety disorder, which may predominate in the
active CL phase [36,38] post-traumatic stress disorder [33] and mixed anxiety and depressive
disorder [41], the latter of which is not independently considered within the GBD framework
at present.
Conclusion
Social stigma, disfigurement, and patient suffering are some of the most identifiable features of
NTDs, as emphasized by the case of cutaneous leishmaniasis. However, the suffering of those
with active infection as well as those who remain disfigured by NTDs post-infection is not ade-
quately factored into NTD programmes or burden estimates. We reason that there is value in
striving for both goals by placing the individual at the centre of such programmes to achieve
the holistic care of individuals affected by NTDs. After all, focusing on the disease alone
ignores the characteristic disability associated with NTDs such as cutaneous leishmaniasis, lep-
rosy, and filariasis, and risks leaving affected individuals behind.
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